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BHPR RESEARCH: QUALITATIVE
1. COMPLEX REASONING DETERMINES PATIENTS’
PERCEPTION OF OUTCOME FOLLOWING FOOT SURGERY
IN RHEUMATOID ARHTRITIS
Michael R. Backhouse1,2, Karen A. Vinall1, Anthony Redmond1,2,
Philip Helliwell1,2 and Anne-Maree Keenan1
1Section of Musculoskeletal Disease, University of Leeds, Leeds,
United Kingdom; 2Leeds Musculoskeletal Biomedical Research Unit,
University of Leeds, Leeds, United Kingdom
Background: Foot surgery is common in patients with RA but
research into surgical outcomes is limited and conceptually flawed
as current outcome measures lack face validity: to date no one has
asked patients what is important to them. This study aimed to
determine which factors are important to patients when evaluating the
success of foot surgery in RA
Methods: Semi structured interviews of RA patients who had
undergone foot surgery were conducted and transcribed verbatim.
Thematic analysis of interviews was conducted to explore issues that
were important to patients.
Results: 11 RA patients (9 9, mean age 59, dis dur¼22yrs, mean of 3
yrs post op) with mixed experiences of foot surgery were interviewed.
Patients interpreted outcome in respect to a multitude of factors,
frequently positive change in one aspect contrasted with negative
opinions about another. Overall, four major themes emerged.
Function: Functional ability & participation in valued activities were
very important to patients. Walking ability was a key concern but
patients interpreted levels of activity in light of other aspects of their
disease, reflecting on change in functional ability more than overall
level. Positive feelings of improved mobility were often moderated by
negative self perception (‘‘I mean, I still walk like a waddling duck’’).
Appearance: Appearance was important to almost all patients but
perhaps the most complex theme of all. Physical appearance, foot
shape, and footwear were closely interlinked, yet patients saw these
as distinct separate concepts. Patients need to legitimize these
feelings was clear and they frequently entered into a defensive
repertoire (‘‘it’s not cosmetic surgery; it’s something that’s more
important than that, you know?’’).
Clinician opinion: Surgeons’ post operative evaluation of the
procedure was very influential. The impact of this appraisal continued
to affect patients’ lasting impression irrespective of how the outcome
compared to their initial goals (‘‘when he’d done it . . . he said that
hasn’t worked as good as he’d wanted to . . .but the pain has gone’’).
Pain: Whilst pain was important to almost all patients, it appeared
to be less important than the other themes. Pain was predominately
raised when it influenced other themes, such as function; many still felt
the need to legitimize their foot pain in order for health professionals to
take it seriously (‘‘in the end I went to my GP because it had happened
a few times and I went to an orthopaedic surgeon who was quite
dismissive of it, it was like what are you complaining about’’).
Conclusions: Patients interpret the outcome of foot surgery using a
multitude of interrelated factors, particularly functional ability, appear-
ance and surgeons’ appraisal of the procedure. While pain was often
noted, this appeared less important than other factors in the overall
outcome of the surgery. Future research into foot surgery should
incorporate the complexity of how patients determine their outcome
Disclosure statement: All authors have declared no conflicts of
interest.
2. AN EVALUATION OF PATIENTS’ PERSPECTIVES OF
PARTICIPATING IN A TWO WEEK INPATIENT ANKYLOSING
SPONDYLITIS REHABILITATION PROGRAMME
Rebecca M. Dale1,2, Amanda Thomas1, Diane Aronson1,
Julie Turner-Cobb2, Raj Sengupta1, Brisa France1 and Ingrid Hill1
1Rheumatology Department, Royal National Hospital for Rheumatic
Diseases, Bath, United Kingdom; 2Health Psychology Department,
University of Bath, Bath, United Kingdom
Background: The Royal National Hospital for Rheumatic Diseases
in Bath provides a specialist 2 week inpatient course promoting
self-management of AS, with a combination of education, exercise,
hydrotherapy, pain management strategies and the opportunity to
meet others with the condition.
The AS course at the RNHRD has not previously been investigated
in terms of how patients perceive the course and their condition after
taking part; this study explored the experience of being on the course
using qualitative research techniques.
Methods: 12 participants were interviewed at the end of, or shortly
after, the AS programme. Interviews lasted between 30 and 90 minutes
and were audio recorded and transcribed verbatim to allow in-depth
analysis of the data. Data was analysed manually using an Inter-
pretative Phenomenological Analysis method, following the four-stage
process described by Smith and Osborn (2003). An idiographic
approach was used, taking a single case and moving on to examine
the others (Chapman, Parameshwar, Jenkins, Large, & Tsui, 2007).
Quotes were selected for inclusion if they provided a powerful
expression of a recurring theme.
Results: 12 participants were recruited into the study over a 6-week
period in June-July 2011. 8 participants were male, 4 female, ranging
in age from 29 to 66 years (M¼ 44 years 9 months, SD¼10.3). Onset
of symptoms varied from 2 to 50 years (M¼ 22 years). Length of time
since diagnosis varied from 6 months to 31 years (M¼13 years).
5 participants had previously attended, 7 were attending for the
first time. The data clustered around four main themes with related
sub-themes:
1. Knowledge: with awareness comes power. Learning in the long-
term, sense of enlightenment, deeper level of understanding and
awareness of condition.
2. Coping: acceptance and motivation. Self-motivation, acceptance
and benefit finding
3. Improvement: physically and emotionally. Physical improvement
and attitude shift.
4. Relating to others: comparisons and social support. Experiences of
others, identification with others, learning from other patients and
relating to health professionals.
Conclusions: ‘I refer to my AS as carrying a rucksack. I come before
my AS, unfortunately I have to bring it with me, wherever I go . . . I prefer
not to make it a front pack instead of a back pack . . . some days that
rucksack might be a bit fuller than other days’.
Patients were unequivocally positive about their experience of
coming on the programme. The increase in knowledge and awareness
meant that patients felt more able to take responsibility for the self-
management of their condition. Patients felt that the programme
equipped them with the coping skills they needed, whether these were
learnt from the experiences of others or the information provided by
the healthcare professionals. The programme facilitated an improve-
ment on a physical and a psychological level.
Disclosure statement: All authors have declared no conflicts of
interest.
3. ‘YOU MAKE YOUR OWN LUCK’: THREE DIFFERENT
PERCEPTIONS OF LIVING WITH RHEUMATOID ARTHRITIS:
A Q-METHODOLOGICAL STUDY
Caroline A. Flurey1, Marianne Morris1, Jon Pollock1, Rod Hughes2,
Pam Richards3 and Sarah Hewlett1
1Faculty of Health and Life Sciences, University of the West of
England, Bristol, United Kingdom; 2Rheumatology, St Peter’s
Hospital, Chertsey, United Kingdom; 3Rheumatology, University
Hospitals Bristol, Bristol, United Kingdom
Background: Most research about daily life with RA was conducted
before current more aggressive medication. The aim of this research is
to explore daily life on current therapies.
Methods: Q-Methodology: 30 RA patients sorted 39 statements
(generated in previous qualitative interviews) about daily life with RA
across a forced distribution, in ranked order of agreement. Data were
analysed using centroid factor analysis with varimax rotation (i.e. in Q
the participants are the variables). Demographic and clinical data were
collected and patients completed comments booklets about their
rationale for sorting the statements.
Results: Three factors were generated, which explained 33% of the
study variance and accounted for 23 of the 30 participants. None of
iii52 Tuesday 1 May 2012, 10.30 – 11.30 POSTER VIEWING I
the Q-sorts were confounded (loading on more than one factor). A
participant loading of 0.41 reached significance at p< .01.
Factor A: Taking Control: ‘‘Just a fact of life’’: Seven participants:
mean disease duration 22.7yrs (SD 10.8), age 61.7yrs (SD 10.3), HAQ
score 2.0 (SD 0.6), patient global 3.1 (SD 1.7), 86% female, 71% on
biologic therapies.
These patients constantly micromanage their RA, find different
ways of doing the things they want to and will not let RA interfere with
their responsibilities. They take their medication exactly as prescribed
and will not over-do it. They also use tools as aids and plan rest time
into their week. They do not believe in alternative medicines or special
diets.
Factor B: Struggling Through: ‘‘It gets me down every single day’’:
Eight participants: mean disease duration 15.3yrs (SD 14.3), age
55.5yrs (SD 7.1), HAQ score 1.3 (SD 0.9), patient global 4.8 (SD 2.5),
63% Male, 50% on biologic therapies.
These patients are never symptom free, experiencing pain and
fatigue daily. They worry and get angry and frustrated about their RA. It
gets them down daily. They report being unable to be spontaneous or
to exercise and they struggle to explain their experience to their family.
They feel their body has let them down and consider themselves
unlucky.
Seven participants: mean disease duration 9.9yrs (SD 10.1), age
42.4yrs (SD 11.2), Factor C: Keeping RA in its place: ‘‘It’s a very small
part of you’’: HAQ score 0.5 (SD 0.5), patient global 1.7 (SD 1.0), 100%
female, 71% employed, 86% mothers, 43% on biologic therapies.
These patients do not allow RA to interfere with their responsi-
bilities, nor hold others back. Fatigue is their highest ranked symptom,
but they do not plan rest time into their week as they are too busy.
They are often able to forget about their RA as they do not need to use
tools or ask for help and they will not consider their RA when choosing
their clothes. They do not allow RA to get them down and consider
themselves lucky in comparison to others.
Conclusions: Many patients report coping well with their RA. Others,
mainly men, struggle to accept and adapt to RA, indicating a need for
an increased awareness of the support needs of male RA patients.
Disclosure statement: All authors have declared no conflicts of
interest.
4. ‘WHAT I WANT THE HEALTH PROFESSIONAL TO KNOW’:
THE EXPERIENCES OF PEOPLE WITH OSTEOARTHRITIS AND
RHEUMATOID ARTHRITIS
Sarah Ryan1, Kate Lille1, Jo Adams2 and Inam Haq3
1School of Nursing & Midwifery, Keele University, Stoke-on-Trent,
United Kingdom; 2School of Health Sciences, University of
Southampton, Southampton, United Kingdom; 3Medical Education,
Arthritis Research UK, London, United Kingdom
Background: In 2010 Arthritis Research UK commissioned a study to
identify education needs of nurses, allied health professionals (AHPs)
and associate practitioners (APs) working with people with osteoar-
thritis (OA) and rheumatoid arthritis (RA).
Methods: Four focus groups were conducted with people with OA and
RA in England and with nurses, AHPs and APs in England and
Scotland. The focus groups used a semi-structured topic guide to
identify the educational needs of nurses and AHPs and APs. The
duration of the focus groups was 1 to 1.5 hours. The focus group
discussion was audiotaped and transcribed verbatim. The transcripts
were analysed by two researchers using content analysis and the
results used to design an electronic questionnaire which was
distributed to members of professional organizations including BHPR
and the RCN Rheumatology Forum.
Results: 23 people participated in the focus groups including 5 people
with OA, 8 people with RA, and 10 health professionals including 2
APs. 162 health professionals responded to the electronic survey. The
main themes identified from the transcripts and the survey included:
(1) Living with pain. Pain was the dominant symptom for all
participants and was described as ‘‘having radios on at different
volumes’’. Participants wanted to learn how to manage their pain but
this service was not available to them. Survey participants responded
that they did not have the knowledge or were unsure about providing
advice on pain medication for people with OA (45%) or RA (30%).
(2) Participants with OA had no access to any services and referred
to ‘‘the absent health care professionals’’ yet wanted advice on
exercise, pain and fatigue to optimize their independence. Survey
participants responded that they did not have the knowledge or were
unsure about providing advice on exercise to people with OA (61%) or
RA (37%), despite exercise being a core treatment in the NICE OA
guidelines.
(3) To be treated as an individual. All participants wanted health
professionals to listen, empathize, understand the impact of the
condition on physical, psychological and social function, have
condition-specific knowledge, provide support and be accessible.
Survey participants felt they had the skills to conduct a biopsycho-
social consultation with people with OA (72%) and RA (80%).
Conclusions: We need to provide training in the 3 ‘‘e’s’’ easing pain,
education and exercise to enable nurses, AHPs and APs to respond to
the needs of people with RA and OA. We also need to ensure that
people with RA and OA can access the expertise that is available
to them.
Disclosure statement: All authors have declared no conflicts of
interest.
5. EXPLORING OCCUPATIONAL GAIN IN PEOPLE WITH
INFLAMMATORY ARTHRITIS RECEIVING ANTI-TNFa
Margaret McArthur1, Lynne Goodacre1 and Linda Birt1
1School of Allied Health Professions, University of East Anglia,
Norwich, United Kingdom
Background: AntiTNFa therapies have had a significant impact on the
management of RA and AS, significantly reducing disease activity,
improving function and quality of life. The evidence base for these
therapies is informed predominantly by RCTs that do not reflect the
nuanced ways in which individuals’ accommodate changed life
trajectories. The increasing use of antiTNFa poses new questions for
patients and occupational therapists (OT) in a disease profile
previously associated with long-term functional occupational decline.
This study aims to develop an in-depth understanding of the
experience of occupational gain in people receiving antiTNFa therapy,
exploring the implications for OT interventions.
Methods: People with a good clinical response to treatment were
recruited through clinics in East Anglia and the North West. Purposive
sampling enhanced transferability of findings with recruitment of 26
people aged 21-77. Their antiTNFa therapy ranged from 6 months to
7 years. Single semi-structured interviews provided detailed narratives
focusing on their journey to accessing antiTNFa and subsequent
occupational gain. Interviews were transcribed verbatim and analysed
using interpretative phenomenological analysis. Trustworthiness was
enhanced by triangulating patient and OT experiences, participant
validation, and sharing findings with lay and professional peers.
Results: Whilst antiTNFa led to an improvement in quality of life with
reduced pain, fewer flare ups and increased function, participants still
experienced physical and psychological challenges. If symptoms did
not improve soon after starting therapy there was fear that drugs
would be withdrawn; improving clinical markers provided reassurance.
They experienced a time of transition as symptoms receded and they
tested how far they could extend participation in daily living activities,
leisure and employment. However, where there had been significant
pathological damage, participants were still restricted in activities.
Many reported continuing fatigue. There appeared to be limited
information on the benefits of planning and pacing activities. They
were fearful of changing employment, citing uncertainty about the
long-term efficacy of the therapy. If ill health had led to them
temporarily stopping antiTNFa, the decline in their well-being left
participants fearful of having to stop treatment again. Very few
participants reported having any meaningful contact with OTs after
receiving antiTNFa
Conclusions: Personal experiences of patients and OTs and robust
interpretative analysis led to propositional knowledge indicating that
there should be an increased focus on supporting patients during the
early stages of receiving antiTNFa. We argue that contact with OTs
could enhance patients’ experiences and optimized the benefits of
treatment. Reassessing pathways of care could ensure patients are
readily able to access support on symptom management, planning
and pacing and engagement with employment.
Disclosure statement: All authors have declared no conflicts of
interest.
6. ‘JUST DO SOMETHING ABOUT MY FEET’: FOOT
PROBLEMS AND ACCESS TO FOOT CARE IN PEOPLE
WITH RHEUMATOID ARTHRITIS
Oonagh Wilson1, John Kirwan2, Emma Dures1, Enid Quest2 and
Sarah Hewlett1
1Faculty of Health and Life Sciences, University of the West of
England, Bristol, United Kingdom; 2Academic Rheumatology Unit,
University of Bristol, Bristol, United Kingdom
Background: The foot is often involved in RA but the impact of foot
involvement in patients with RA and patients’ beliefs regarding access
to and efficacy of foot care services are unknown.
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Objective: To explore patients with RA experiences of foot
problems and their access to foot care provision.
Methods: Inductive thematic analysis of the transcripts from semi
structured face-to-face interviews with patients purposively sampled
for self-reported foot problems and a range of personal/disease
characteristics. Themes were identified within and across data sets.
Analysis was by OW with a subset independently analysed (SH, ED
and patient partner EQ). Emerging themes were discussed and agreed
by all authors.
Results: 12 patients (7F); aged 29-72 yrs (mean 56.8); 42% accessed
foot care services; disease duration 2-27 yrs (mean 12); with 92% on
DMARDs; 42% on biologics; HAQ 0-2.875 (mean 1.58); and global
opinion numerical scale 0-9 (mean 5.9). An overarching theme of
Access to Foot Care was identified, comprising three themes.
Access supported. ‘‘I’d put them [feet] top priority’’: This included
proactive discussions of foot problems generated by patients and
health care professionals (‘‘He generally asks’’); having feet examined
(‘‘Took my shoes and socks off and showed the woman’’); previous
positive experiences of foot care (‘‘The podiatrist is keeping an eye on
them’’); and continuing access to foot care (‘‘It helps’’).
Access perceived unnecessary. ‘‘It’s not where I want to go
[prescribed footwear], another nail in the coffin’’: This included:
fluctuating foot symptoms (‘‘Some days I can’t walk, then it goes’’);
general RA disease activity (‘‘Just took it as part of the RA’’); ability to
self-manage foot problems (‘‘I know how to look after my feet’’); feet
not being considered a major concern (‘‘Not a big problem’’).
Access hindered. ‘‘It seems to be an area where medical staff don’t
know an awful lot do they?’’: This included patients’ perceptions of
feet being ignored in clinical practice (‘‘Not on any RA form’’); limited
knowledge of how or when to access care foot care (‘‘Didn’t know you
could access it on the NHS’’); expectations that the rheumatology
team would initiate access to foot care (‘‘He will refer me’’);
assumptions that no treatment options were available (‘‘I’ve just
plodded on’’); and previous negative experiences of foot care (‘‘All
they did was cut my nails’’).
Conclusions: Patients who had accessed foot care services prior-
itized their foot problems as an important health care need. However,
for others who would like foot care services, personal knowledge and
values, and perceived barriers in clinical practice, appear to interact to
inhibit foot care access. The extent which these interactions affect
overall access to foot care in RA patients in general now needs to be
quantified to help to inform and improve the effectiveness of the
organization and delivery of foot care.
Disclosure statement: All authors have declared no conflicts of
interest.
7. OBSERVATIONAL STUDY OF EXERCISE AND
RHEUMATOID ARTHRITIS: PATIENTS’ PERCEPTIONS AND
EFFECT ON DISEASE ACTIVITY MEASURES
Rizwan Rajak1, Tasmin Thomas1 and Tom Lawson1
1Rheumatology Dept, Princess of Wales Hospital, ABM Health
Board, Bridgend, United Kingdom
Background: The link between rheumatoid arthritis (RA) activity and
decline in physical ability is well established. Historically, RA patients
were discouraged from weight-bearing exercise but contemporaneous
studies have determined that exercise (EXC) is safe in stable RA and
can inhibit disease progression. Only 19% of RA patients achieve the
recommended levels of physical activity compared to 35% of the
normal population.
We performed an observational study to assess patient’s percep-
tions on EXC in relation to RA. Also, we assessed for correlations
between level of EXC with RA disease activity & CVD risk.
Methods: Data was collected prospectively using a patient ques-
tionnaire covering the following: EXC type undertaken; intensity,
duration & effort of EXC; change in level of EXC since diagnosis of
RA; knowledge & education regarding appropriate EXCs in RA. RA
patients >18 years old were recruited from Princess of Wales Hospital,
Rheumatology Dept. DAS28-CRP, CRP & 10-year CVD risk scores
(using QRISK2) were obtained.
Results: 50 patients were assessed (M¼13, F¼ 37; mean age 62yrs)
who participated in a diverse range of activities including vigorous EXC
(24%) - zumba,cycling & swimming - to mild/moderate EXCs (42%) -
walking or seated exercises - & no EXC at all (34%). 64% patients felt
less able to participate in EXC after diagnosis of RA; pain after EXC
was the main barrier to participation. Few patients felt they received
EXC education by their healthcarers & <50% felt they knew what EXCs
to do. Overall, participation in EXC (vigorous EXC type, longer
duration, more effort & intensity in EXC) correlated with a reduction
in meanDAS28-CRP, meanCRP and mean relative risk QRISK-2
scores(p> 0.05). One confounding result was that those who did no
EXC had a lower meanDAS28; this was mainly due to lower pain
scores.
Conclusions: In this observational study, there appears a correlation
between EXC participation & lower RA disease activity, though of
course it is difficult to determine if EXC is a cause or effect of better
arthritis control. The lower DAS28 found in patients who do no EXC
could be due to their VAS scores: meanVAS was lower in those who
did no EXC but other composite scores improved with EXC. CRP &
QRISK2 were lower in patients who undertook EXC.
Majority of patients reported a decrease in the amount of EXC since
diagnosis but with 19% of subjects having had disease for >20years,
some of the decline is attributable to aging. Perceptions on EXC
were similar to previous studies, with patients not reporting having
discussed EXC with their healthcare professionals. Most patients
believed that EXC had a beneficial effect but were reluctant to
participate due to uncertainty regarding appropriate EXCs.
With better understanding of the beneficial effects of EXC on RA
disease activity, CVD risk and patient well-being, it is imperative
that a more committed approach to promoting fitness and EXC be
established.
Disclosure statement: All authors have declared no conflicts of
interest.
8. EXPLORING THE EXPERIENCES AND NEEDS OF YOUNG
ADULTS (16–25 YEARS) WITH A CHRONIC INFLAMMATORY
MUSCULOSKELETAL DISEASE WITHIN AN ADULT
RHEUMATOLOGY SERVICE: A QUALITATIVE STUDY
Sharon Petford1,3, Elizabeth Hale1, George D. Kitas1 and
Sarah Ryan2,3
1Rheumatology, The Dudley Group of Hospitals NHS Foundation
Trust, Dudley, United Kingdom; 2Rheumatology, The Haywood
Hospital, Stoke-on-Trent, United Kingdom; 3Nursing, Keele
University, Newcastle-under-Lyme, United Kingdom
Background: The experiences of transition for sixteen to twenty
five years olds are now becoming the focus of research within adult
care. This is a complex process which includes the relationships that
young people enter with health care professionals, attitudes towards
their condition and support networks from family and friends. One
aspect is the transition from paediatric service, although some young
adults enter into adult care immediately. The literature supports
developmentally appropriate information delivered in methods which
will engage the future users of the health care system.
Methods: The aim of the study was to explore the experiences of
young adults who had transitioned or entered directly into an adult
rheumatology secondary care service. This is an exploratory qualita-
tive study utilizing Interpretative Phenomenological Analysis (IPA). Six
participants, with an equal split of gender, varying in age between 16-
25 years old were recruited from the West Midlands, UK. Semi-
structured interviews were carried out and transcribed verbatim.
Results: Two main themes emerged from the data which included
‘facets of transition’ and young people’s ‘expectations of an adult
service’. Trusting and concordant relationships with healthcare
professionals were viewed as essential in easing the transition
process. Whilst young adults want to be viewed as ‘special’ within
their support networks (including the hospital setting) they also want a
sense of normality as well.
Conclusions: Improving services will help to engage young people
with a chronic illness and should cover the spectrum of medication,
vocational issues, education and independent living. The dynamics for
adolescent care are different to adult care with longer consultation
time requirements, and particular skills required that are appropriate
for younger adults. Further training for those working with this age
group may be appropriate to maximize concordant relationships.
Disclosure statement: S.P. has received an educational grant from
Wyeth (Pfizer) and an education bursary from Arthritis Research UK.
All other authors have declared no conflicts of interest.
9. INVOLVING SERVICE USERS IN TRIAL DESIGN:
OUTCOMES, SPLINT SELECTION AND PLACEBO DESIGN IN A
TRIAL OF TREATMENT FOR THUMB BASE OSTEOARTHRITIS
Rachael Gooberman-Hill1, Clare Jinks2, Krysia Dziedzic2, Sofia
Barbosa Bouc¸as3, Kelly Hislop3, Carol Rhodes2 and Jo Adams3
1Musculoskeletal Research Unit, School of Clinical Sciences,
University of Bristol, Bristol, United Kingdom; 2Primary Care
Sciences, Keele University, Keele, United Kingdom; 3Faculty of
Health Sciences, University of Southampton, Southampton,
United Kingdom
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Background: Thumb base osteoarthritis (OA) affects 20% of people
aged 55. It is associated with long-term pain, work disability,
reduced quality of life and overall function. Optimal management for
thumb base OA has the potential to deliver benefits for patients, health
services and society. A common approach is splinting. However,
previous trials of splints for thumb base OA have not included placebo
groups and it is not clear if they assess outcomes or splints that are
important or acceptable to patients. To address these gaps, and in
light of recent evidence about the value of patient involvement in
research, we conducted a patient involvement project to inform the
design of a new trial of splints.
Methods: Two involvement sessions comprised a total of eight people
who all wore hand splints for thumb base OA. Sessions aimed to
identify outcomes to include in a future trial; to identify splints to
assess in a subsequent Delphi study prior to the trial; and to design
placebo splints. Sessions were facilitated by a researcher experienced
in patient involvement, and a research-lead in occupational therapy.
Another staff member took notes, and a user support worker attended
one session. Group members were encouraged to discuss their
experience of OA, their use of splints and outcomes of importance to
them. They were shown 45 splints, which they discussed and tried.
Finally, the idea of a placebo splint and possible design options were
introduced. Group members worked alongside facilitators to identify
key elements of a placebo that would make it convincing and
acceptable. At the end of each session, group members completed
brief satisfaction questionnaires.
Results: Group members identified outcomes centring on everyday
activities such as housework, driving, gardening and other tasks
requiring dexterity and grip. Through trying on a variety of splints, they
defined acceptable and unacceptable design features. These focused
on two areas: wearability and support/immobilization. Factors that
affected wearability included warmth, colour, material, method of
fastening and washability. Factors relating to support and immobiliza-
tion included rigidity, fit and pressure. Groups discussed placebo
design and arrived at a consensus about a potential placebo splint.
Questionnaire responses showed that all group members were very
satisfied that their views had been taken into account; were satisfied or
very satisfied that the group had made decisions about splint types;
and all were very satisfied that the group had made decisions about
how to design a placebo splint.
Conclusions: This project provides a case study of patient involve-
ment as an efficient and satisfactory way to include service users in
early stages of trial design. The impact of the activity on the pilot trial is
still to be evaluated and it will be important to assess the acceptability
of the placebo in practice to patients and health professionals.
Disclosure statement: All authors have declared no conflicts of
interest.
10. ‘. . .WELL, I PUT IT DOWN TO HAVING A CLEAR
CONSCIENCE, BEING POLITE TO ALL PEOPLE AND BEING
A MEMBER OF THE LABOUR PARTY’: PREVENTION OF KNEE
PAIN: A QUALITATIVE STUDY IN SYMPTOMLESS OLDER
ADULTS
Fizzah Ali1, Clare Jinks1 and Bie Nio Ong1
1Arthritis Research UK Primary Care Centre, Primary Care Sciences,
Keele University, Keele, United Kingdom
Background: English health policy on prevention focuses predomi-
nantly on major diseases. Various documents detailing self-manage-
ment and prevention of osteoarthritis (OA) exist, including NICE
guidelines and the Arthritis Foundation’s National Public Health
Agenda for Osteoarthritis. Yet, few studies explore preventative
knowledge of knee OA amongst the population. In particular, asympto-
matic members of the population may provide further information in
considering how to prevent knee pain. This study aims to explore
perceptions around the prevention of knee pain amongst an
asymptomatic population, which may provide further insights for
stimulating preventative behaviours.
Methods: A semi-structured interview study of 28 people detailed their
views on prevention of knee pain, and a sub-sample of thirteen
patients without current knee pain were selected from this larger
sample. Interviews were tape recorded and fully transcribed.
Qualitative computer software package NVivo2 was used to manage
the data. Thematic analysis was conducted using the constant
comparative method.
Results: Participants interpreted the definition and causes of knee
pain in a variety of ways. The importance of prevention was recognized
by a sub-set, while a small proportion of individuals denied the role of
prevention. Early adoption and a range of social factors influenced the
implementation and continuation of preventative behaviours. Individual
responsibility for prevention was a principal theme. Exercise was
recognized as a key preventative strategy, but not all participants
viewed exercise in a beneficial way. Some participants deemed
pharmacotherapy to be harmful, and preferred to adopt preventative
behaviour.
Conclusions: Our asymptomatic population demonstrated consider-
able breadth of knowledge around preventative strategies for knee
pain, and similarities in perceptions of prevention exist within
the symptomatic population. These include emphasis on individual
responsibility, and considerations on the role of exercise and
pharmacotherapy in knee pain. When individuals consult they are
willing to act upon recommended treatments as per NICE guidance,
and this suggests the potential of widening preventative strategies in
order to improve the musculoskeletal health in the general population.
Disclosure statement: All authors have declared no conflicts of
interest.
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11. CONCURRENT VALIDATION OF THREE NOVEL ACTIVITY
MONITORS IN PATIENTS WITH RHEUMATOID ARTHRITIS
Michael R. Backhouse1,2, Derrick White2, Elizabeth Hensor1,2, Anne-
Maree Keenan2, Philip Helliwell1,2 and Anthony Redmond1,2
1Section of Musculoskeletal Disease, University of Leeds, Leeds,
United Kingdom; 2NIHR Leeds Biomedical Research Unit, University
of Leeds, Leeds, United Kingdom
Background: Physical activity is a frequently reported outcome in
rheumatology and a key concern to patients yet it is difficult to
objectively measure outside the gait lab. A new generation of activity
monitors offers the potential to objectively measure activity as well as
temporal & spatial gait parameters but these have only been validated
in healthy populations. This study aimed to evaluate a new generation
of activity monitors in patients with RA.
Methods: Three activity monitors: Activ4Life Pro V3.8 (A4L), Step-N-
Tune, and the Intelligent Device for Energy Expenditure and Activity
(IDEEA) were concurrently tested in patients with RA and in a healthy
control group. Participants walked at a self selected speed for a two
minute period and were filmed for later review. Temporal and spatial
gait parameters were validated using the GAITRite instrumented
walkway and total step counts compared to a gold standard derived
from a mean of three manual step counts from half speed video
replays.
Results: Data were collected on 12 RA pts [2 Male, 10 Female; mean
(SD) age 51.6 (18); BMI 31.1 (7.1); disease duration 18 (13.4); median
(IQR) DAS28 5.02 (3.76 to 5.75); HAQ 1.5 (1.0 to 2.13)] and 12 healthy
controls [6 Male, 6 Female; mean (SD) age 41.6 (9.8); BMI 23.4 (2.8)].
RA patients took fewer steps than the control group during the study
period according to the gold standard [mean (SD) RA: 159.50 (19.2);
Controls: 221.75 (19.21)]. Activity monitor performance varied between
devices but all showed decreased performance in the RA group (see
Table 1). Bland-Altman plots demonstrated wider 95% limits of
agreement in the RA group and a systematic increase in agreement
between activity monitors and the gold standard with increasing
functional ability. Agreement between the GAITRite walkway and
activity monitors was less uniform for temporal & spatial gait
parameters but again showed marked differences between disease
groups.
Conclusions: Despite some variation between devices, the activity
monitors tested performed reasonably well in healthy young volun-
teers. All except the A4L showed a marked decrease in performance in
patients with RA suggesting A4L could be the most suitable for use in
this patient group, although further work is needed to assess its use in
real world situations. The marked between group variation, and
systematic increase in device performance with improving gait,
indicate that activity monitors must be validated in target clinical
populations before they can be used in clinical studies.
TABLE 1 Regression based Bland-Altman 95% limits of agreement between activity
monitors and the video gold standard
RA Control
Step-N-Tune y¼221.59þ 1.11x89.46 y¼ 8.71 - 0.011x 11.94
A4L y¼44.14þ 0.38x 27.88 y¼5.25þ 0.13x 23.16
IDEEA y¼280.84þ 1.53x119.32 y¼31.47þ 0.05x32.42
y¼ interceptþ (slope*x) 95% limits of agreement x¼mean of gold standard and
test measurements intercept <0 and slope >0¼ agreement increases with mean
step count
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Disclosure statement: A.R., D.W.: The A4L data was derived under
the terms of a non-disclosure agreement between the company and
university which protects the proprietary intellectual property asso-
ciated with the computer algorithms used to derive step count data.
A4L provided devices for the study but no commercial benefits arose
from the agreement. All other authors have declared no conflicts of
interest.
12. FACTORS ASSOCIATED WITH ADHERENCE IN
RHEUMATOID ARTHRITIS
Anna M. Ferguson1, Abdel Douiri2, David L. Scott1 and Heidi Lempp1
1Academic Rheumatology, King’s College, London University,
London, United Kingdom; 2Department Of Primary Care And Public
Health Sciences, King’s College London, London, United Kingdom
Background: Adherence to medication is a key challenge for patients
with rheumatoid arthritis (RA) and those clinicians working with the
patient population. Current research suggests that less than 50% of
patients adhere to their medication. We have prospectively evaluated
those factors which are associated with adherence. Our overall goal is
to identify patients most likely to benefit from interventions to improve
adherence.
Methods: We studied 125 patients from a cross-sectional study
evaluating patients attending an outpatient rheumatology clinic.
Questionnaires assessed their beliefs about illness and medication,
disability and quality of life. Medication adherence was assessed using
the 5-item self-report Medication Adherence Rating Scale (MARS).
Patients with MARS scores of 23 and under were classified as poorly
adhering to their medications. Factors associated with poor adherence
to medication were investigated using a multivariate logistic regression
model. To determine the strength of associations between predictors
and poor adherence to medications, stepwise logistic regression
analysis was employed.
Results: Fifty-two percent of patients had sub-optimal adherence
(MARS 24 or less); the prevalence of poor adherence was 34%. A
dominant factor associated with better adherence was older age (odd
ratio (OR):0.92, 95% CI [0.88-0.95]). Other significant associations with
good adherence included patients viewing their medication as
‘necessary’ (OR: 0.88, 95% CI [0.79-.0.98]) and high levels on the
subdomain of energy and vitality on the SF-36 (OR: 0.96, 95% CI
[0.94-.0.99]). Poor adherence in contrast was associated with stronger
illness identity (OR: 1.3, 95% CI [1.03-1.64]) and worse general health
status scores on the SF-36 (OR: 1.03, 95% CI [1.004-1.063]).
Conclusions: Poor adherence was associated with patients who were
younger, those who did not see their medications as necessary,
patients who rated their general health as lower and reported higher
levels of fatigue. This research can help clinicians to identify patients at
risk of lower adherence to their RA medications as well as patients
who would benefit from appropriate interventions.
Disclosure statement: All authors have declared no conflicts of
interest.
13. HEALTH PROFESSIONALS’ PERCEPTIONS OF THE
EFFECTS OF EXERCISE ON JOINT HEALTH IN RHEUMATOID
ARTHRITIS PATIENTS I: A QUESTIONNAIRE STUDY
Serena Halls1, Rebecca-Jane Law1, Jeremy Jones1,2,
David Markland1, Peter Maddison1 and Jeanette Thom1
1School of Sport, Health and Exercise Sciences, Bangor University,
Bangor, United Kingdom; 2Rheumatology, Betsi Cadwaladr
University Health Board, Bangor, United Kingdom
Background: Exercise is an important factor in the treatment and
management of RA. Our previous research has indicated that RA
patients perceive that health professionals lack certainty and clarity
regarding exercise in RA management and its relationship to joint
damage (Law et al., 2010). Therefore we set out to investigate
perceptions of health professionals regarding the effects of exercise
on joint health in RA patients using a questionnaire.
Methods: The online questionnaire included a brief introduction
followed by 3 questionnaire sections. Section 1 incorporated demo-
graphics questions. Section 2 included a measure of participants’
current physical activity levels (IPAQ). Section 3 included 40 items
concerning participants’ thoughts about exercise and RA patient joint
health. Questionnaires were distributed via professional networks and
websites, and sent to rheumatology HPs identified from the BSR
handbook. Confirmatory factor analysis (CFA) was conducted and
total percentage responses for each theme were calculated. One-way
ANOVAs were conducted on each of the variables of practitioner
category, IPAQ classification, age, gender and location of practice.
Results: 137 rheumatology HPs (95 females, 42 males; 76 rheumatol-
ogists, 24 nurses, 18 physiotherapists, 10 occupational therapists,
9 other HPs; age: 27-65 years) completed the questionnaires.
Following removal of four items with low factor loadings CFA
showed that a four factor solution provided an acceptable fit to the
data (SB 2¼863.04, df¼588, p<0.000, RMSEA¼ 0.06, CFI¼0.93,
SRMR¼0.094). The factors were: 1. HPs lack of exercise knowledge;
2. Worry about causing harm to joints; 3. Not wanting to recommend
exercise as patients are in pain; 4. Having to recommend exercise
because it is helpful. Large percentages of respondents strongly
disagreed or disagreed with factors 1, 2 and 3 with responses of 78%,
86% and 90%, respectively. Only 63% of respondents strongly agreed
or agreed with factor 4. These responses varied depending on
practitioner category only.
Conclusions: HPs believed they did not lack exercise knowledge, they
mostly did not worry about exercise causing harm to joints and did not
avoid recommending exercises to patients due to concerns about
pain. This is in direct contrast to our findings about the perceptions of
RA patients (Law et al., 2010). However, only two-thirds of HPs felt that
exercise was helpful for RA patients. Further qualitative research is
required to investigate the differences between RA HPs and patients
and the underlying reasons for this in greater detail. Variation in the
responses from the different practitioner categories also need to be
investigated further so that education and resources can be provided
where appropriate.
Disclosure statement: All authors have declared no conflicts of
interest.
14. CARTILAGE TURNOVER, SYSTEMIC AND SYNOVIAL
INFLAMMATION: THE ACUTE RESPONSE TO HIGH-
INTENSITY AEROBIC AND RESISTANCE EXERCISE
Rebecca-Jane Law1, Jeanette M. Thom1, Peter Maddison1,
Anne Breslin2 and Alexandra Kraus3
1School of Sport, Health and Exercise Sciences, Bangor University,
Bangor, United Kingdom; 2Rheumatology, Betsi Cadwaladr
University Health Board, Bangor, United Kingdom; 3Radiology, Betsi
Cadwaladr University Health Board, Bangor, United Kingdom
Background: Continued, high-intensity exercise has been shown to
be safe and effective for patients with rheumatoid arthritis (RA).
However, the potential detrimental effects for large weight-bearing
joints have previously been highlighted and the effects of exercise per
se are unknown. Furthermore, research suggests that patients are
concerned about the effects of exercise on joint health. Therefore, to
enhance the information available for this population, our aim was to
investigate the acute effect of high-intensity aerobic and resistance
exercise on cartilage turnover, synovial and systemic inflammation.
Methods: 8 stable RA patients (age: 60 12 years; disease duration:
19 12 years; meanSD) with a history of knee symptoms and 8 age
and gender-matched, healthy control participants performed two
types of exercise (aerobic and resistance), one week apart. The
aerobic exercise session involved 30 minutes walking including 4
intervals of 3 minutes at 70-90% of maximum heart rate (MHR) and
2 minutes at 50-70% MHR. The resistance exercise session involved 3
sets of 8 repetitions at 80% of 1 repetition-maximum of three lower
body exercises; leg press, leg extension, leg curl. The main outcome
variable was serum cartilage oligomeric matrix protein (COMP), a
biomarker of cartilage turnover. Both knees were assessed for synovial
inflammation using colour Doppler ultrasound and colour fraction (CF)
was determined for quantitative analysis. Serum CRP provided a
measure of systemic inflammation. Blood samples and US assess-
ments were taken prior to, immediately following and 30 minutes, 1
hour, 2 hours, 6 hours and 24 hours post-exercise. Mixed model
ANOVA with repeated measures was used for statistical analysis.
Results: Baseline COMP and CRP were significantly higher in the RA
group (CRP: 16.2 17.3 mg/L; COMP: 1359381.9 ng/ml) when
compared to the healthy control group (CRP: 1.3 1.2 mg/L; COMP:
1179446.3 ng/ml; p¼ .046 and p> 0.00, respectively). However,
there were no significant differences in serum COMP or CRP between
the time points after either the resistance or aerobic exercise session.
There were no clinically significant levels of synovial inflammation prior
to exercise and no change in CF for either group following both
exercise conditions. Furthermore, patients were able to tolerate high-
intensity exercise of both types.
Conclusions: Cartilage turnover, synovial and systemic inflammation
showed no statistically or clinically significant changes in the 24 hours
following 30 minutes of high-intensity aerobic or resistance exercise.
This preliminary research offers further confirmation that high-intensity
exercise is not detrimental to joint health in patients with inactive RA.
These findings will help facilitate the transfer of positive information
relating to exercise and joint health. Further research will determine if
continued high-intensity training affects the acute response to
exercise.
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15. THE CONTINUING NEED OF BME COMMUNITIES FOR
ARTHRITIS EDUCATION
Chandrika Gordhan1,2, Sean Dennis1, John Connor1,
Bhavani Chowdhary1, Neena Lottay1, Parmjit Juneja1 and
Paul A. Bacon2,1
1Birmingham Arthritis Resource Centre, Birmingham Central Library,
Birmingham, United Kingdom; 2Rheumatology, University of
Birmingham, Birmingham, United Kingdom
Background: Public ignorance about arthritis is widespread, despite
its frequency. Our needs assessment a decade ago revealed a huge
local desire for more information in plain English and in languages
relevant to our large BME communities (1/3rd of population).
Birmingham Arthritis Resource Centre was set up to meet this need
and together with City Hospital provides multi-lingual educational
material (including audio CD’s and a web site) plus personal support to
local and phone callers. The extent to which this meets current
community needs or the drive for early arthritis diagnosis was
assessed in 2 new surveys.
Methods: 500 people entering the Birmingham Central Library foyer
completed a survey to explore their interest in arthritis and need for
further information. A second survey assessed the extent of public
health education available to BME groups. A team of BARC volunteers
screened 4309 articles over a 3/12 period in the 5 available Asian
language newspapers (ALP) versus 10 English dailies (EN) for arthritis-
related articles. 4/10 EN and 4/5 ALP ran health articles, often weekly.
Results: 1.Library Survey respondents ranged from age 16 to 76,
majority< 50 years. Half were Caucasian and half came from 11 BME
groups (including 35% S. Asians). 87% had some direct interest in
arthritis; 33% recorded a personal arthritis problem while 54% were
carers for a sufferer. 86% wanted a service providing arthritis
education and support available in the emerging new city library.
2.The newspaper survey included 1638 ALP versus 1496 EN articles.
The percentage of health to total articles was fairly similar (3.5% in ALP
v 5.7%) but with several important differences. 1. Choice: EN offer >4
dailies for readers but ALP only one per language - leaving several
local ethnic groups with no newspaper they could read. 2. Length:
most ALP have very brief health articles (100–200 words), compared to
substantial ones (>1000w) in EN. 3. Content: 60% of health features in
ALP are on herbal remedies, unlike EN. In addition >10 health
magazines in English exist at Central library but none for ethnic
communities. Here only 0.9% of 1172 features scanned related to
arthritis, which was even more uncommon across newspapers -
0.33% of total EN but only 0.12% of ALP articles. Prominent press
reports on the RA session at the 2010 British Science Festival featured
in 7 national plus 4 regional EN - but no ALP. Similiarly, 6 locally-active
arthritis support groups operate only in English.
Conclusions: Ignorance about arthritis persists even among people
complaining of arthritis and their carers. This is particularly marked
among BME groups who often hold concepts of arthritis very different
to the western medical model. Both journal information in their own
language and community support are lacking for these groups. There
is a continuing need for community education provided by voluntary
groups collaborating with health professionals in this area, in line with
the new WHO focus on non-transmissible diseases.
Disclosure statement: All authors have declared no conflicts of
interest.
16. MEASURING THE RESPONSE OF EXTRA-HEPATIC
SYMPTOMS AND QUALITY OF LIFE TO ANTIVIRAL
TREATMENT IN PATIENTS WITH HEPATITIS C
David Isaacs1, James Jack2, Majella Keller2, Jeremy Tibble2 and
Inam Haq1
1Brighton & Sussex Medical School, Brighton, United Kingdom;
2Medicine, Royal Sussex County Hospital, Brighton, United Kingdom
Background: Hepatitis C (HCV) infection is associated with muscu-
loskeletal manifestations such as chronic widespread pain, sicca
syndrome, polyarthritis and a reduced health-related quality of life
(HRQOL). Little data is available on the effect of treatment on these
manifestations. This study measured changes in extra hepatic symp-
toms before and after antiviral treatment in a large UK patient cohort.
Methods: 93 patients with HCV treated at the Royal Sussex County
Hospital completed standard antiviral treatment with pegylated
interferon and ribavirin and had also answered the hepatitis quality
of life questionnaire (HQLQ) and a survey of symptoms affecting the
spine, muscles, bones and joints before treatment and six months
after finishing treatment. Outcome measures included presence/
absence of chronic widespread pain (CWP) according to the
Manchester criteria, pain intensity and impact as scored on a visual
analogue scale (VAS), and a subjective reporting of sicca symptoms
using questions from the Vitali questionnaire. Pre and Post treatment
results were compared and tested against patient demographic data
and serological markers such as presence/absence of sustained viral
response (SVR) to treatment and rheumatoid factor.
Results: There was a statistically significant improvement in scores in
the following 6 out of the 12 domains of the HQLQ: Physical
functioning, Physical disability, Social functioning, Limitations due to
hepatitis, Health distress due to hepatitis, and General health. There
was a statistically significant decline in 3 of the domains (Positive well
being, Health distress, and Mental health), and no significant change in
the rest of the domains (Body pain, Motivation, and Vitality). There was
a statistically significant decline in the level of pain reported by patients
on the VAS before and after treatment (mean start score 3.4/10
versus mean end score 2.8/10, p¼0.029). Scores of CWP and sicca
symptoms showed improvement without statistical significance. There
were positive associations between SVR and changes in all HQLQ
scores excluding General health, Vitality and Mental health, as well as
positive associations between SVR and changes in CWP and the
number of painful joints, but these were not statistically significant.
A high rheumatoid factor was slightly more prevalent in people with
pre-treatment CWP (31.2%) than in those without CWP (24.5%), this
was not significant.
Conclusions: Antiviral therapy with interferon and ribavirin significantly
improves both HRQOL and pain symptoms in HCV patients. This
suggests a role of the virus in contributing to musculoskeletal
symptoms. Further work with larger numbers of patients and longer
follow-up is needed.
Disclosure statement: All authors have declared no conflicts of
interest.
17. DEVELOPMENT OF THE EVALUATION OF DAILY
ACTIVITY QUESTIONNAIRE IN MUSCULOSKELETAL
CONDITIONS: PHASE ONE
Alison Hammond1, Rachel Gill1, Sarah Tyson1, Alan Tennant2 and
Ulla Nordenskiold3
1Centre for Health Sciences Research, University of Salford, Salford,
United Kingdom; 2Academic Rehabilitation, University of Leeds,
Leeds, United Kingdom; 3Rehabilitation Medicine, Sahlgrenska
Academy, Goteborg, Sweden
Background: The Evaluation of Daily Activity Questionnaire (EDAQ) is
a comprehensive patient reported outcome measure of activity/activity
limitations [1]. It was developed in Sweden and is used in Occupational
Therapy for clinical, audit and research purposes. We have already
revised this for the UK and tested its reliability and validity in
rheumatoid arthritis (RA). It now includes 14 sub-scales of personal
and instrumental activities of daily living (with 6-14 activities in each;
138 in total). We now aim to test its psychometric properties in six
other musculoskeletal conditions. In Phase 1 we are identifying
whether or not people with these conditions consider these 138
activities are also important to include.
Methods: Cognitive debriefing interviews were conducted with people
with either of these six musculoskeletal conditions. Participants
completed the UK-EDAQ and rated items for inclusion on a 1¼not
to 5¼ very important scale. Items were considered for exclusion if
rated <3. Participants were also asked to identify if there were any
other activities causing difficulty which should be included. If two or
more participants suggested the same activity, these were considered
for inclusion.
Results: Forty participants (28 women: 12 men) were recruited from
five rheumatology departments. Their mean age was 55.22 years
(range 19-85); mean condition duration 11.98 years (SD 9.29); modified
HAQ score¼ 0.75 (SD 0.66). Participants were diagnosed with:
osteoarthritis (n¼11), ankylosing spondylitis (n¼ 6); systemic lupus
erythematosus (n¼10), systemic sclerosis (n¼4); chronic pain (n¼5)
or a chronic hand condition (e.g. carpal tunnel, de Quervains, n¼4).
No items were rated < 3; 34/138 were rated as 3; 97/138 as 4; and 7/
138 as 5. Some activities were rated as <3 by people in specific
condition groups. A further 32 activities were suggested by 13
participants. Only four activities were suggested by two or more
participants. These could be integrated into existing items: using a
mobile (added to ‘‘using a phone’’); managing wood burners/fires
(added to ‘‘manage heating’’); handling cards/using ATM (added to
‘‘handle money’’); and bicycling (added to ‘‘doing physical activities,
eg dancing, active sports, swimming’’).
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Conclusions: The UK-EDAQ content was appropriate for people with
these musculoskeletal conditions. The next stage will be to test the
reliability and validity of the assessment in these six conditions.
Disclosure statement: All authors have declared no conflicts of
interest.
Reference
1. Nordenskiold U, Grimby G, Dahlin-Ivanoff S. Questionnaire to
evaluate effects of assistive devices and altered working methods
in women with rheumatoid arthritis. Clinical Rheumatology
1998;17:6–16.
BHPR: CLINICAL EVALUATION AND
AUDIT DELIVERY
18. AUDIT: ARE POTENTIAL REACTIVE ARTHRITIS
PATIENTS SCREENED FOR A SEXUAL AETIOLOGY?
Emily E. Pease1 and Colin T. Pease1
1Rheumatology, Chapel Allerton Hospital, Leeds, United Kingdom
Background: The most common cause of a sexually acquired reactive
arthritis (SARA) is chlamydia, affecting 5-10% of sexually active people
<24 years in the UK. There are no internationally validated diagnostic
criteria or guidelines to aid in the investigation of reactive arthritis
(ReA), potentially leading to inconsistencies in patient management. In
2008, the British Association of Sexual Health and HIV (BASHH)
published guidelines on SARA, recommending all patients suspected
of ReA are screened for sexually transmitted infections (STIs). BASHH
recommends asymptomatic screening should involve a first pass urine
test in males and either a cervical or vulvo-vaginal swab in females, for
whom urine specimens are inadequate. Vulvo-vaginal swab can be
self-taken. Symptomatic patients should be referred to genitourinary
medicine. This audit aimed to establish whether patients <30 years
referred to a Teaching Hospital Rheumatology Department were
screened for STIs if they potentially had a ReA, which screening tests
were used and which other investigations were routinely carried out.
Methods: The 2008 BASHH guideline on the management of SARA,
as well as the revised 2010 chlamydia guidelines were referred to as
audit standards. Data collection was retrospective using the first clinic
letter and hospital results server. All new patient referrals <30 years
old to any general or early arthritis clinic in the preceding 6 months
were audited.
Results: 244 patients were referred of which 202 had a clear
alternative diagnosis and 42 had a potential ReA and audited further.
The most common presenting complaints of these included: back
pain/stiffness, n¼22; oligoarthritis (any joint) n¼14; monoarthritis (any
joint) n¼11. Some patients had multiple presenting complaints. In
total, 10/42 (24%) were screened for an STI, all were negative. Of
these, 6 were female, 83% (n¼ 5) of which were tested with urine
samples. Therefore, only 5/42 patients (12%) were screened using the
correct test. In patients with high risk ReA (lower limb only mono/oligio
arthritis, n¼19), 5/19 (26%) were tested for an STI. Other investiga-
tions carried out included: HLA B27, 16 tested, 6 positive (38%);
Rheumatoid Factor, 30 tested (all normal); Anti CCP, 29 tested (all
normal).
Conclusions: SARA may be an under-recognized diagnosis, due to
reluctance from both the patient and the rheumatologist to discuss
and investigate such matters, but also due to high rates of
asymptomatic chlamydia. Less than a quarter of patients had an STI
screen and a ‘high risk’ presentation commonly failed to prompt
screening. There was a reliance on urine samples for testing chlamydia
which does not offer acceptable specificity or sensitivity in females.
The audit also revealed a large variation between clinicians as to the
baseline investigations performed and coupled with inadequate STI
screening this demonstrates the need for national guidelines for this
disease.
Disclosure statement: All authors have declared no conflicts of
interest.
19. CONNECTIVE TISSUE DISEASE SERVICE IN A DISTRICT
HOSPITAL: ARE WE ACHIEVING QUALITY OF CARE?
Anne Trehane1, Fouz Rahmeh1, Patricia Cornell1 and Sarah
L. Westlake1
1Rheumatology, Poole Hospital NHS Trust, Poole, United Kingdom
Background: Connective Tissue Diseases (CTD) are a group of
rheumatological conditions characterized by multi-organ inflammation
and autoimmunity, though uncommon they have a significant impact
on a persons quality of life and can be life threatening. The Department
of Health has suggested people with long term conditions should be
treated within their locality, with access to more tertiary services if
needed. A District General Hospital (DGH) can meet these criteria
by ensuring patients with these chronic debilitating conditions can
have specialist care provided locally with access to a multi speciality
team (dermatology, respiratory, gastroenterology etc). Arthritis and
Musculoskeletal Alliance (ARMA) developed a set of standards of care
for people with CTD’s in response to evidence that showed peoples
experiences and quality of care varied widely across the UK
depending on their local services (1). We decided to audit our service
against the ARMA standards of care for Connective Tissue Disorders
to evaluate our service.
Methods: A Trust approved questionnaire based on nine of the
relevant standards set out by ARMA was given to all adult patients
attending the connective tissue clinic during a 3 month period. The
questionnaires were anonymous and collected in a box. The
questionnaires were analysed using excel.
Results: 37 completed questionnaires were received during the
3 month period. Demographics were M:F 1:5, mean age was 56 yrs.
The CTD’s included SLE, olymyositis, CREST, scleroderma, Sjo¨gren’s,
temporal arteritis, Raynaud’s and PMR. 95% of patients strongly
agreed or agreed that their diagnosis was given with care and
sensitivity, 92% of patients either agreed or strongly agreed that their
needs were supported by the specialist connective tissue disease
clinic.
Conclusions: The audit demonstrates the ARMA standards of care
are met in the connective tissue service at this DGH. The results have
highlighted a need to raise awareness of support organizations and
cardiovascular risks to the patients with CTD although it was apparent
that patients didn’t realize that monitoring blood pressure, checking
weight and lipids addressed the issue of cardiovascular disease.
Lifestyle changes including smoking, exercise and weight control
needs to be reinforced at every clinic appointment.
TABLE 1 Results from audit of ARMA standards of care for CTD, n (%)
n¼ 37 Yes No N/A
Explanation of disease and prescribed
medication
37 (100) 0 0
Access to specialist doctor 37 (100) 0 0
Access to specialist nurse/practitioner 35 (95) 1 (2.5) 1 (2.5)
Appointment time long enough 37 (100) 0 0
Information given about support
organizations
29 (78) 8 (22) 0
Aware of increased risk of cardiovascular
disease
24 (65) 12 (32.5) 1 (2.5)
Information on telephone advice line 35 (95) 2 (5) 0
Lifestyle advice 31 (84) 6 (16) 0
Advice on work/daily activities 35 (95) 2 (5) 0
Risk/benefits of non-prescribed medication 31 (84) 6 (16) 0
Disclosure statement: All authors have declared no conflicts of
interest.
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20. MONITORING IGG FOLLOWING RITUXIMAB THERAPY
FOR RHEUMATOID ARTHRITIS
Katy Rose1, Catherine Fouad Alber1, Liam Watson1,
Richard Stratton2,1 and Mark Lazarus2
1Medical School, UCL, London, United Kingdom; 2Rheumatology,
Royal Free Hospital, London, United Kingdom
Background: To investigate whether IgG levels are being monitored in
patients receiving Rituximab (RTX) therapy for Rheumatoid Arthritis
(RA) according to the recently published BSR guidelines and if there is
a relationship between IgG levels and the incidence of severe
infections.
Methods: An audit was carried out of 35 RA patients who had been
given RTX therapy since 2005. The dates of first infusion, numbers of
infusions and frequency of IgG monitoring were collated. In addition,
the incidence of severe infections leading to hospital admission and/or
death was examined.
Results: Of the 35 patients 27 (77%) were female and 8 (23%) male,
the mean age was 55.7 years and 28 (80%) were white. Thirty-two
(91%) patients had received previous anti-TNF therapy. The mean
duration of follow up was 18.5 months. Twenty-nine patients (83%)
had an IgG level measured at any point since 2005. Ten (29%) had an
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IgG level measured 3 months prior to infusion. Although 17 (49%) had
IgG levels measured after initiation of RTX therapy only 6 (17%) were
measured within 4-6months after RTX therapy, and only 1 (3.5%) had
IgG levels measured both before and 4-6 months after RTX therapy as
per BSR guidelines. There were 4 incidences of severe infection; an
infection rate of 7.3/100 patient years. None of the patients who
suffered a severe infection had low IgG levels (defined as <6 g/L).
However, 3 of the 4 patients had IgG levels <8 g/L and all 4 had IgG
levels <12 g/L. Of these four patients, 3 also had a history of cardiac
and/or respiratory disease.
Conclusions: The audit shows that there was insufficient awareness
of the need to monitor IgG levels following RTX therapy, with only one
patient having their IgG levels monitored as per the BSR guidelines.
However, the data in the audit were generated prior to the publication
of the guidelines. The patients who developed severe infections were
not found to have an IgG level below the minimum threshold
recommended by the BSR guidelines (<6 g/L) but did have other risk
factors for infection associated with RTX therapy. Our study therefore
suggests that, in addition to low IgG levels, attention must also be paid
to these risk factors, in particular cardiac and respiratory disease.
More research is needed to determine the appropriate minimum IgG
threshold for RTX therapy in patients with such co-morbidities. RTX
therapy has similar short-term infection rates as other biologic
therapies but due to the potential for irreversible hypogammaglobu-
linaemia that has been reported following RTX therapy more care may
be necessary in high risk patients. Consideration should be given to all
of the potential risk factors for infection and complications that are
associated with RTX therapy before recommending its use in patients
with RA who do not respond to anti-TNF therapy. There should also be
greater awareness of the need to monitor IgG levels after commencing
RTX therapy.
Disclosure statement: All authors have declared no conflicts of
interest.
21. A SERVICE EVALUATION OF A PHYSIOTHERAPY
EXTENDED SCOPE PRACTITIONER COMMUNITY-LED
INJECTION SERVICE
Natasha E. McNeilly1,2 and Jackie Waterfield2
1Musculoskeletal Service, Solihull Community Services (HEFT),
Solihull, United Kingdom; 2Physiotherapy, Keele University, Keele,
United Kingdom
Background: Musculoskeletal pain is a common problem seen in the
community, which injections can be effective in treating. The NHS
drive to maintain quality of care, whilst reducing costs, has
encouraged traditional medical procedures to be undertaken by ESP
physiotherapists. In the current NHS climate, it is vital that this service
proves that it is meeting the needs of patients and its commissioners
ensuring that the service continues to be funded.
Methods: The two main aims were i) to determine if the physiotherapy
ESP community-led injection service meets the needs of patients and
achieves a good clinical outcome (by decreasing pain and increasing
function) and ii) to assess overall patient satisfaction. All patients
attending the service, across seven community clinic sites in the
Solihull Borough between July and September 2011, were invited to
participate. The evaluation involved a two stage questionnaire: stage
one administered at the injection clinic and stage two, a postal
questionnaire completed two weeks after the injection. In an attempt
to increase the response rate to stage two, a stamped addressed
envelope was enclosed with the questionnaire and a reminder letter
was sent to patients two weeks after the stage two questionnaire was
sent. The results were analysed using Microsoft Excel 2007, with
statistical significance set at p 0.05.
Results: In stage one of the service evaluation 75 patients were
recruited, with 50 patients (66.67%) responding to stage two. The
most commonly injected site was the knee (51%). Interferential
statistic calculations were based on only patients who completed
both stages of the quesetionnaire (n¼ 50).There was a statistically
significant decrease in pain post injection (p¼ 0.00000003), with the
mean change of VAS score being 2.29. There was no statistically
significant change between pre- and post- injection function with all
functional activities (p¼ 0.423). A possible reason for the lack of
functional change may be due to the chronicity of some of the
conditions injected and also due to existing co-morbidities. Patients
were happy with both the waiting time for (83%) and the location of
(96%) their appointment and 86% of patients would like to self refer to
the service. Patients were happy with the ESP consultation and felt
they received sufficient explanation (88%), had sufficient involvement
in decision making (96%), had enough time with the ESP (100%), and
had opportunity to ask questions (100%). Overall, 94% of patients said
they would use the service again if required and 92% of patients were
either very satisfied (64%) or satisfied (28%) with the service.
Conclusions: This service evaluation demonstrates that this service is
meeting its aims. This study provides new information on what a
physiotherapy ESP community- led injection service can provide.
This type of service is clearly considered valuable by patients. The
results of this service evaluation will be used to improve patient care.
Disclosure statement: All authors have declared no conflicts of
interest.
22. POST-OPERATIVE REHABILITATION PROVIDES AN
UNMET NEED FOR BETTER PATIENT SUPPORT AND ADVICE
FOLLOWING LUMBAR SPINAL FUSION
Mike Hurley1 and James Greenwood2
1School of Rehabilitation Sciences, St George’s, University of
London, London, United Kingdom; 2Physiotherapy Department,
University College Hospital, London, United Kingdom
Background: In the absence of evidence-based post-operative
rehabilitation, following fusion surgery for severe persistent low back
pain, people receive advice to rest for 3 months then progressively
resume normal function. Such unclear, generic advice is unhelpful, and
post-operative recovery may be delayed or suboptimal. We introduced
a structured post-operative rehabilitation programme of individualized
progressive exercise and self-management advice for people who had
undergone lumbar fusion. We wanted to evaluate how helpful
participants found the program.
Methods: 15 patients attending follow-up appointments were asked
about their concerns, experiences, perceptions and needs. Four
patients on the programme (small group, once a week for 10 weeks)
were asked if and how the programme helped them. The main themes
that emerged were documented.
Results: Patients primarily reported concerns about musculoskeletal
or psychosocial issues rather than technical surgical problems, e.g.
residual pain and disability, how to reduce analgesia, when to resume
certain activities, etc, but complained of a lack of advice and support.
The programme enabled access to a healthcare professional who
could fully address people’s concerns ‘‘. . .my GP said to ask my
consultant but I never get to see him, so it is great that I can ask you . . .’’
Four areas raised most concerns:
 Residual symptoms: People didn’t know what to expect and
presence of residual symptoms concerned them ‘‘. . . if the opera-
tion was a success why do I still have pain . . .’’.
 Prognosis: They wanted to know what would happen ‘‘. . .will this
metalwork wear out . . .will it have to come out . . .’’. The programme
allowed them to ask questions and learn from others ‘‘. . . I am glad
to hear that exercise will not cause my spine to wear out. The others
in the class have helped me see that I can get better . . .’’.
 Physical function: People were keen to return to more normal
physical function but were unsure what to do, how and when
‘‘. . . they told me to gradually increase my activity, but which activity
and when . . .’’.
 Comorbidity: People were unclear how comorbidity might affect
outcome ‘‘. . . how does my diabetes affect exercise . . .’’ ‘‘. . .my
neck hurts as well . . .’’ but advice was lacking, unhelpful or
impractical. The program gave individuals specific advice and
they experienced benefits first-hand ‘‘. . . the consultant just kept
telling me to walk, but my knee hurt and I was scared. It is so helpful
that you can help me manage all of these problems . . .’’.
Conclusions: There is a need for better support to answer concerns
that cause distress, anxiety and may impede post-operative recovery.
Surgeons are primarily concerned about infection, implant failure, etc.
Our post-operative rehabilitation program improved access to health-
care professionals who gave advice and support that might improve
outcome. The programme warrants more thorough evaluation.
Disclosure statement: All authors have declared no conflicts of
interest.
23. SELF-REFERRAL TO RHEUMATOLOGY
PHYSIOTHERAPY: A VITAL COMPONENT OF
SELF-MANAGEMENT
Ann M. Clayton1,2, Michael Lynch1, Adrian Clewes1, Julie Dawson1,
Veronica Abernethy1 and Ann E. Griffiths1,2
1Rheumatology, St Helens & Knowsley Teaching Hospitals,
St Helens, United Kingdom; 2Secondary Care Therapy Service,
KIPS at 5 Boroughs Partnership, St Helens, United Kingdom
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Background: Nurse Advice Lines have been a long accepted practice
in Rheumatology. At St. Helens Hospital we expanded this to a
Therapy Advice Line, and noticed an increasing tendency for self
referral by our patients. From working parties on management of Early
RA and Stable RA we emphasized our self referral facility to
patients.NICE Guidelines (section 1:3) recommends ongoing access
to SPECIALIST Physiotherapy and Occupational Therapy. ARMA
(Arthritis and Musculoskeletal Alliance) Standard 2 encourages self
management, and Standard 6 recommends access to safe evidence-
based care and management. Our concern was whether the self
referrals were appropriate and relevant so this was the basis of our
investigation. The recent National Rheumatoid Arthritis Society (NRAS)
survey reported in October 2011 in a national newspaper, as well as
in professional publications, raised concerns around access to
SPECIALIST Rheumatology physiotherapy.
Methods: We audited physiotherapy self referrals between September
2010 and August 2011. We randomly selected 3 of these from each
month. They were then scored on relevance on a scale of: 0
(inappropriate) to 5 (wholly appropriate), from information provided in
discharge letters. The conditions covered and attendance rates were
noted.
Results: Self referrals per month varied between 7 and 22 out of total
monthly referrals between 39 and 89, which worked out as between
16% and 26% of the total referrals.
67% of referrals selected for investigation (36) were wholly
appropriate, each scoring 5. Only 2 scored 0; one patient cancelled
and one did not attend. Conditions reported as requiring treatment
included neck and back, shoulders, elbows, wrists, hips, knees, ankles
and feet. Attendance rates were excellent at 94%. It was encouraging
to discover that the details were available in all discharge letters, and
that the Physiotherapy correspondence reviewed was of a high quality.
Conclusions: Patients have become more aware of our self referral
facility. A variety of problems presented, which were felt to be largely
appropriate, with excellent outcomes and attendance. This suggests
that if patients know how physiotherapy can help them and are well
informed in this respect they can utilize this service to help manage
their long term condition. As outcomes were decided from information
in discharge letters, it highlighted the importance of recording
appropriate and relevant details in these communications.
In a speciality where we strongly encourage appropriate self
management, self referral is a vital component of this approach. This
method of accessing Physiotherapy is consistent with NICE guide-
lines, ARMA standars and NRAS recommendations.
Disclosure statement: All authors have declared no conflicts of
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24. DOES OUR TELEPHONE ADVICE LINE SERVICE MEET
CURRENT NATIONAL GUIDANCE?
Victoria A. Chamberlain1, YokeMei McLoughlin1, Sophie Campbell1,
Janita Hayes1, Claire Moffat1, Frank McKenna1 and Preeti Shah1
1Rheumatology, Trafford Healthcare NHS Trust, Manchester,
United Kingdom
Background: Current NICE guidance and recent reports advocate the
availability and value of a telephone advice line within rheumatology
services. A rheumatology advice line service has been available at
Trafford General Hospital for the last 20 years. It is manned by 4
Rheumatology Nurse Specialists (RNS) and has recently been
enhanced by the services of a clerk. This audit was undertaken to
identify:
 How many calls were answered directly.
 Who answered the call.
 Reason for the call.
 Resolution of the call.
 Level of patient satisfaction with the advice line service.
Methods: All patients who telephoned the advice line one or more
times during December 2010 were sent a questionnaire by post with a
covering letter explaining the aims of this survey and asking them to
answer it retrospectively. Verbal consent was obtained at the
resolution of each call. All responses were anonymous and only one
form was sent per patient.
Results: 104 questionnaires were posted to patients: 76 (73%) were
returned; 48 (63%) calls were answered directly, of which 37 (77%)
were answered by a RNS and 11 (23%) by the clerk. 18 (24%)
responders left a message on the answerphone, 8 did not answer this
question. Of the 18 callers who left a message on the answerphone, 13
calls were returned on the same day, 1 call within two working days
and 4 people stated that their call had not been returned. However
these 4 patients did state that their call had been resolved at least to
some extent. Reasons for calling the helpline were broken down as
follows:
 26% general questions or advice about their condition/medication;
 20% requesting repeat prescriptions;
 18% patients experiencing a flare of their arthritis;
 8% requesting blood forms;
 4% with an appointment query;
 24% other reasons, usually 2 or more of the reasons listed above.
The majority of these patients felt that their query had been
resolved in a timely fashion, 56% felt it had been answered
immediately and 19% of queries were answered once more informa-
tion was available. Only 1% felt that their query was not resolved. The
remainder felt a verbal response was not required as they were asking
for prescription and/or blood forms. Overall, 73 patients (99%) were
satisfied with the service they had received. Only one patient felt that
they would have liked more information. 44% of the total calls received
were for clinical reasons- either a flare or general advice on their
condition/medication. 12% of all calls received could be dealt with
directly by the clerk.
Conclusions: This audit demonstrates that calls are dealt with
promptly and with a high degree of patient satisfaction. Having a
clerk involved increases efficiency by releasing RNS time for clinical
duties. The telephone advice line meets current guidance by offering
an easily accessible point of contact for patients and their carers. It
also gives patients ongoing access to information and support both in
general and when experiencing a flare of their condition.
Disclosure statement: All authors have declared no conflicts of
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25. EVALUATION OF PRE-EXISTING PULMONARY DISEASE
IN RA PATIENTS INITIATING ANTI-TNF
Rizwan Rajak1, Ann Williams1, Ceril Rhys-Dillon1, Rhian Goodfellow1
and James C. Martin1
1Rheumatology, Cwm Taf Health Board, Llantrisant, United Kingdom
Background: Interstitial pulmonary fibrosis (IPF) can be a manifesta-
tion of rheumatoid arthritis(RA), side-effect of immunosuppressive
drugs eg methotrexate and, as is increasingly recognized, a
consequence of biologics especially anti-tumour necrosis factor
(aTNF). In our department, 2 RA patients treated with humira
developed aTNF induced IPF, one of whom had preexisting IPF prior
to starting therapy. We audited our practice of pretreatment lung
evaluation for the presence of existing lung disease in all our RA
patients who had commenced aTNF.
Methods: A retrospective audit was conducted on all RA patients who
started their first aTNF through the rheumatology dept of Royal
Glamorgan Hospital,Wales. 109 patients were identified. Data was
gathered relating to respiratory symptoms, smoking status, CXR
findings & any subsequent assessments requested.
Results: Data on 100 subjects was obtained. Subjects were
predominantly female (81%); mean age 55 yrs. Most patients(93%)
reported no respiratory symptoms prior to starting treatment. Of the 7
with symptoms, diagnoses were established in 5 cases (via chest
HRCT/lung function testing): 1 mild and 1 moderate IPF, 2 obstructive
pulmonary disease and 1 bronchiectasis. Most patients were non-
smokers (58%). Only 42% of patients had a CXR within 6 months
before commencing aTNF as per NICE guidance. 87% of subjects had
normal CXRs; of the remaining 13%, 7 correlated with abnormalities
on HRCT - 5 were the symptomatic patients, the other 2 were found to
have mild asymptomatic IPF and COPD. In total 3 cases had
preexisting IPF, 2 of whom were symptomatic, however all had
abnormal CXRs which compared with HRCT scanning.
Conclusions: The findings from the BSRBR show a poor prognosis of
aTNF induced IPF with an overall mortality of 1/3 which rises to 2/3 in
patients with preexisting IPF, however identifying those patients at risk
remains difficult. This audit shows that preexisting pulmonary disease
is uncommon. Screening prior to initiating aTNF revealed few patients
with symptoms or radiological abnormalities. Smoking exposure
correlated with those who had COPD but no other lung disease.
Clinically significant symptoms, that is symptoms that correlated with a
diagnosis, were only found in 5% of patients, and clinically significant
radiological findings, where CXR and HRCT abnormalities correlated
with a clear diagnosis, were only found in 6%. Of the 2 patients who
developed aTNF induced IPF, one subsequently died and the other
survived upon cessation of treatment but left with significant lung
morbidity. The patient who died had mild asymptomatic IPF but no
other obvious risk factors which could have helped to predict her risk
of developing aTNF induced IPF. The second patient who survived had
no symptoms, CXR abnormalities or any other risk factors to predict
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her risk. More parameters, whether clinical or biological, are needed to
help stratify patients who are at risk of developing fatal/disabling
pulmonary complications from aTNF.
Disclosure statement: All authors have declared no conflicts of
interest.
26. ALL WALES RE-AUDIT OF THE INITIAL MANAGEMENT
OF GIANT CELL ARTERITIS (GCA)
Rizwan Rajak1, Farhan Bari1, Gwenan Hughes1 and Eleri Thomas1
1Rheumatology Dept, Princess of Wales Hospital, ABM Health
Board, Bridgend, United Kingdom
Background: In 2007, a national audit on the initial management of
GCA was undertaken across all the Welsh rheumatology centres, the
results of which were published as an abstract in the 2008 BSR
conference. That audit highlighted many areas that needed improve-
ment in GCA management and with the publishing of BSR/BPHR
guidance on GCA, we re-audited our practice to reassess whether our
collective performance had improved.
Methods: Patients diagnosed with GCA between Jan 2008 and Oct
2011 were assessed using a tick-box proforma covering the following
categories(as per BSR guidelines): presenting features, examination
findings, investigations, initial steroid dosing, temporal artery biopsy
(TABx) details, concomitant medication prescribing & patient educa-
tion. All rheumatology centres across Wales participated.
Results: 73 subjects were audited from across all the welsh health
boards. There was a 2:1 female:male ratio with a mean age of 70 years
(median 74yrs). 63% cases were initially assessed in secondary care
by a rheumatologist, 30% by non-rheumatologists and 7% unknown.
Akin to the 2007 audit, review for limb claudication and cerebrovas-
cular events were poorly reported and there was deficient documenta-
tion in examination of cranial nerve status, large vessel signs and visual
assessment (fundoscopy/visual fields/acquity). Baseline assessment
of immunoglobulins/electrophoresis, CXR and urinanalysis was worse
in this audit than in 2007 (42 v 50%, 33 v 36% and 27 v 44%,
respectively). Appropriate steroid dosing occurred in 53% of patients
compared with 52% in 2007. TABx was requested in 56% (v 66% in
2007), 78% of which were performed within 2 weeks of symptom
onset. Prescribing of concomitant medications had all significantly
improved - bisphosphonates 66 to 79%; calcium & vitamin D
supplements 60 to 83%; aspirin 14 to 52%; gastric protection 50 to
64%. Documentation of patient education provision had improved
from 7% in 2007 to 24%.
Conclusions: While this national re-audit shows a significant
improvement in some areas of the initial management of GCA, there
are some important areas where the guidelines are not being followed.
There has been a decline in the rates of TABx requests and other
secondary investigations. Also there has not been an improvement in
the appropriate initial starting dose of steroids. The chief reasons for
the drop in biopsy rates was due to difficulty in obtaining TABx from
local surgical services and that the interval between starting steroids
and time of assessment was too delayed to obatin a viable result. To
remedy this, better lines of coordination and communication are
needed between surgical/primary care systems with the rheumatology
departments.
GCA remains one of the commonest vasculitides and indications
for steroids in the elderly population and the importance of improving
our performance using available guidance was reinforced in our recent
bi-annual All Wales Audit meeting in Oct’11.
Disclosure statement: All authors have declared no conflicts of
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27. CHRONIC KIDNEY DISEASE MAY BE
UNDERRECOGNIZED IN RHEUMATOLOGY PATIENTS ON
DMARDS
Sarah Baker1, David Collins1, Elizabeth Price1 and Lyn Williamson1
1Rheumatology, Great Western Hospital, Swindon, United Kingdom
Background: Chronic kidney disease (CKD) is increasing in pre-
valence. Royal College of Physicians and NICE guidelines were issued
in 2008 defining 5 stages of CKD based on eGFR measurements
(Table 1). The guidelines cover management of blood pressure,
proteinuria, cardiovascular risk and NSAID use in CKD patients, and
indications for referral. Rheumatology patients may be at increased
risk of CKD, and DMARD blood monitoring provides an opportunity to
identify those requiring further assessment.
Methods: We studied CKD in 1006 rheumatology patients from our
DMARD monitoring database whose eGFR had been measured within
the preceding 12 months. The age range was 19-92 (median 59 years),
66% were female. 50/1006 (5%) of patients had an eGFR indicating
stage 3-5 CKD confirmed on 2 consecutive occasions, and were
studied in more detail from their records and by contacting GPs.
Results: Patients with CKD stage 3-5 had the following diagnoses: RA
31/50 (62%), other inflammatory arthritis 10/50 (20%), vasculitis 3/50
(6%), SLE 1/50 (2%), other 5/50 (10%). The breakdown by CKD stage
was: stage 3a - 29 patients (58%), stage 3b - 18 patients (36%) and
stage 4 - 3 patients (6%). 3/50 had a documented cause of CKD in
their notes and 8/50 (16%) had diabetes. The most common DMARD
used was methotrexate (22 patients, 44%); others included lefluno-
mide, sulphasalazine, hydroxychloroquine and azathioprine. 11
patients (22%) were on an NSAID. 6/50 (12%) patients with CKD
had been referred to a renal physician. 37 had not been referred; in 7
patients this information could not be obtained. Of 37 patients not
referred, 28 (76%) were being monitored elsewhere (GP 27, diabetic
clinic 1); 7 were not actively monitored (in 2 eGFR has since improved)
and in 2 data was incomplete. 10/50 patients (20%) had had their
blood pressure measured in rheumatology clinic in the past year.
Measurement of proteinuria using protein:creatinine (PCR) or albu-
min:creatinine ratio (ACR) had been performed in 37/50 (74%) patients.
Conclusions: Our data show that not all CKD patients in our database
had been identified for increased monitoring, and simple assessments
such as blood pressure measurement were often not recorded in
this high-risk group. We highlight the significance of eGFR for the
identification of CKD in rheumatology patients and the relevant
guidelines. Rheumatologists have a role in recognizing CKD in patients
undergoing monitoring, and ensuring appropriate investigation and
management in cooperation with primary care colleagues and renal
physicians.
TABLE 1 Chronic kidney disease classification by stage (RCP 2008)
CKD stage eGFR
1 90 ml/min/1.73 m2 with other evidence kidney damage
2 60-89 ml/min/1.73 m2 with other evidence kidney damage
3(a) 45-59 ml/min/1.73 m2
3(b) 30-44 ml/min/1.73 m2
4 15-29 ml/min/1.73 m2
5 <15 ml/min/1.73 m2
Disclosure statement: All authors have declared no conflicts of
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28. AUDIT: IN A ROUTINE RHEUMATOLOGY OPD WHAT
IS THE UTILITY OF WHOLE SPINE MRI IN PATIENTS WITH
SUSPECTED INFLAMMATORY BACK PAIN?
Lisa Dunkley1 and Matthew J. Youll1
1Rheumatology, Sheffield Teaching Hospitals NHS Trust, Sheffield,
United Kingdom
Background: Following the publication of new research (Rudwaleit M,
Schwarzlose S et al Ann Rheum Dis 2008, Bennett AN et al Arthritis
Rheum 2009 and Rudwaleit M, Jurik AG et al Ann Rheum Dis 2009)
and national guidelines (NASS 2010; NICE TA143), a revised local
pathway for the management of patients with Ankylosing Spondylitis
[AS] was developed. Magnetic Resonance Imaging [MRI] of the whole
spine and sacroiliac joints [SIJs] was a key diagnostic tool in this new
pathway. Locally this lead to questions about the utility of MRI and
how it would affect the subsequent pathway of patients. We hoped to
demonstrate that by using early MRI in patients with possible IBP, we
could efficiently discharge those with negative MRI scans (if clinically
appropriate), and could swiftly offer treatment to those with proven
spinal inflammation.
Methods: A list of all rheumatology patients that underwent spinal MRI
over a six month period was obtained. The clinical records were then
manually searched to identify those patients being investigated for IBP
and a retrospective analysis of MRI, plain film results and subsequent
clinical management was then carried out. The group of patients not
investigated for IBP was excluded from further data collection.
Results: Of the 146 patients, it was found that 79 were being
investigated for IBP. 20 patients (25%) had definite MRI signs of
inflammatory disease, 58 (74%) had no signs of inflammatory disease
and 1 patient had an equivocal scan. 50/79 patients (63%) had also
undergone plain film investigation of the lumbar spine and bilateral
SIJs. Within this group 18 (36%) had positive signs of inflammatory
disease on plain film, but 5 patients with negative plain films were
subsequently found to have a positive MRI scan (10% of total).
Following investigation, 26 (33%) patients were discharged, 14 (18%)
underwent treatment with NSAIDs and 12 (15%) started Anti-TNF
therapy. For the remaining patients, management fell into 3 broad
groups: ongoing/new DMARD therapy for peripheral arthritis,
pain management, or further clinical review. New vs. Existing
Patients: 56 (71%) were newly presenting patients; 23 (29%)
POSTER VIEWING I Tuesday 1 May 2012, 10.30 – 11.30 iii61
pre-existing rheumatology patients. 29% of new patients and 17% of
existing patients had positive MRI findings. Of the new patients 25/56
(45%) were discharged following investigation.
Conclusions: Early utilization of MRI in patients with possible IBP,
allows more rapid direction of patients to appropriate management
streams. It facilitates discharge or alternative treatment of patients with
non-inflammatory disease, and early initiation of appropriate medical
therapy in those with inflammatory disease. A discharge rate of 45%
from new, in a group of patients with initial clinical suspicion of
inflammation, offsets the cost of MRI scanning and more importantly
prevents diagnostic uncertainty for patients and unnecessary repeat
visits to the rheumatology clinic.
Disclosure statement: All authors have declared no conflicts of
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29. A RE-AUDIT OF SERUM 25-HYDROXY VITAMIN D IN A
RHEUMATOLOGY OUTPATIENT CLINIC
Mia Rodziewicz1,2, John A. Reynolds2, Jacqueline Berry3,2,
Chee Pavey2, Kimme Hyrich2, Rachel Gorodkin2, Kate Wilkinson2,
Ian Bruce2, Anne Barton2, Alan Silman2 and Pauline Ho2
1Medical School, The University of Manchester, Manchester, United
Kingdom; 2The Kellgren Centre for Rheumatology, Manchester Royal
Infirmary, Manchester, United Kingdom; 3Vitamin D Research Group,
Manchester Royal Infirmary, Manchester, United Kingdom
Background: The prevalence of vitamin D deficiency in rheumatology
outpatients has received much attention over the last few years
although no screening guidelines exist specifically for these patients.
We previously suggested that clinical suspicion could identify more
vitamin D deficiency than Australian Working Party guidelines (AWP).
Recently, the American Endocrine Society (ES) published its guidelines
for the identification of hypovitaminosis D in the general population.
We aimed to determine whether our previous audit led to increased
testing for hypovitaminosis D and the cost implications of this. We also
determined rates of vitamin D deficiency predicted by AWP and ES
guidelines in patients suspected of being vitamin D deficient by their
treating rheumatologist.
Methods: Requests for serum vitamin D levels were identified from
laboratory records from April 2007 to March 2010 were linked to
patient details. Vitamin D deficiency was defined as 25-hydroxy
vitamin D (25(OH)D) <10 ng/ml and insufficiency as 11 20 ng/ml.
Analysis was performed using STATA v10 and non-parametric tests.
Results: 345 requests were identified in the initial audit period (April
2007-March 2009) and 651 in the reaudit period (April 2009-March
2010). The 2 groups were not significantly different; both were
predominantly female (80% and 76%) with median (IQR) age of 48
(37-59) and 50 (38-61) years. Hypovitaminosis D (<20 ng/ml) was
identified in 222/345 (64.3%) and 418/651 (64.2%). Median serum
25(OH)D was not different between the 2 groups (13.0[7.7-20.9],
16.5[9.9-26.0]ng/ml, p¼0.87). Serum 25(OH)D varied significantly with
season, being highest in summer (20.5[13.3-30.7], 20.2[12.8-29.1]ng/
ml and lowest in spring (13.0[8.2-23.6] and 12.6[7.9-23.7]ng/ml,
p<0.01). Serum 25(OH)D also varied significantly with ethnicity,
being greatest in Caucasian patients (18.3[10.6-29.6], 18.5[11.8-
28.1]ng/ml). In the first audit, median serum 25(OH)D was significantly
lower in patients with undiagnosed muscle or joint pain, but this was
not confirmed in the second audit. The cost of performing serum
25(OH)D assays on the patients screened and treating all of those with
vitamin D deficiency (<10 ng/ml) was £16,163. The cost of empirically
treating all of those patients suspected to have hypovitaminosis D
without screening would have been £15,936.
Conclusions: Hypovitaminosis D appears to be common in rheuma-
tology patients. In our audits serum 25(OH)D varied significantly with
season and between ethnic groups. In a rheumatology outpatient
population, clinical suspicion seems to better identify vitamin D
deficiency than both AWP and ES guidelines. It also appears more
cost effective to empirically treat all patients suspected of being
vitamin D deficient. Although this audit points towards at-risk groups,
the true prevalence of vitamin D deficiency in our inner city population
remains to be determined. Further study is needed to develop
guidelines directly relevant to rheumatology patients.
Disclosure statement: All authors have declared no conflicts of
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30. DOES INFORMING PATIENTS ABOUT THE LINK
BETWEEN GUM DISEASE AND RHEUMATOID ARTHRITIS
ENCOURAGE BETTER DENTAL CARE?
Tricia Cornell1, Sarah L. Westlake1 and Selwyn Richards1
1Poole Hospital NHS Foundation Trust, Poole, United Kingdom
Background: Evidence has shown that people with RA have a higher
incidence of periodontal disease (PD) and the extent and severity of
both the PD and RA are linked. Periodontal therapy has been shown to
have a beneficial effect on the severity of the RA. Smoking and PD are
also linked and are a risk factor for developing RA. An important factor
in oral care is access to dental care. We decided to audit the access to
dental care in a sample of our patient cohort with RA. Following the
audit we produced a patient dental care leaflet highlighting the
importance of dental care which was distributed to all our inflammatory
arthritis patients. We then re-audited a sample of patients to determine
if there had been any change in behaviour or access to dental care.
Methods: Two audits took place, the first in 2009. All adult patients
attending the rheumatology clinic were asked to complete an
approved questionnaire. These were anonymous and included ques-
tions on access to both NHS and Private dental care. During 2010 an
approved patient leaflet about the importance of dental care was given
to all patients with RA who attended the rheumatology department.
Six months later all adult patients attending the rheumatology clinic
were asked to complete a second questionnaire. This included
questions on the dental care leaflet and access to dental care.
Results: Demographics for both audits were similar: audit 1 M:F
1:1.63, age range 25-90 years (median 64), diagnosis: RA 129, AS 2,
PsA 27. Audit 2 M: F 1:1.65, age range 21-98 (median 62), diagnosis:
RA 126, AS5, PsA 15. In the second audit 139 (95%) patients admitted
to receiving the leaflet on dental care. All patients agreed or strongly
agreed that the leaflet was easy to understand. Only 10 patients
thought the leaflet contained no new information. 74 patients thought
the leaflet applied to them and 125 patients thought the leaflet was
helpful. Despite this very little change in behaviour was seen although
8 patients admitted that hey could not afford the dentist.
Conclusions: Dental care has become increasingly important in the
light of new evidence linking severity of RA disease with both smoking
and poor periodontal health,however a patient education leaflet led to
minimal change in behaviour. Increasing the awareness of the potential
link between poor oral hygiene and RA may have a useful impact on
disease severity, but future studies may need to concentrate on
barriers to changing behaviour which may be due to cost or fear of
dentists.
TABLE 1 Results from audits of dental health questionnaire
2009, n (%) (n¼ 158) 2010, n (%) (n¼ 146)
Yes No No answer Yes No No answer
Annual review with dentist 126 (80) 19 (12) 13 123 (84) 18 (12) 5
Annual review with hygienist 55 (35) 103 (65) 0 59 (40) 87 (60) 0
Registered with NHS dentist 81 (51) 52 (32) 25 95 (65) 34 (23) 17
Admitted to smoking 19 (12) 139 (88) 0 19 (13) 127 (87) 0
Offered help to stop smoking 19 NA NA 19 NA NA
Use an electric toothbrush 64 (40) 89 (56) 5 63 (43) 83 (57) 0
Disclosure statement: All authors have declared no conflicts of
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31. IMPACT OF ANTI-TNF THERAPY ON BASDAI AND
EMPLOYMENT IN ANKYLOSING SPONDYLITIS
A. Holmes1, S. Parker1, H. Smith1, N. Briggs1, S. Arthanari1 and
M. Nisar1
1Department of Rheumatology, Burton Hospitals NHS Foundation
Trust, Burton on Trent, United Kingdom
Background: Patients with Ankylosing spondylitis (AS) are usually
symptomatic in their early adult life. As the condition affects working
age population, it is imperative that AS is diagnosed and treated early
and optimally in order to improve their employment prospects. NICE
guidelines of 2008 approving anti-TNF(aTNF) therapy for patients with
AS who have failed two NSAIDS was a landmark step in this direction.
The National Ankylosing Spondylitis Society (NASS) survey of 2009
highlighted the importance of these guidelines and made further
recommendations emphasizing the role of the MDT in enabling
patients to remain in work. This audit examines the impact of biologic
therapy on BATH indices and employment status in patients with AS.
Methods: Patients with AS who had been commenced on aTNF in our
unit in the time period between 2003-10 were identified from our
biologics database. Their case notes were examined for work status
and BATH indices prior to and up to one year post aTNF. Compliance
with NICE guidelines and NASS recommendations where applicable
were assessed.
Results: 40 patients (32 M, 80%) were identified in the time period;
mean age was 53 yrs, range 20-84yrs and median 52 yrs. All
40 patients had met the NICE criteria for commencing aTNF therapy
and had been seen by our specialized physiotherapists and
nurse specialist since presentation. Following the introduction of
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multidisciplinary AS review clinics in 2008 designed to review all AS
patients on an annual basis, 29 (72%) had been assessed by our
occupational therapists with emphasis on employment and ADLs. 19
(47%) were working pre aTNF with 16 (40%) continuing to work 1 year
on. Of those that no longer worked 1 had retired. Of the remaining 21
(52%) patients, 14 (35%) were not available for employment but
7(17%) were considered unemployed. 30 (75%) patients showed a
reduction in BASDAI scores to below 4.0. 32 (80%) had achieved a
50% reduction or fall of more than 2 units. Reasons for no
improvement in the BASDAI in the remainder include lack of efficacy
(6%), other medical problems arising during study period (6%) and
withdrawal of aTNF due to multiple DNAs in clinic (3%). In the 7 (17%)
who remained unemployed, BASDAI improved by mean of 2.58 while
in the 16 (40%) employed patients, BASDAI impovement (4.13) was
significantly greater.
Conclusions: All our patients were found to comply with NICE
guidelines and as per NASS recommendations, our MDT was closely
involved in their management. In unemployed patients, improvement in
BASDAI at one year did not correlate with employment gains. Although
this may reflect the short review period, and the subjective elements of
BASDAI, we postulate that BASFI/BASMI may better reflect patient
fitness to work. Our audit highlights the need to accurately document
work status at every consultation. A larger cohort and longer term
analysis is required to fully assess the impact of biologic therapy on
quality of life and employment prospects
Disclosure statement: All authors have declared no conflicts of
interest.
32. A REVIEW OF THE IMPLEMENTATION OF CURRENT
GUIDELINES REGARDING TRIPLE DMARD THERAPY FOR
EARLY RHEUMATOID ARTHRITIS: IS IT HAPPENING IN
PRACTICE?
Catharine Thwaites1,2, Sarah Ryan2,1, Sanjeet Kamath2 and
Shyra Price2
1School of Nursing and Midwifery, Keele University, Newcastle-
under-Lyme, United Kingdom; 2Rheumatology Department,
Haywood Hospital, Stoke-on Trent, United Kingdom
Background: Current guidelines for the management of Rheumatoid
Arthritis (RA) recommend early commencement of triple DMARD
therapy as part of a more aggressive approach to managing active
disease. Locally the early RA pathway was reviewed to incorporate a
multidisciplinary package of care as well as a designated nurse-led
clinic. Initiation of triple therapy has been adopted although in some
patients this may be a staggered process.Once prescribed triple
DMARD therapy, patients are seen by a rheumatology nurse specialist
(RNS) for counselling and initiation of treatment, then monthly for
three months to assess the effectiveness of triple therapy as well as
optimizing physical and psychological function. A review of practice
was conducted to ascertain the number of patients starting and
remaining on all three drugs.
Methods: A review of the nurse-led early RA clinic (x 1 per week)
between February and July 2011, was undertaken to identify; 1) the
numbers of early RA patients who commenced and continued with
triple therapy 2) the reasons why triple therapy was discontinued.
Results: The number of newly diagnosed RA patients who were
reviewed in the nurse-led early RA clinic was identified (n¼69). The
percentage of patients who commenced triple therapy of
Methotrexate, Sulfasalazine and Hydroxychloroquine was 46% (32/
69). A large percentage remained on all three DMARDS (36%; n¼ 25),
whereas 6/32 had discontinued triple therapy but remained on
combination therapy with two DMARDS. Only one patient stopped
all three DMARDs. Reasons for stopping drugs included nausea and
vomiting (n¼5), diarrhoea (n¼1), patient choice (n¼1). Further
analysis revealed that 16% (11/69) had commenced combination
therapy with two DMARDS and 38% (26/69) were prescribed
monotherapy. Corticosteroid use was not included in the analysis.
Conclusions: Combination therapy is recommended in the manage-
ment of early RA, however monotherapy or combination therapy with
two DMARDs may be more appropriate than triple therapy, depending
on the assessment of the individual and consideration of other
comorbidities and patient choice. The results reveal that the total
number of patients on triple therapy is lower than expected, which may
suggest that changes in prescribing practice are slower to become
established,reflecting prescriber confidence,patient choice or toler-
ability of combination therapy.Further work to explore patients’
opinions of taking multiple medications needs to be explored as well
as ascertaining the number of patients who reach early remission or
progress to biologic therapy.
Disclosure statement: All authors have declared no conflicts of
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33. NEGOTIATING TARGETS FOR THERAPY ACROSS THE
RANGE OF FOLLOW-UP RHEUMATOLOGICAL CONDITIONS
Sandra M. Robinson1 and David Walker1
1Musculoskeletal Directorate, Newcastle upon Tyne Hospitals NHS
Foundation Trust, Newcastle upon Tyne, United Kingdom
Background: NICE guidelines for Rheumatoid Arthritis (RA) suggest
negotiating targets for treatment with patients. We have previously
shown that these negotiations usually result in a target to maintain or
regain a physical activity (1). The benefit should be that a longer term
view is taken of a person’s condition, minimizing the effect in a busy
clinic of a patient not wanting to cause problems and saying ‘‘I’m fine’’.
The same benefit should also apply to other conditions that we see.
We were interested to explore whether it was possible to negotiate
targets for treatment with other groups of Rheumatology patients
under routine follow-up.
Methods: Consecutive patients under regular ongoing review by one
consultant, seen in outpatient clinics, were included. An attempt was
made to negotiate a target for treatment of their condition regardless
of diagnosis. In addition, any patients with fibromyalgia (FMS) were
negotiated with, even though they were likely to be discharged.
Results: Twelve consecutive clinics were used. These contained 108
patients who were on treatment, under regular review and with plans to
continue indefinitely. Diagnoses were
RA n¼66; Sero-negative arthritis n¼ 29; Soft tissue and degen-
erative problems for steroid injections n¼7 and others (OA, PMR,
Myositis) n¼5. In addition there were 7 patients with FMS. For the 66
RA patients, it was not possible to negotiate a target with 7. Two
because of intellectual comprehension and 5 because a condition
other than RA predominated. Of the remaining 59, 36 chose to
maintain and 23 to regain an activity. The targets chosen are shown in
Table 1 and are similar to the previous study. For the 29 sero-negative
patients, one could not negotiate as Psoriasis predominated.
Seventeen wished to maintain and 11 to regain an activity. The targets
are shown in the table and are similar to the RA group. The Injection
group all wished to regain. Four could only express this as improved
pain. For most this was for a 3 month period. The FMS patients could
only express their targets as improved pain (4) or fatigue (3).
Conclusions: It is possible to negotiate targets with patients in busy
clinics. Targets are predominantly based on walking. Sero-negative
arthritis was similar to RA. Temporary treatments such as injections
require a time as well as an efficacy scale. FMS patients can only see
feeling better as a target for treatment.
TABLE 1 Chosen targets
Diagnosis RA Sero-negative Injection Other FMS
Walk 42 16 2 4 0
Work 4 3 0 0 0
Domestic 5 3 0 0 0
Leisure 6 3 0 1 0
Personal care 2 0 0 0 0
Sleep 0 2 1 0 0
Symptoms 0 1 4 1 7
Total 59 28 7 6 7
Disclosure statement: All authors have declared no conflicts of
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34. AN AUDIT ON VACCINATIONS IN PATIENTS WITH
AUTOIMMUNE RHEUMATIC DISEASES
Hazel Coop1 and Wahab Al-Allaf1
1Rheumatology, Royal Wolverhampton NHS Trust, Wolverhampton,
United Kingdom
Background: Locally there had been an awareness that many patients
with rheumatic diseases were presenting with pneumonia with
significant morbidity and mortality, which was mainly related to the
infection. In April 2011 the European League Against Rheumatism
(EULAR) released guidelines on vaccinations in patients with auto-
immune rheumatic diseases. The guidelines discussed the increased
risk of this cohort of patients contracting infections due to the diseases
themselves and due to the immunosuppressive treatment. Two of their
recommendations were that these patients should receive the annual
flu vaccine and the pneumococcal vaccine. We audited the com-
pliance with this advice.
Methods: During September 2011 a questionnaire was given to
patients attending the rheumatology outpatient department. Data was
collected on whether the patients had had the annual flu and
pneumococcal vaccine, whether they had had a cold, flu or pneumonia
and if they had pneumonia were they admitted to hospital. Information
was collected on the medications they were prescribed and whether
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they stopped their disease-modifying medication (DMARDs) if they
had an infection. The aim was to have a 100% uptake of annual flu
vaccine and the pneumococcal vaccine.
Results: 272 questionnaires were completed, 66 were excluded
because they were either incomplete or they had a non immune related
condition. 213 patients were reviewed. Of this population 63% were
immunized with the annual flu vaccine, 36% had the pneumococcal
vaccine and 31% had both vaccines. Patients over the age of 65 years
were more likely to be vaccinated. However, we found that the
vaccinations did not provide any statistical significant protection from
pneumonia or flu (p>0.25) in our cohort. It was also illustrated that
42% cohort did not stop their DMARD medications during their acute
illness.
Conclusions: There was inadequate uptake of both the flu and
pneumococcal vaccines. Only a third of the patients reached our
target, with more uptake of the vaccination in elderly patient. However,
we found that the vaccine did not seem to have statistically significant
protection in preventing infections. Awareness needs to improve about
stopping DMARDs during acute illness as only 42% stopped their
DMARDs. These findings have highlighted areas to improve the local
practice. Specialist nurses are going to actively promote vaccinations
and educating patients about stopping DMARDs during acute illness.
Disclosure statement: All authors have declared no conflicts of
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35. PERSISTENCE WITH HYDROXYCHLOROQUINE IN
A RHEUMATOLOGY COHORT
Sarah Baker1, Lyn Williamson1, Elizabeth Price1 and David Collins1
1Rheumatology, Great Western Hospital, Swindon, United Kingdom
Background: Hydroxychloroquine (HCQ) is a commonly prescribed
DMARD. Its use is likely to increase as part of combination therapy in
early RA and SLE; in addition there is an emerging role in osteoarthritis,
CPPD and general cardiovascular protection. It is generally considered
safe and better tolerated than other DMARDs. We studied indications
for HCQ use, and persistence with the drug by diagnosis after first
prescription.
Methods: All new HCQ prescriptions issued by a rheumatologist
during the period May - November 2010 were included. At the
endpoint (May 2011) we determined which patients were still taking the
drug; persistence was defined as continuing treatment for at least
6 months. Information was obtained from electronic script issues /
renewals and casenotes; where incomplete, patients were telephoned.
Results: 150 new HCQ prescriptions were issued during the study
period. Indications for treatment were: RA (45%), unspecified
inflammatory arthritis (UIA) (24%), connective tissue diseases (CTD)
(13%), OA (14%), other (4%) (including CPPD, n¼ 3). At the endpoint 5
patients (3%) could not be contacted and 5 patients (3%) had died;
these were excluded from later analyses. Of the remaining 140
patients, 97 (69%) were still taking HCQ and 43 (31%) had
discontinued. Persistence with HCQ by diagnosis was as follows: RA
47/64 (73%), CTD 17/19 (89%), other inflammatory arthritis 21/32
(66%) and OA 8/19 (42%). Patients with OA were significantly less
likely to continue treatment compared with RA patients (p<0.025),
and the rest of the sample combined (p<0.01). The mean age was
lower in the RA group compared with the OA group (59.1 years v
68.2 years). Reasons given for discontinuing HCQ were: side effects
(51%), lack of effect (23%), other reasons (21%), unknown (5%). None
of the RA group stopped treatment due to lack of effect, compared
with 4 patients with OA and 5 with unspecified inflammatory arthritis.
Side effects were commonly gastrointestinal (n¼ 10) but also head-
aches (n¼3), rash / pruritis (n¼2), dizziness (n¼2) and others. Other
reasons for stopping included forgetting to take the drug (n¼1), not
renewing the script (n¼ 2), advice from a doctor (n¼1) and cost
(n¼ 1). 4 patients elected not to start HCQ as prescribed.
Conclusions: The use of HCQ in rheumatology patients in a DGH
rheumatology practice was associated with a 31% early withdrawal
rate, most often due to side effects. The majority of new HCQ
prescriptions were for RA, undifferentiated inflammatory arthritis and
CTD. 14% were for OA. Persistence in this cohort was highest in the
CTD and RA groups and lowest in the OA group. Lack of effect was
uncommonly reported in the RA and CTD groups but relatively
common in the OA and UIA group. The observed poor persistence with
HCQ in OA patients, despite a relatively higher age in this group,
warrants further study.
Disclosure statement: All authors have declared no conflicts of
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36. AN AUDIT OF THE EFFECTIVENESS OF SILDENAFIL IN
THE MANAGEMENT OF PATIENTS WITH MULTI-TREATMENT
RESISTANT RAYNAUD’S PHENOMENON
Rebecca C. Charleton1 and Bridget Griffiths1
1Rheumatology Department, Newcastle Hospitals Foundation Trust,
Newcastle upon Tyne, United Kingdom
Background: Secondary Raynaud’s phenomenon associated with
connective tissue disease can cause significant morbidity e.g. digital
ulceration and soft tissue infection. Effective vasodilatory therapy in
Raynaud’s is limited by treatment failure and side effects. Where usual
oral options e.g. calcium channel blockers have failed, infusion of an IV
prostaglandin analogue is tried over several days. These infusions are
time consuming and expensive to administer, and associated with a
range of side effects. Increasing evidence suggests a role for sildenafil
in controlling vasospastic symptoms in resistant Raynaud’s. Sildenafil
is already used with success in non-erectile indications such as
pulmonary hypertension. We aimed to assess whether sildenafil is
beneficial in controlling symptoms and incidence of digital ulceration,
in patients with secondary Raynaud’s phenomenon who have failed IV
prostaglandin therapy due to lack of efficacy or lack of tolerance.
Methods: 12 patients attending our rheumatology department were
identified as taking sildenafil. They met local criteria for treatment i.e.
had an inadequate response to IV epoprostenol (epo) (needing 3 or
more infusions/year) or suffered intolerable side effects. Patients
completed a questionnaire assessing the impact of sildenafil on
frequency and duration of Raynaud’s attacks, the presence of drug
side effects, incidence of digital ulceration and ulcer healing time.
Results: 9/12 patients completed the questionnaire. All had scler-
oderma and took up to 20 mg TDS of sildenafil. Number of attacks
experienced/week fell from a median of 70 (IQR 35-70) on epo to 4
(IQR 2-7) on sildenafil. Median attack duration (minutes) fell from 30
(IQR 12-80) on epo to 7.5 (IQR 1-12) on sildenafil. All patients had had
multiple digital ulcers on IV epo; since starting sildenafil only 3
developed ulcers. Ulcer healing time ranged from 6 weeks to 6 months
on epo and 1 to 6 weeks on sildenafil. Patients had been using
sildenafil for 7-18 months: 6 experienced no side effects, 2 suffered
mild headaches and 1 reported improved erectile function. 5 patients
reported independently reducing the dose of sildenafil to 20 mg OD or
20 mg BD. Reasons reported for reduction were attaining adequate
symptom control at lower doses, and awareness of drug cost. No side
effects led to disontinuation of treatment or dose reduction.
Conclusions: Sildenafil has led to marked improvements in symptoms
in this small group, beyond that seen with previously tried epo. Further
evaluation in a RCT e.g. IV epo vs sildenadil may be appropriate.
Disclosure statement: All authors have declared no conflicts of
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37. THE APPROPRIATENESS OF ANA REQUESTING BY
GENERAL PRACTITIONERS AND THE RELEVANCE OF
A POSITIVE TEST
Elizabeth A. Edwards1, Rosamund Partlett1, Keith Martin2,
Mike Tarzi2 and Sathianathan Panthakalam1
1Rheumatology, East Sussex Healthcare NHS Trust, Eastbourne,
United Kingdom; 2Immunology, East Sussex Healthcare NHS Trust,
Eastbourne, United Kingdom
Background: Antinuclear antibodies (ANAs) are commonly used as a
diagnostic tool in connective tissue disorders. ANAs can however, be
non-specific with significant numbers of false positives noted in
women and the elderly. Sensitivity has also been found to be varied
within different connective tissue disorders. Literature reviews calcu-
late the positive predictive value of ANA tested by immunofluores-
cence assay (IFA) for the presence of connective tissue disease to be
around 29%. Our objectives were to establish the proportion of
inappropriate ANA requests made by general practitioners to a District
General Hospital and to establish the positive predictive value of the
ANA IFA testing currently in use at the hospital.
Methods: We looked retrospectively at positive ANA results that had
been requested by general practitioners during a period of 12 months
in 2010. The ANA pattern and titre for each positive result and the
reason for the request was analysed, to see if it was clinically
indicated. We also looked to see whether these patients had been
referred and seen by a rheumatologist and if so what their underlying
final diagnosis was to assess the relevance of the ANA request.
Results: In total there were 414 positive ANA results that were
analysed [85 M: 329 F, Median age: 51, Age range: 14-88].
Approximately 30% (n¼123) of them were referred and seen by a
rheumatologist. 71% (n¼87) of patients were found not to have a
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connective tissue disorder, making it an inappropriate request of an
ANA. The positive predictive value was found to be 26%.
Conclusions: We conclude that ANA tests are being inappropriately
requested by general practitioners. This amounts to a considerable
waste in terms of cost and NHS resources, with inappropriate referrals
to rheumatology clinics. ANA tests are not diagnostic and therefore
positive results must be considered in the clinical context.
Disclosure statement: All authors have declared no conflicts of
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38. AN AUDIT TO ASSESS THE EFFICACY OF THE OXFORD
MUSCULOSKELETAL REFERRAL HUB SERVICE
Tanya Freeman1, Louise Ainley1 and Michael Turner1
1Oxford University, Oxford, United Kingdom
Background: 30% of GP consultations in primary care are muscu-
loskeletal. In order to reduce the number of inappropriate referrals in
rheumatology, a Musculoskeletal Referral Hub has been developed in
Oxford. We have audited the diagnoses and outcomes of new
rheumatology outpatient appointments both before and 1 year after
the inception of the Hub to investigate its’ effect on reducing non-
rheumatological referrals. The Oxford Musculoskeletal Referral Hub
uses a multi-disciplinary approach to triage patients. All rheumatology
referrals are triaged at Stage 1 electronically and referred to
rheumatology outpatients, back to the GP or seen face to face at
Stage 2 of the Hub by either a Sport and Exercise Medicine Consultant
or Specialist Rheumatology Physiotherapist. At Stage 2, patients can
then be referred on for appropriate outpatient review, sent back to the
GP, to community physiotherapy or orthotics services. There is limited
evidence on whether remote triage systems can be effectively
implemented. Morton et al. showed that remote photo-triage in
Dermatology allowed more specific referrals to be made, resulting in
definitive care at first visit (91% vs. 63%), as well as saving a small
amount of money. Lakkaraju et al. demonstrated that ultrasound may
be used to accurately triage soft tissue masses. There are also several
studies ongoing into the effective deployment of triage at the primary-
secondary care interface. These studies are further supported by a
review of referral services in Wales, which concluded that clinical
triage is a ‘‘successful method of diverting cases to more appropriate
services.’’
Methods: We surveyed the diagnoses and clinical outcomes of
patients referred from primary care before and after the introduction of
the Hub service. We examined 2 groups of 150 newly referred patients
from May to June 2010 and May to June 2011, using the rheumatology
outpatient department clinical outcome forms. We evaluated the
diagnoses, number of rereferrals and rate of discharge or follow up.
Results: We found there was a drop in the percentage of patients
discharged at their first appointment from 48% to 39%. There was also
an increase in the percentage of diagnosis of rheumatological
conditions from 50% to 60%. However, there was an increase in re-
referrals from 5 to 9.
Conclusions: The Hub system is shown to have an impact in reducing
inappropriate referrals to rheumatology as demonstrated by the
decrease in first appointment discharges and non-rheumatological
diagnosis rate. In future we would like to examine how these changes
have impacted on waiting times for rheumatology outpatient referrals.
There do not yet exist any firm criteria which may be used to assess
whether patients need to see a specialist. These could considerably
improve the efficacy of the system. We await the results of studies
such as the SAMBA trial which aim to determine simple prognostic
factors which would enable accurate and expedient triaging of
referrals from primary care.
Disclosure statement: All authors have declared no conflicts of
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39. DO PATIENTS WITH RHEUMATOID ARTHRITIS WANT
SMS TEXT MESSAGES TO REMIND THEM ABOUT HOSPITAL
APPOINTMENTS AND DRUG ADHERENCE?
Lyndsay Hughes1, Bridget Russell1, Suzanne Jenkins2, John Done1
and Adam Young2
1Centre for Lifespan and Chronic Illness Research, University of
Hertfordshire, Hatfield, United Kingdom; 2Rheumatology, West Herts
Hospital NHS Trust, St Albans, United Kingdom
Background: Information and Communication Technology (ICT) has
the potential to improve adherence to treatment and clinic attendance
in order to improve prognosis and reduce costs. Sending SMS
reminders of outpatient appointments has become routine in some
specialties in the NHS, although not in local Rheumatology
departments. We have previously shown that the majority of patients
<65 with RA regularly use mobile phones despite RA disability. 48%
would be willing to receive an SMS appointment reminder and 28% a
medication reminder [1].
Methods: Interviews were carried out with key regional NHS Trust
service managers to establish historical, technical and feasibility facts.
Face-to-face interviews were conducted with 63 patients to inform a
potential SMS appointment and medication reminder service. Finally,
20 patients agreed to participate in a pilot SMS reminder study in which
text messages were sent 2 working days before appointments. Ethical
approval was given by the Hertfordshire NHS REC; 09/H0311/105.
Results: Service manager interviews revealed no local evidence base
or systematic guidance on the use of SMS. Attempts to establish these
services have been affected by cost & objections from patients
(intrusive). Only one service in this Trust uses SMS for appointment
reminders.
60% of interviewed patients wanted an appointment reminder.
Reasons given included forgetting six monthly/annual appointment
times, an anticipated reduction of waiting times if all patients had
reminders and having all details easily to hand. The majority who did
not want reminders did not own a mobile phone, with a very small
number having mobile phone restrictions at work. Only 5% expressed
an interest in medication reminders for methotrexate, with the rest of
the sample not wanting or needing reminders. 20 patients trialled SMS
appointment reminders that were sent 2 working days before the
appointment, 17 of which subsequently attended and were followed
up. 100% of these patients were satisfied with the arrival of the SMS
and happy with the wording indicating the usefulness of having all
details being readily available. 25% admitted they would have missed
the appointment without the SMS (2 forgot, 1 had wrong location and 1
wrong time of day). The majority felt that 2 working days was sufficient
time although two patients would have preferred 5 days notice.
Conclusions: Overall feedback was positive for the use of ICT to
remind patients of their appointments in rheumatology clinics, but not
to aid adherence to drugs. Technical aspects and set up cost were the
main reasons why the Trust is reluctant to establish this service as
routine.
Disclosure statement: All authors have declared no conflicts of
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40. THE FEASIBILITY, ACCEPTABILITY AND USEFULNESS
OF EXTENDED DATA COLLECTION IN RHEUMATOID
ARTHRITIS
Tadeusz Jones1, Ian C. Gaywood1, Ira Pande1 and Marie-
Jose`phe Prade`re1
1Rheumatology, Nottingham University Hospitals NHS Trust,
Nottingham, United Kingdom
Background: Routine consultations on patients with RA focus on
assessing disease activity, monitoring drugs and adjusting treatments.
The impact of the disease on the personal, recreational, occupational
and psychosocial circumstances of the person is dealt with less well.
The aim of this project was to look at the feasibility and usefulness of
extended data collection in rheumatology outpatients.
Methods: Consecutive English-speaking patients with established RA
attending routine follow up appointments were approached by their
consultant. Immediately following that consultation each participating
subject had a face to face interview with the research nurse and
completed the following questionnaires: Scoreable SF-36v.2½ Health
Survey, BRAF-NRS, HAQ, Annual review of Services and Needs
(similar to the Client Services Receipt Inventory) and Supplementary
Annual Information (modified from the King’s Mill model and addres-
sing co-morbidities (including sexual health) and unmet therapy
needs). Patients could choose nurse-assisted or self-completion of
the questionnaires. Time for data collection and consultation were
noted. Subjects were encouraged to discuss any issues raised by the
questionnaires. They provided feedback on how useful and onerous
they found the process.
Results: Forty patients, (mean age 61.5yrs; range 42-83yrs, 10M, 30F)
took part. Consultations took between 20 and 40 minutes including
questionnaire completion. Face to face nurse time ranged from 5 to
40 minutes. Five patients required extensive nurse assistance to
complete the questionnaires because of difficulties with literacy or
comprehension. One patient asked her husband to record her answers
because of poor hand function. For the remainder, completion time for
the questionnaires ranged from 5 to 15 minutes. Collection of
additional data by the nurse took between 5 and 10 minutes. Ten
subjects (including the six requiring extensive assistance) expressed a
preference for completing the questionnaires with the nurse present.
The remaining 30 either expressed a preference for completing the
questionnaires at home prior to attendance or had no preference.
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All subjects answered all questions. All expressed a willingness to
provide these data on an annual basis though one subject expressed
misgivings about the usefulness of the process. Previously unidentified
issues were revealed or raised by 12 subjects. In all cases advice or
assistance was given.
Conclusions: Collection of extended data in patients with RA is
feasible, acceptable and produces new and important information in a
significant proportion of subjects. It addresses a shortcoming of
routine clinic consultations. Feedback suggests that this service could
largely be delivered by annual postal questionnaires linked to annual
nurse review clinics. Further work is required to demonstrate the
applicability of this process to patients with different cultural
perspectives or for whom English is a second language.
Disclosure statement: All authors have declared no conflicts of
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41. AN AUDIT OF ASSESSING RISK AND TREATING
MYCOBACTERIAL INFECTION IN PATIENTS WITH
INFLAMMATORY ARTHRITIS PRIOR TO STARTING AN
ANTI-TNF AGENT
Mahua Bhaduri1, Angela Smith1, Haley Cook1 and Sonya Abraham1
1Imperial College London, London, United Kingdom
Background: There is little consensus on the use of Elispot testing in
preference to Mantoux, the appropriate length of treatment, treatment
regimen and the delay in receiving anti-Tumour Necrosis Factor
(TNF)treatment in the investigation and management of TB anti-TNF
patients. The aim of this study was to review our hospital’s practices
for screening latent TB, the TB treatment prior to anti-TNF therapy and
the delay in receipt of receiving anti-TNF treatments.
Methods: Data was obtained retrospectively from 301 patients
receiving anti-TNF treatment over a 10 year period in a central
London hospital.
Results: Prior to commencing treatment, 81% of the patients had
chest radiographs within 3 months, all which were normal. All had a
symptom assessment. Out of 301 patients, 29 had either a positive
Mantoux or Elispot test recorded of which 52% had rheumatoid
arthritis (RA), 28% had ankylosing spondylitis (AS) and 20% had
psoriatic arthritis (PSA).
83% underwent Mantoux tests of which 2/3 were positive results.
93% underwent Elispot testing, with 56% positive outcome. 79% of
patients received both tests of which only 26% were positive for both
Mantoux and Elispot. Of interest, 66.67% with PSA had a positive
Mantoux but negative Elispot. All positives had appropriate respiratory
referral.
From the positive cohort, 69% were treated with TB chemopro-
phylaxis. 60% were treated with 3 months of Rifampicin and Isoniazid,
35% were treated with 6 months of isoniazid and 5% was treated with
isoniazid for 3 months. In 15% treatment was discontinued due to side
effects. The average delay between the decision to start anti-TNF and
the start of anti-TNF treatment in the TB prophylactic cohort was
5 months and 27 days (range: 4 months-11 months). Patients showing
positive results without TB chemoprophylaxis had an average
treatment delay of 3 months 16 days (1 month 14 days- 8 months).
To date, no patient has shown recurrence of TB.
Conclusions: Our study has emphasized the delay in receiving anti-
TNF treatment in patients with positive Mantoux or Elispot testing.
Contrary to BTS guidelines, our study has shown that prophylactic TB
treatment can be successful if used for 3 months. It is important to
assess the risk of reactivation of TB against the morbidity of the
rheumatological disease.
It is our trust practice to perform Mantoux and Elispot on all
patients as part of the screening process as Elispot has proven to have
greater specificity and sensitivity. However when you apply the
guidelines, 62.5% of Mantoux tests performed were unreliable as
patients were on immunosuppressive treatment at the time. We found
that a normal chest radiograph did not exclude latent TB. Our data
demonstrates the need for a review of the guidelines on screening,
length and type of chemoprophylactic treatments in inflammatory
arthritis patients with positive Mantoux or Elispot results.
Disclosure statement: All authors have declared no conflicts of
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42. IMPACT OF SEXUAL DYSFUNCTION AND
PSYCHOLOGICAL EFFECTS IN WOMEN WITH SYSTEMIC
SCLEROSIS
Tanaka Ngcozana1, Christopher P. Denton1, Louise Parker1, Carol
M. Black1 and Voon Ong1
1Department of Rheumatology, Royal Free Hampstead NHS Trust,
London, United Kingdom
Background: Scleroderma (SSc) is a complex connective tissue
disease associated with various life-threatening complications but also
with significant co-morbidities, including sexual dysfunction. The
objectives of this study were to explore the prevalence of sexual
problems amongst women with SSc, to examine the effects of
scleroderma on sexual relationship, sexual activities and the difficulties
faced by women with SSc.
Methods: 100 women diagnosed with either limited (lcSSc) or diffuse
(dcSSc) systemic sclerosis were invited to complete a validated
Female Sexual Function Index Questionnaire (FSFI) which was
expanded to assess the psychological effects of the sexual difficulties.
The FSFI comprises of six domains including desire, arousal,
lubrication, orgasm, satisfaction and pain. Severe impairment in all
domains is defined as minimum full scale score range of 2 and normal
function as maximal score of 36.
Results: Mean age (n¼50) was (mean SD, years) 56 1.41. 52% of
the women who responded had diffuse subset while 40% had been
diagnosed with the limited disease. The mean disease duration for
both subsets was (mean SD, years) 12 2.8. 54% of the patients
developed sexual difficulties after their diagnosis and the mean
duration from diagnosis to emergence of sexual complications was
(mean, SD, years) 4.0 5.8. For the 20% who developed difficulties
before diagnosis the mean duration to onset of sexual dysfunction was
(mean SD, years) 9.5 6.3.The overall FSFI domains showed that
84% of the patients had significant sexual problems (Interquartile full
scale score range 3 - 17.4). 62% (n¼31) of the patients had a score
below the mean of 10.8. Pain fared the worst of the six domains with
65% (n¼28) of patients having no sexual activity over the last month.
40% (n¼20) of patients did not have any sexual activity due to lack of
lubrication. 60% of the affected women revealed that their sexual
complications had caused strain in their relationships. 46% of the
respondents reported to discussing their problems with their partners,
whilst 30% admitted not able to discuss the problems, preferring to
keep it to themselves or being embarrassed to do so. Among the 32
(64%) women who discussed the problems with their partners, 56%
found it to be helpful. 76% of the subjects reported that they had never
been asked about sexual health by a health professional. However
52% revealed that they would have discussed their sexual problems if
they were concerned. Interestingly 72% of these women admitted to
not raising any concern about their sexual problems.
Conclusions: Our study revealed that sexual health is an important
aspect of life but can be of significant burden for these women. It is a
subject that is usually neglected yet it has been associated with
depressive symptoms and can have a negative impact for women with
SSc and their partners. It is a subject worth exploring and actively
enquiring in order to help our patients and improve their quality of life.
Disclosure statement: All authors have declared no conflicts of
interest.
IMAGING
43. AN OBSERVATIONAL STUDY OF THE UTILITY OF
CRANIAL ULTRASOUND IN SUSPECTED GIANT CELL
ARTERITIS
Nicola Thompson1, Catherine White1, Martin Duddy2 and
Paresh Jobanputra1
1Department of Rheumatology, Queen Elizabeth Hospital,
Birmingham, United Kingdom; 2Department of Radiology, Queen
Elizabeth Hospital, Birmingham, United Kingdom
Background: Giant cell arteritis (GCA) is usually diagnosed from a
constellation of clinical and laboratory features. Arterial duplex
ultrasound scans (US) can provide valuable supportive evidence of
an arteritis but its role in suspected GCA is not clearly defined. We
studied the utility of US combined with a cluster of clinical and
laboratory features in the evaluation of patients referred with
suspected GCA.
Methods: All patients undergoing cranial duplex US scans between
Jan 2005 and July 2011 were identified and clinical data obtained from
electronic records, and, if necessary primary care providers. ACR
criteria for GCA (3 or more of: age >50 years, a new headache,
abnormal temporal artery palpation, ESR >50 mm and an abnormal
temporal artery biopsy) were used to classify patients. US reports were
independently classified according to whether there was evidence of
an arteritis or not. Explicit US features of GCA such as a halo sign were
not required to make this determination. The relationship between the
ACR criteria alone or in combination with US and a final clinical
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diagnosis of GCA (made after a minimum of 3-month follow-up) was
analysed.
Results: Forty-eight patients, mean age 68 (range 44-92) years, were
investigated by US for suspected GCA. ACR criteria for GCA were met
by 47.9% (23/48) of patients: 5 of these patients and overall 8 patients
had a temporal artery biopsy - all biopsies were negative. Detailed
data is shown in Table 1.
Conclusions: In this cohort of patients the strongest positive predictor
for GCA was the US, independent of ACR criteria. Only a minority of
patients had a temporal artery biopsy, all of which were negative.
Biopsy results had limited utility. ACR criteria alone were insufficient
for ruling in or ruling out a diagnosis of GCA at 3 months. Patients
fulfilling ACR criteria and with a positive US were highly likely to be
managed as GCA regardless of biopsy result where this was done. It is
possible that a blinded study, nuances of clinical presentation not
examined in this study, or longer follow up and further investigation for
more robust diagnostic confirmation are required to understand these
relationships better.
TABLE 1 Summary of descriptive data & likelihood ratios
Total (%) Diagnosed
GCAa (%)
Positive
likelihood
ratio (95%
confidence
interval)
Negative
likelihood
ration (95%
confidence
interval)
All patients 48 (100) 13/48 (27.1) – –
ACR criteria þve (3) 23 (48) 7/23 (30) 1.2 (0.6–2.2) 0.9 (0.4–1.6)
ACR criteria ve (<3) 25 (52) 6/25 (24) 0.9 (0.4–1.6) 1.2 (0.6–2.2)
US artery þve 14 (29) 12/14 (86) 16.1 (4.1–62.2 1.0 (0.6–1.5)
US artery ve 34 (71) 1/34 (3) 1.0 (0.6–1.5) 16.1 (4.1–62.2)
ACR þve & USþve 7 (15) 6/7 (86) 16.2 (2.1–121.7) 0.6 (0.3–0.9)
ACR þve & US ve 16 (33) 1/16 (6) 0.2 (0.03–1.2) 1.6 (1.2–2.2)
ACR ve & US þve 7 (15) 1/34 (3) 16.2 (2.1–121.7) 0.6 (0.3–0.9)
ACR ve & US ve 18 (37.5) 0/18 (0) 0.07 (0.004–1.1) 2.0 (1.4–2.8)
Biopsied 8 (16.7) 4/8 (50) – –
No biopsy 40 (83.3) 9/40 (23) – –
aClinical judgment after a minimum of 3 months follow up.
Disclosure statement: All authors have declared no conflicts of
interest.
44. DEVELOPMENT OF AN ACCREDITED, INNOVATIVE,
FOCUSED ULTRASOUND TRAINING COURSE FOR
REGISTERED HEALTH PROFESSIONALS
Pauline Bacon1, Jacqueline Smith2, Ann Richardson3,
Giorgio Giancola3, Vicky Soh3, Simon Spencer3, Ann Greenhalgh3,
Mark Hanson1 and Denise De Lord2
1Medical Physics, EKHUFT, Canterbury, United Kingdom;
2Rheumatology, EKHUFT, Canterbury, United Kingdom; 3Radiology,
EKHUFT, Canterbury, United Kingdom
Background: Ultrasound (US) is an important diagnostic tool
recognized by NICE for use in the management of Rheumatoid
arthritis (RA). Provision of US training varies widely; from short duration
introductory seminars with no assessment of operator competency, to
University accredited musculoskeletal US courses. Short US courses
do not provide a professionally recognized certificate of sonographic
training. Conversely a PgC, PgD or MSc is time-consuming, requiring
large numbers of supervised scans. Such courses tend to omit the
more specialist requirements of the rheumatologist diagnosing sub-
clinical synovitis, including early RA. Our aim was to provide a
standardized, rheumatologist-focussed US training course with pro-
fessional sonographic accreditation, allowing the successful partici-
pant to report on Trust radiology reporting systems.
Methods: The EKHUFT US course was developed jointly by the
departments of Medical Physics, Radiology and Rheumatology and
has 2 core components. Firstly, a 4 day foundation course introduces
the science & technology of US; anatomy, pathology and US
assessment of hands, wrists and feet; and practical US training
sessions. Satisfactory completion (assessed by practical and written
examination) leads to the second, vocational, component wherein the
practical US skills acquired in the foundation course are reinforced and
extended through the completion of a series of weekly supervised
training sessions in an out-patient clinic setting
Results: Scans were performed by members of the Rheumatology
department, on each of the 3 Trust hospital sites and the scans
reported on the Trust radiology reporting system. The final practical
assessment of US clinical competency will be undertaken by
consultant radiologists, at the end of the training period.
Competency will be assessed by the satisfactory completion of a set
of training objectives. A portfolio will be submitted for assessment to
include 120 hours of documented US clinical skills learning, of which at
least 50 hours must be directly mentored. A log book, case study and
reflective discussion will also be assessed. It is envisaged that the first
cohort of trainees will achieve accreditation in January 2012.
Conclusions: This course provides an exciting opportunity for
specialist registrars, consultants and other registered health profes-
sionals to complete clinical competency and theoretical training within
a relatively short time frame (6 months). CASE (Consortium for the
Accreditation of Sonographic Education) has accredited this focussed
ultrasound course in partnership with Canterbury Christchurch
University who are acting as moderators. It provides a nationally
recognized and validated qualification for the use of US as a diagnostic
tool in Rheumatology, with the possibility of linking in to an established
MSc programme.
Disclosure statement: P.B. has received a sessional support grant
from Pfizer, and an equipment grant from Abbott. D.D. has received a
training and course grant from Pfizer, a sessional grant from Pfizer, and
an equipment grant from Abbott. A.R. has received a sessional grant
from Pfizer. All other authors have declared no conflicts of interest.
45. THE POWER OF PET/CT
Mark Lloyd1, Henna Wong2, Damian Wren3, Bob Grover4, John Hall5,
Cai Neville6 and Peter Alton7
1Rheumatology, Frimley Park Hospital, Frimley, United Kingdom;
2Immunology, John Radcliffe Infirmary, Oxford, United Kingdom;
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Background: We present 4 cases in which FDG positron emission
computed tomography (PET/CT) gave critical diagnostic information in
difficult rheumatological cases.
Methods: See results.
Results: Case 1: Giant cell arteritis. 69 yr old woman admitted Oct
2009 c/o 3 wk history of neck and parietal pain. CT head NAD. CRP
33 mg/L, ESR 24 mm/hr. Dischargedþ referred to rheumatology via
OPD. Seen Dec 2009. Asymptomatic. CRP 23 mg/L. Chest XR, abdo
US, Igs, echocardiogram normal. Reviewed Feb 2010. Still asympto-
matic. CRP 27. PET/CT: increased uptake subclavian, axillary, iliac
arteries and aorta. Temporal artery biopsy (prior to steroids):
prominent multinucleated giant cell infiltrate. Rx prednisolone: rapid
fall in CRP.
Case 2: Large vessel vasculitis. 65 yr old woman presented with
acute onset thigh weakness, malaise. CRP 76, ESR 53. MRI L-spine,
thighs and CT body: NAD. Autoantibodies -ve, CK N. Symptoms
settled spontaneously; recurredþ sweats and fever 6 mths later. CRP
210, ESR 133. Repeat CT NAD; PET/CT:widespread uptake in large
vessels. Rx prednisoloneþ cyclophosphamide: CRP/ESR resolved,
symptoms improved.
Case 3: Non Hodgkin’s lymphoma. 79 yr old woman presented with
a 3 mth history of lethargy, night sweats and recent onset headache.
Past history included PMR (steroids stopped 2 yr previously). ESR
104 mm/hr, Platelets 1381 109/L. WCC and Hb normal. Blood flim -
atypical lymphocytes. IgM lambda paraprotein on electrophoresis. TA
Bx: normal. CT abdo: 13 cm splenomegaly. While awaiting bone
marrow results, PET/CT was performed to help differentiate between
vasculitis and malignancy: diffuse activity in the spleen. Bone marrow
immunophenotyping: Non-Hodgkin’s Lymphoma. Rx: standard che-
motherapy with improvement in symptoms.
Case 4: Polymyalgia rheumatica. 55 yr old man presented in July
2009 with bilateral VII nerve palsies following a tick bite. CSF protein
2.88 g/L, 95% lymphocytes. Lyme titres equivocal. MRI brain NAD.
Responded to ceftriaxone. ESR 2 mm/hr Oct 2009. In May 2010 he
developed a sudden onset of hip and shoulder girdle stiffness. CRP
110 mg/L, ESR 83 mm/hr. Because of the previous complexity of his
case PET/CT arranged: marked increase in uptake in both shoulders
and hips. Rx prednisolone 30 mg daily: rapid resolution of symptoms
and inflammatory markers.
Conclusions: These cases show the benefit of PET/CT in rheumatol-
ogy practice. Cases 1þ2 emphasize the potential for silent large
vessel involvement in GCA; also, significant vessel inflammation can
occur with minimal symptoms and mildly raised inflammatory para-
meters. Case 3 illustrates a common conundrum where sepsis,
malignancy and autoimmune disease all cross the differential
diagnosis. Case 4 suggest that PET/CT may be useful in diagnosing
atypical cases of PMR, as well as GCA in association with PMR. PET/
CT scanning is expensive (£980 per scan) and involves significant
radiation exposure (equivalent to 25mSv). However, in carefully chosen
cases it can be an important rheumatological investigation.
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46. ULTRASOUND GUIDED SYNOVIAL BIOPSIES: SAFETY,
TOLERABILITY, AND TISSUE QUALITY
Stephen Kelly1, Michele Bombardieri1, Fran Humby1, Nora Ng1,
Maria Di Cicco1, Rebecca Hands1, Oscar Epis2, Andrew Filer3,
Christopher Buckley3, Iain McInnes4, Peter Taylor5 and
Costantino Pitzalis1
1Experimental Medicine and Rheumatology, Queen Mary’s University
of London, London, United Kingdom; 2Rheumatology, A.O.
Ospedale Niguarda Ca’ Granda, Milan, Italy; 3Rheumatology
Research Group, University of Birmingham, Birmingham, United
Kingdom; 4Glasgow Biomedical Research Centre, University of
Glasgow, Glasgow, United Kingdom; 5Nuffield Department of
Orthopaedics, Rheumatology and Musculoskeletal Sciences,
University of Oxford, Oxford, United Kingdom
Background: Currently, synovial tissue analysis is restricted to early
phase drug trials and academic research. However, if synovial tissue
analysis can be shown to have clinical utility, it is important that the
harvesting procedure be well tolerated, safe and provides tissue of
sufficient quality both in large and small joints. We report the safety,
tolerability and tissues quality in 93 consecutive patients undergoing
ultrasound (US) guided synovial biopsies at Barts and The London, as
part of a MRC-funded Pathobiology of Early Arthritis Cohort (PEAC).
http://www.peac-mrc.mds.qmul.ac.uk/
Methods: A questionnaire was administered to all patients asking
them to grade joint pain, stiffness and swelling before and after the
biopsy procedure on a VAS. In addition, patients were asked to
indicate the tolerability of the procedure using a 5-point scale and
whether they would consider a repeat biopsy. The post-biopsy
assessment was undertaken between 3-5 days following the proce-
dure. Complications were compared with published data for arthro-
scopy. Laboratory analysis assessed tissue quality and the RNA yield.
Biopsies were taken from knee, elbow, wrists, MCP, MTP and PIP
joints.
Results: The rate of complications for US guided synovial biopsy
compared favorably with published data for arthroscopy with no
reported cases of wound or joint infection, haemarthrosis, DVT,
thrombophlebitis and no evidence of a flare of the underlying disease.
3 patients reported feeling faint during the procedure but satisfactory
completion was achieved in all subjects. No difference was seen with
either pain (p¼0.22), stiffness (p¼ 0.25) or swelling (p¼0.37) following
biopsy. A higher percentage of patients reporting no discomfort in
respect to small joint compared to large joint synovial biopsies (89% vs
82%), however overall no significant difference was demonstrated in
patient reported tolerability (p¼0.19). 98% of all biopsies were able to
be graded with RNA yields similar between different joints (p¼0.224).
All patients agreed to a subsequent synovial biopsy as part of the
PEAC protocol. Analysis of RNA yield depending upon US grey scale
synovial thickness (ST) prior to biopsy demonstrated a significantly
higher yield from joints with grade 3-4 / 4 for US ST score compared to
grade 1-2 (p¼0.002).
Conclusions: US guided synovial biopsies appear to be well tolerated
from both large and small joints providing good quality tissue for
grading and RNA extraction. In our experience, there are no safety
concerns and over 95% of patients agreed to a subsequent biopsy. All
joints may be considered for synovial biopsy. A pre-biopsy US
examination may help target joints with higher grades of synovial
thickening and improve subsequent RNA yield. This approach may not
be feasible in subsequent biopsies where synovial thickness may be
reduced following treatment, however our data would suggest that
suitable tissue can still be harvested from joints with low grade ST.
Disclosure statement: All authors have declared no conflicts of
interest.
47. USEFULNESS OF NOVEL WHOLE BODY MULTIPLE
JOINT MRI IMAGING IN ESTABLISHING ACCURATE AND
TIMELY DIAGNOSES IN PATIENTS PRESENTING WITH
INFLAMMATORY ARTHRITIS
Jane Freeston1,2, Philip Conaghan1,2, Andrew Grainger3, Philip
J. O’Connor3, Rob Evans2, Paul Emery1,2 and Richard Hodgson2
1Section of Musculoskeletal Disease, University of Leeds, Leeds,
United Kingdom; 2Leeds Musculoskeletal Biomedical Research Unit,
Chapel Allerton Hospital, Leeds, United Kingdom; 3Leeds Teaching
Hospitals NHS Trust, Chapel Allerton Hospital, Leeds, United
Kingdom
Background: Making an accurate and timely diagnosis of inflamma-
tory arthritis is crucial to allow rapid instigation of appropriate therapy
with prevention of long term disability. However, diagnosis can be
delayed due to the reduced sensitivity of clinical examination (CE) for
synovitis and plain radiographs for early bone damage. MRI offers
increased sensitivity for detecting pathological changes but in early
disease it may be difficult to know which joints should be imaged, and
targeted joint imaging does not necessarily reflect the overall disease
load or distribution. Recent developments in whole body scanning
offer the potential to scan most of the joints in a single session. The
aim of this work was to (i) examine the effect of MRI findings on clinical
diagnosis and (ii) demonstrate the feasibility of a whole body multiple
joint MRI (WBMJ-MRI) protocol in early arthritis patients.
Methods: 15 patients newly presenting to the Rheumatology
Early Arthritis Clinic were studied. A clinical diagnosis was made
using clinical (swollen joint count, Leeds Enthesitis Index1), laboratory
(rheumatoid factor, anti-CCP antibody, CRP) and plain radiographic
(hands and feet) assessments. Involvement of joints and entheses was
determined clinically based on joint swelling and entheseal
tenderness.
WBMJ-MRI was performed using a 3T Siemens Verio scanner with
multiple radiofrequency coils. T2-weighted fat suppressed images of
the spine and sacroiliac joints were acquired, followed by images of
the joints and entheses using VIBE Dixon sequences post intravenous
contrast.
Images were scored by a MSK radiologist blinded to the clinical
findings for presence/absence of the following: (i) Spinal inflammatory
change, sacroiliac oedema and erosion; (ii) Synovitis, osteitis or
erosion at the glenohumeral, sternoclavicular, wrist, MCP, PIP, hip,
knee, ankle, mid/hind foot, MTP and interphalangeal joints; (iii)
Enthesitis at the shoulder, ASIS, greater trochanter, knee, Achilles
and plantar fascia. Findings from Groups (ii)-(iv) were compared with
those from clinical examination. The clinical diagnoses were then
reviewed in light of the MRI findings.
Results: Clinical diagnoses at presentation were rheumatoid arthritis
(RA, n¼8) and undifferentiated arthritis (UA, n¼7). MRI revealed
pathology at more sites per patient than CE (10 vs. 6, p<0.05,
Wilcoxon) and showed abnormalities at more sites per patient in those
with RA than UA (14 vs. 6, p<0.05, Mann Whitney U). In 4/15 (27%)
patients, MRI findings led to a change in diagnosis.
Conclusions: WBMJ-MRI is novel, feasible and more sensitive than
CE. The combination of axial and peripheral imaging enables
identification of both seropositive and seronegative disease patterns
and disease severity. Long-term follow-up is required to confirm the
accuracy of the MRI-attributed diagnoses.
Disclosure statement: All authors have declared no conflicts of
interest.
Reference:
1. Healy PJ et al. Arthritis Care Res 2008;59:686.
48. PREDICTORS OF RADIOGRAPHIC PROGRESSION IN
METHOTREXATE-NAI¨VE PATIENTS WITH RHEUMATOID
ARTHRITIS BASED ON ONE-YEAR RADIOGRAPHIC DATA
FROM THE GO-BEFORE GOLIMUMAB CLINICAL TRIAL
Paul Emery1, Roy Fleischmann2, Chenglong Han3, Desiree van der
Heijde4, Philip Conaghan1, Weichun Xu5 and Elizabeth Hsia5,6
1NIHR Leeds Musculoskeletal Biomedical Research Unit, University
of Leeds, Leeds, United Kingdom; 2Metroplex Clinical Research
Center, University of Texas Southwest Medical Center, Dallas, Texas,
United States of America; 3Worldwide Market Access, Janssen
Global Services, LLC, Malvern, Pennsylvania, United States of
America; 4Rheumatology, Leiden University Medical Center, Leiden,
Netherlands; 5Immunology, Janssen Research & Development, Inc.,
Pennsylvania, United States of America; 6Rheumatology, University
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Background: The purpose of this study was to identify variables
associated with radiographic joint damage in patients with rheumatoid
arthritis (RA) before and after treatment with golimumab
(GLM)þmethotrexate (MTX) or MTXþplacebo (PBO).
Methods: GO BEFORE was a double-blind, PBO-controlled study.
637 MTX-naı¨ve adult patients with active RA (4 tender joint and 4
swollen joints) were randomized to PBO q4wksþMTX 20 mg/wk, GLM
100 mg q4wksþPBO capsules/wk, GLM 50 or 100 mg (q4wksþMTX
20 mg/wk). Radiographs of the hands and feet were evaluated at
baseline, wk28, and wk52 using the van der Heijde-Sharp (vdHS)
score. Linear regression modeling was performed to identify baseline
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variables that predict radiographic damage at baseline or change in
vdHS score from baseline at wk52.
Results: Mean (SD) disease duration was 3.5 (5.6) years, baseline
vdHS was 14.7 (27.0) and baseline DAS28 (CRP) score was 5.7 (1.06).
In linear regression models, baseline CRP (or baseline ESR), HAQ
score, disease duration and number of swollen joints were significantly
associated with baseline vdHS score (p< 0.05, for all). After adjusting
for other baseline characteristics (age, gender, disease duration, ESR,
RF, counts of swollen and tender joints, HAQ) in the linear regression
model, higher baseline CRP concentration and treatment with
MTXþPBO were significantly correlated with greater progression in
vdHS from baseline to wk52. In separate models analysed by
treatment groups, a greater correlation of baseline CRP level with
radiographic progression was observed in the MTXþPBO group
compared with the GLMþMTX group. GLMþMTX-treated patients
demonstrated less radiographic damage, and more had no progres-
sion (change in vdH-S score 0) than MTXþPBO-treated patients
regardless of baseline disease activity (DAS28>5.1 vs. 5.1), baseline
inflammation level measured by CRP (>2 vs.2 mg/dl) or ESR (>28 vs.
28 mm/hr), disease duration (3 years vs. >3 years), or clinical
remission (Yes/No) at wk52.
Conclusions: MTX-naı¨ve RA patients with an elevated CRP level or
high baseline disease activity had an increased likelihood for greater
joint damage if treated with MTX-alone compared with GLMþMTX.
Disclosure statement: P.C. is an investigator for Janssen. P.E. is an
investigator for Janssen. R.F. is an investigator for Janssen. C.H. is
an employee of Janssen. E.H. is an employee of Janssen. D.V. is an
investigator for Janssen. W.X. is an employee of Janssen.
49. GOLIMUMAB TREATMENT INHIBITS PROGRESSION OF
JOINT DAMAGE IN PATIENTS WITH PSORIATIC ARTHRITIS
REGARDLESS OF BASELINE DISEASE SEVERITY
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Chenglong Han5
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Background: To identify variables associated with radiographic
joint damage in pts with PsA treated with golimumab(GLM) or
placebo(PBO) (standard therapy with MTX or/and NSAIDs) in a Ph3
randomized, PBO-controlled study(GO-REVEAL).
Methods: Adult PsA pts with  3 swollen &  3 tender joints were
randomized to subcutaneous placebo (PBO) or GLM (50 or 100 mg)
q4wks. At wk16, pts with <10% improvement in swollen and tender
joint counts entered early escape in a blinded fashion to GLM50mg
(PBO pts) or GLM100mg (GLM50mg pts). Starting at wk 24, pts
remaining on PBO were crossed over to GLM50mg. Changes from
baseline in PsA modified vdH-S scores of hands and feet were
compared at wk24 and wk 52 by stratification of baseline disease
activity (DAS28>5.1 vs. 5.1) or CRP level (>0.6 vs. 0.6 mg/dL).
Logistic regression model was used to adjust for covariates (age,
gender, disease duration, body weight, baseline MTX use) when
examining association of baseline DAS28 with joint progression from
baseline to wk 24 or from wk 24-52. In logistic regression model, only
pts who had no missing X-ray data were evaluated.
Results: 405 pts were enrolled with mean (SD) total PsA modified vdH-
S scores of 18.15 (27.76) to 23.85 (35.41) and baseline DAS28 score
of 4.9 (1.0) to 5.0 (1.1). At wk24, GLM-treated pts had significantly
less radiographic damage than PBO (mean change from baseline
0.091.32 vs. 0.271.26, p¼0.015) or had no progression
(change0) than PBO-treated pts (77.7% vs. 62.7%, p¼0.003),
These differences were greater among pts with high disease activity
(DAS28> 5.1) (p< 0.01) or elevated CRP (CRP> 0.6 mg/dL) (p¼ 0.01)
than pts with moderate disease activity or normal CRP. After adjusting
for baseline characteristics using a regression model, higher baseline
disease activity was significantly associated with radiographic pro-
gression at wk24 in the PBO group (p<0.01), but baseline disease
activity was not associated with radiographic progression in the GLM
group. Similarly, disease activity at wk24 in all pts randomized to GLM
or switched to GLM at wk24 was not associated with radiographic
progression from wk24 to 54, suggesting that irrespective of disease
activity at wk24, there was absent or nominal progression in joint
damage at wk52.
Conclusions: PsA pts with high arthritis disease activity or CRP level
at baseline experience more joint damage if treated with standard
therapy only. Adding GLM provides additional benefit in inhibiting
radiographic progression, especially for pts with more severe disease
activity. The beneficial effect of GLM on joint damage was also
observed in pts with baseline DAS28 <5.1 or CRP <0.6 mg/dl but to a
lesser degree than in pts with high disease activity.
Disclosure statement: A.B. is an employee of Janssen. C.C. is an
employee of Janssen. D.G. is an investigator for Janssen. C.H. is an
employee of Janssen. A.K. is an investigator for Janssen.
50. ULTRASOUND DETECTED BONE EROSIONS: ARE THEY
SPECIFIC FOR RHEUMATOID ARTHRITIS?
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Background: Bone erosions are commonly considered to be the
hallmark of RA. Although US is highly sensitive in detecting bone
erosions, there are limited data about the specificity of US-detected
bone erosions for the diagnosis of RA. The aims of this study were (a)
to determine if the frequency of bone erosions in RA is significantly
higher than seen in other arthritis groups and normal controls, (b) to
determine the specificity of ultrasound detected erosions in the
classical ‘target’ joints for RA, (c) to determine the effect of erosion
size and grade on their specificity for RA.
Methods: Patients fulfilling the diagnostic criteria for RA, PsA, OA or
gout in addition to healthy volunteers were included in the study.
Ultrasound examination was performed with using a GE Logiq E9
ultrasound machine. Sonographer was blinded to clinical diagnosis.
The following areas were examined: radial styloid, ulnar styloid, 2nd
MCP, 3rd MCP, 5th MCP, 2nd PIP, 3rd PIP, 1st MTP and 5th MTP
joints. All joints were scanned in four quadrants. Each quadrant was
assessed for erosions using a 0-3 semi-quantitative scoring system.
A mean or total score of 0-3 was then given to each joint. The diameter
of the largest erosion in each joint was recorded in mm. The inter- and
intra-reader reliability was examined.
Results: A total of 216 subjects were recruited including 50 RA,
50 PsA, 36 Gout, 30 OA and 50 healthy volunteers. US-detected bone
erosions were more frequent in RA. However, they were not a specific
finding. The presence of erosions with score >1 or large in diameter
(2.5 mm) in four target joints (2nd, 3rd MCP, 5th MTP joints and ulnar
styloid) was highly specific for RA (Table 1). The presence of erosions
in the 5th MTP joint was both sensitive and specific for RA. The inter-
and intra-reader agreement were excellent (kw was 0.86 and 0.87
respectively, p< 0.001).
Conclusions: The presence of erosions per se is not specific for RA.
The erosions of RA were more extensive and generally larger than
other diseases. Erosions in the ulnar styloid, 2nd, 3rd and 5th MCP
joints were highly specific for and predictive of RA, especially when
larger in size
TABLE 1 Summary of specificity and sensitivity results
Criterion Area Specificity
(95% CI)
Sensitivity
(95% CI)
Erosion >0* All joints 28.3 (22.0 to 35.6) 94.0 (83.8 to 97.9)
Erosion >1 All joints 84.3 (78.0 to 89.1) 52.0 (38.5 to 65.2)
Erosion >0 US/MCP2,3,5/MTP5 60.2 (52.7 to 67.4) 86.0 (73.8 to 93.1)
Erosion >1 US/MCP2,3,5/MTP5 94.0 (89.3 to 96.7) 50.0 (36.6 to 63.4)
Diameter2.5 mm US/MCP2,3,5/MTP5 90.4 (84.9 to 94.0) 54.0 (40.4 to 67.0)
Erosion >0 MCP2 proximal 84.9 (78.8 to 89.6) 46.0 (33.0 to 59.6)
Erosion >1 MCP2 proximal 99.4 (96.7 to 99.9) 14.0 (7.0 to 26.2)
Erosion >0 MCP3 proximal 96.4 (92.3 to 98.3) 26.0 (15.9 to 39.6)
Erosion >1 MCP3 proximal 99.4 (96.7 to 99.9) 14.0 (7.0 to 26.2)
Erosion >0 Ulnar styloid 88.6 (82.8 to 92.6) 48.0 (34.8 to 61.5)
Erosion >1 Ulnar styloid 99.4 (96.7 to 99.9) 10.0 (4.4 to 21.4)
Erosion >0 MTP5 Proximal 83.7 (77.4 to 88.6) 74.0 (60.5 to 84.1)
Erosion >1 MTP5 Proximal 98.8 (95.7 to 99.7) 42.0 (29.4 to 55.8)
*Erosion semiquantitative score> 0
Disclosure statement: All authors have declared no conflicts of
interest.
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51. THE USEFULNESS OF A MUSCULOSKELETAL
ULTRASOUND (MUS) SCORING SYSTEM FOR 22 HAND
JOINTS EXAMINATION FOR THE DETECTION OF EARLY
UNDIFFERENTIATED INFLAMMATORY ARTHRITIS AND
TREATMENT DECISION MAKING IN ESTABLISHED
INFLAMMATORY ARTHRITIS
Coziana Ciurtin1, Maria Leandro1, Dzifa Dey1, Anupama Nandagudi1,
Ian Giles1, Mike Shipley1, Vanessa Morris1, John Ioannou1,
Michael Ehrenstein1 and Debajit Sen1
1Department of Rheumatology, University College London Hospitals,
London, United Kingdom
Background: Our study aimed: 1) To evaluate the usefulness of a 22
hand joints scoring system, adapted from the OMERACT recommen-
dations in assessing and differentiating patients with established
rheumatoid arthritis (RA) from those with possible or definite early
undifferentiated inflammatory arthritis. 2) To establish the usefulness of
the MUS findings in guiding treatment decisions.
Methods: 98 patients referred to the University College London
Hospital Musculoskeletal Ultrasound Service during July-October
2011, with established inflammatory arthritis and a clinical suspicion
of early inflammatory arthritis, were examined. MUS examination
(7.5 MHz probe) was employed for the assessment to the dorsal
aspect of 22 joints (wrists and all MCP and PIP joints bilaterally). We
assessed for the presence of synovial hyperthorphy (grade 2-4), joint
effusions (grade 1-3), Doppler signal (grade 1-2), and erosions.
Results: 1) This scoring system allowed us to differentiate the group
with established RA from the group with early undifferentiated
inflammatory arthritis (the larger two groups) with respect to the
presence of synovial hypertrophy grade 3 (24 patients vs. 7, p< 0.001)
and grade 4 (5 patients versus none, p< 0.0001); the presence of
erosions (17 patients versus 7, p<0.003); the number of joints with
erosions (12.3þ/-4.3 vs. 3.2þ/-1.4, p< 0.002), joint effusion grade 2
(24 patients with RA, affecting 7.5þ/-2.7 joints vs. 2, affecting only one
joint in the early inflammatory arthritis group, p<0.0001) and grade 3
(13 patients with 4.6þ/-1.2 joints involved vs. none).
2).We identified 14 patients with active synovitis with positive
Doppler signal that prompted a change of treatment (9 with active,
erosive RA and 5 with undifferentiated inflammatory arthritis). The
majority of patients on biologics (8/9) had no signs of active disease,
but all had advanced erosive disease (6 with RA, 2 with PSA and one
with AS with peripheral arthritis) - no treatment changes were made as
the patient with active disease was due to have the second Rituximab
course.
Conclusions: This 22 hand joints US scoring addressed all the
purposes of our study. The most common findings that did not
correlate with any laboratory evidence of inflammatory or autoimmune
abnormalities was the presence of joint effusion grade 1, affecting less
than 5 joints and minimal synovial hyperthrophy affecting less than 3
joints.
Disclosure statement: All authors have declared no conflicts of
interest.
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52. AUDIT OF THE ADHERENCE TO BSR GUIDELINES ON
THE MANAGEMENT OF GOUT (2007), IN TWO PRIMARY
CARE CENTRES WITHIN THE MERSEYSIDE REGION
Marian Chan1, Tim M. Quinlan2, Richard Brophy2 and
Devesh Mewar1
1Rheumatology, Royal Liverpool University and Broadgreen Hospital,
Liverpool, United Kingdom; 2General Practice, Mersey Deanery,
Mersey, United Kingdom
Background: Retrospective studies have demonstrated suboptimal
management of gout. Poor patient-concordance and compliance with
urate-lowering therapy (ULT) are contributing factors.Despite EULAR
(2006) and BSR(2007) recommendations, management remains
suboptimal.We present an audit of the adherence to the BSR
guidelines,4 years after publication in two primary care centres(PCC).
Methods: Adherence was audited using an agreed proforma retro-
spectively via electronic case-note(ECN) review of two large PCC
within Merseyside. Practice A-socioeconomically affluent Vs Practice
B socioeconomically-mixed.Only data available from 2006 following
the commencement of ECN were captured. Cases were identified from
EMIS/Synergy platforms, using the search terms ‘‘gout’’, ‘‘acute
gout’’, ‘‘gouty arthritis’’ and ‘‘chronic gout’’.
Results: Total Number¼407(A:B;272:135). Please see Table 1 for
demographics/risk factors.Serum Urate level (SUA) was checked in
179(44%) pts at diagnosis,of which 161(90%) were elevated.
Overall,153 (35%) had SUA checked within previous 24 months.ULT
was started in 213(52%) pts.Initial allopurinol dose varied consider-
ably:74(34%)-100 mg once daily(OD);13(5%)-200mgOD;64(33%)-
300mgOD;62(26%) were unknown.Only 120(38.8%) patients were
co-prescribed (NSAID/Colchicine).Only 60(25%) had SUA checked
after starting ULT.Of these,22(30%) had ULT elevated.Of those who
started ULT,175(82%) remained on treatment based on 24 month
repeat prescriptions -Compliance¼ 92%.Compliant pts who had SUA
checked in last 24 months,mean allopurinol dose¼220.5 mg OD,
mode¼300mgOD (100 mg :200 mg:300mg:400mg:>400 mg: n¼59
(34.4%):22(11%);89(51%);3(2%);1(1%). The mean SUA was 394mmol/
L. For non-compliant pts,mean SUA¼475mmol/L. Target SUA was
achieved in 38(30%) compliant pts who had SUA in 24 mths.Of those
who were compliant,61(42%) were co-prescribed,inversely,26(62%)
non-compliant pts did not have co-prescription.Lifestyle advice given
in 185(45.5%) pts
Conclusions: This audit illustrates that compliance with BSR (2007)
guidelines is suboptimal particularly ULT initiation and acheivement of
target SUA.Patient factors may account for some of this, but there
remains much scope for improvement. Further work will aim to provide
simple primary care based interactive strategies to improve outcomes
with re-auditing.
TABLE 1.
n (%)
Male 337 (83)
Female 70 (17)
Average female age 72
Average male age 64
Diagnosis: primary care vs hospital 237 (57): 16 (4)
Risk factors
BMI> 30 kg/m2 107 (26)
>30 units alcohol/wk 46 (11)
GFR <60 ml/min/1 101 (24.8)
Congestive cardiac failure 169 (41.5%)
Diuretic 74 (18.2) loop diuretic,
95 (23.3) thiazide diuretic
>1 risk factor for gout 121 (29.7)
Disclosure statement: D.M. has received honoraria from A. Menarini.
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53. A CASE OF SPINAL GOUT
Dipti Patel1, M. J. Wilby3, Vincent Pellegrini2, Brian Eyes2,
Daniel Crooks4 and Marina Anderson1
1Rheumatology, Aintree University Hospital NHS Foundation Trust,
Liverpool, United Kingdom; 2Radiology, Aintree University Hospital
NHS Foundation Trust, Liverpool, United Kingdom; 3Neurosurgery,
The Walton Centre NHS Foundation Trust, Liverpool, United
Kingdom; 4Histopathology, The Walton Centre NHS Foundation
Trust, Liverpool, United Kingdom
Background: Gout is a common cause of acute peripheral arthro-
pathy, with a prevalence of 0.2% to 0.4% in western population and an
annual incidence of 0.01% to 0.015% [1]. Gouty involvement of the
spine is rarely considered in routine clinical practice. However, it is
likely that it is under-recognized, as a recent review identified 100
cases [2]. Spinal gout predominantly involves the lumbar region with
the most common finding being facet joint erosion. In addition, the
epidural space, intradural compartment, ligamentum flavum, pedicles
and neural foramen can be affected. We present the challenges
encountered in diagnosing axial gout.
Methods: The clinical presentation, investigation, diagnosis and
management of a case of gout involving the spine is described.
Results: A 62-year old woman, with hypertension, diet controlled
diabetes mellitus and history suggestive of previous untreated gouty
attacks, presented with an acutely painful, swollen, red right foot.
Serum uric acid level was elevated at 0.56 (0-0.30 mmol/L). She
responded to Colchicine and was subsequently commenced on
Allopurinol. She also reported a 2-year history of worsening lower
back pain with recent onset of right sided sciatica. MR scan of the
lumbar spine showed a lesion involving the L4/5 facet joint. A CT scan
of the region confirmed punched-out lesions in the right facet joint at
the L4/5 level. Initial CT guided biopsy of the lesion revealed a foreign
body giant cell reaction with no urate deposits and no evidence of
tumour on histopathology. Her urate levels remained elevated at 0.54
(0-0.30 mmol/L). Although she remained free of acute gout attacks,
over the next 12 weeks her back and leg pain progressed and
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ambulation became difficult.The patient underwent a L4/5 decom-
pression and right-sided L5 foraminotomy and was found to have thick
chalky waxy material on the right side of ligamentum flavum causing
right lateral recess stenosis. Histopathology revealed crystalline
deposits of urate crystals confirming gouty tophi. Her symptoms
improved considerably following the removal of the mass. Current
serum urate level is 0.28 (0-0.30 mmol/L) on Allopurinol. Her peripheral
gout remains well controlled.
Conclusions: Our case highlights the importance of considering the
possibility of axial involvement in those patients with gout, who also
have spinal pain and associated symptoms of radiculopathy. The
challenges in diagnosing spinal gout can be overcome by having a
high index of clinical suspicion, supplemented by radiological
investigations like CT/MRI scans especially with gadolinium protocol.
A biopsy of the involved area for crystal analysis under polarized
microscopy is valuable in making the diagnosis. Although medical
management may be an option in some cases, surgical intervention
has been reported to have good outcomes in patients with
neurological compromise. A multidisciplinary approach involving
Rheumatologists, Spinal Surgeons and Histopathologists will facilitate
diagnosis and ensure timely management.
Disclosure statement: All authors have declared no conflicts of
interest.
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54. STEROID INJECTION IN PLANTAR FASCIITIS:
A PLACEBO CONTROLLED TRIAL
Elisabeth Ball1, Helen McKeeman1, James Burns1, Wing Hoi Yau1,
Owen Moore1, Joanne Foo1, Claire Benson1, Chris Patterson2,
Gary Wright1 and Allister Taggart1
1Rheumatology, Musgrave Park Hospital, Belfast, United Kingdom;
2Medical Statistics, Queen’s University, Belfast, United Kingdom
Background: Plantar Fasciitis is a common cause of heel pain and can
be very debilitating affecting quality of life and work capacity. The aim
of this study was threefold; to compare steroid injection with placebo,
to compare ultrasound guided with unguided steroid injection and to
establish a role for ultrasonography in the management of plantar
fasciitis.
Methods: 65 patients with a clinical diagnosis of plantar fasciitis were
recruited via GP and Podiatry referrals to the Belfast Health and Social
Care Trust between Nov 2008 and June 2011. Patients with a history of
inflammatory arthritis or who had ever received a previous steroid
injection were excluded. Patients were randomized to one of three
groups - ultrasound guided steroid injection, palpation guided steroid
injection or ultrasound guided placebo/saline injection. The 100 mm
visual analogue scale (VAS) of pain and ultrasonography of the plantar
fascia were performed at the baseline visit and at the follow-up visits at
6 and 12 weeks. Blinding was applied to the participants and to the
investigator performing procedures and measuring outcomes.
Analysis of covariance was used to analyse the 6 week and 12 week
VAS results in the three groups using the baseline VAS levels as a
covariate.
Results: The median duration of symptoms was 6 months (range
2.5-60). The mean (st dev) thickness of the plantar fascia at the anterior
calcaneal border on ultrasound at baseline was 6.05 (1.47) mm.
22 Patients were randomized to ultrasound guided steroid injection,
21 patients to palpation guided steroid injection and 22 to ultrasound
guided placebo injection. No adverse events were reported. There was
evidence of a significant difference in VAS scores between the groups
both at 6 weeks and at 12 weeks (p¼0.021 and p¼ 0.009
respectively). There was a 20.8 mm (95% CI¼3.3-38.1) difference in
mean VAS scores at 6 weeks between the ultrasound guided steroid
group and the placebo group and a 22.6 mm (95% CI¼5.4-39.8) mean
difference between the palpation guided steroid group and the
placebo group at 6 weeks. At 12 weeks the mean difference was
23 mm (95% CI¼4-42.8) and 27 mm (95% CI¼ 9.2-46) respectively
between both groups and the placebo group. There was no significant
difference in mean VAS scores following steroid injection between the
ultrasound guided and the palpation guided groups at either time
point.
Conclusions: Despite the widespread use of steroid injection only two
randomized controlled trials have tested its effect over placebo in
plantar fasciitis. Blockey in a study published in the BMJ in 1956 with
19 patients showed no benefit over placebo and Crawford et al in 1999
showed a benefit at one month but not subsequently. In our study of
65 patients steroid injection showed a clear benefit over placebo at 6
weeks and was sustained at 12 weeks. There were no significant
differences in the results achieved using ultrasound guided or
palpation guided steroid injection.
Disclosure statement: All authors have declared no conflicts of
interest.
55. HELPLINE AUDIT: DOES THE NRAS TELEPHONE
HELPLINE SERVICE BENEFIT USERS WHO HAVE BEEN
DIAGNOSED WITH RHEUMATOID ARTHRITIS?
Sarah Drew1 and Lorraine Tanner2
1Fundraising Team, National Rheumatoid Arthritis Society,
Maidenhead, United Kingdom; 2Helpline Team, National Rheumatoid
Arthritis Society, Maidenhead, United Kingdom
Background: The National Rheumatoid Arthritis Society was set up in
2001 to provide support and information to the approximately 690,000
people in the UK who live with rheumatoid arthritis (RA). The provision
of a helpline is central to this and it responds to over 200 contacts a
month covering a wide range of topics. Auditing the helpline is an
important ongoing process but historically only quantitative data has
been collected together with anecdotal evidence. However, we were
fortunate to have been offered the services of a research analyst via
the Rank Foundation’s ‘Time to Shine’ programme. As a result we
have been able to take a more systematic qualitative approach to
demonstrate the outcomes for our callers.
Successful outcomes were identified in two ways: firstly, by
establishing whether callers received the benefits they wanted. This
recognizes that beneficiaries have different needs and priorities
(Lieberman, 1978). Secondly, by determining whether the caller got
any benefits that they didn’t expect. For instance, they may have
called the helpline for information but have also received support.
Methods: 15 respondents were selected to take part in a semi-
structured telephone interview. Criteria for inclusion in the study was:
taking part in a helpline call which lasted over 10 minutes a week
before the interview, having RA and being over 18 years of age.
Interviews lasted approximately 15 minutes and were carried out by
our research analyst intern. Topics covered included motives for
calling, content of the helpline call, the outcomes experienced and any
suggested improvements to the service. Analysis was undertaken by
coding transcripts of the interviews and identifying emerging themes.
Demographic and other characteristics were taken into account during
this process.
Results: Initial findings suggest callers felt that their knowledge
increased in relation to their health, social and working lives and
personal lives, and that they had a greater understanding of the
healthcare systems and how to negotiate them. Emotional support
represented the most important benefit for these callers. Further
analysis of the data is currently being undertaken.
Conclusions: These initial findings suggest that calling the helpline
has a tangible impact on beneficiaries. The audit provides the charity
with the opportunity to review the helpline activities and evaluate the
effectiveness of the service. Our ability to demonstrate a social return
on investment will also enable NRAS to further strengthen funding
applications. This will ensure the continued delivery of the service.
Future areas of research could include looking at the impact of the
service on a specific subset of the population such as those newly
diagnosed. It may also be possible to introduce a qualitative
longitudinal element by revisiting respondents after two months. This
would allow us to evaluate the longer term impact of the service.
Disclosure statement: All authors have declared no conflicts of
interest.
56. PRESENTATION AND CLINICAL OUTCOME OF
SARCOIDOSIS PATIENTS PRESENTING TO
RHEUMATOLOGY: A REGIONAL AUDIT
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Background: Sarcoidosis is a poorly understood condition which may
present to rheumatologists. There are no generally accepted treatment
guidelines.Most previous studies have shown two fairly distinct groups
of patients: young white adult (predominantly male) patients presenting
with acute mostly self-limiting disease (Lofgren’s Syndrome), and an
older, often black population, with a more chronic presentation and
disease course.
Methods: This was a retrospective audit of patients identified by notes
review. Rheumatology departments from 8 hospitals within the South
West Thames region contributed data. A proforma was completed by
rheumatologists on patients referred to their departments between
1990 and 2010 in whom a diagnosis of sarcoidosis was made.
Results: We obtained data in 77 cases: 55% female, 45% male. Mean
age was 51 yrs (range 25-79yrs) with an equal spread between the 30-
39, 40-49 and 50-59 yr age groups. Mean age in the black population
was 46yrs, in the white, 53 yrs. There was a varied ethnic composition:
white 36 (47%); black 23 (30%); Asian 13 (17%); other 2 (6%). 5% were
current smokers; 20% ex-smokers. The commonest occupations were
television industry (4 patients) and teaching (3 patients). Most cases
had several distinct presenting features. As might be expected in a
rheumatology clinic, the commonest presenting features were muscu-
loskeletal, present in 55%. This included oligoarthritis in 38% and
dactylitis in 5%. Oligoarthritis appeared more common as a presenting
feature in the black population (60% vs. 38%). 27% had cutaneous
involvement, most commonly erythema nodosum (17%). Symptomatic
respiratory involvement occurred in 34%. 13% had neurological
manifestations with headache and cranial nerve palsy in 9%. 38%
had hilar lymphadenopathy at presentation. Angiotensin-converting
enzyme levels were raised in 32% and hypercalcaemia present in only
4%. Chest X-rays were abnormal in 79%, the commonest finding
being hilar lymphadenopathy. 47% patients had past or present
treatment with steroids; 17% were currently treated. The commonest
second line agents used were hydroxychloroquine (18%), methotrex-
ate (16%) and azathioprine (14%). Ciclosporin was used in 4%. Two
patients with resistant disease were improved on anti-TNF therapy.
Musculoskeletal features improved in 52%, respiratory features in
70%, mucocutaneous in 78%, eye in 88% and CNS in 50%.
Conclusions: This audit shows the value of regional collaboration in
relatively rare conditions such as sarcoid. The prominence of articular
presentation probably reflects our speciality but cutaneous and
respiratory features were also common and many patients had
multisystem disease involvement. Oligoarthritis appeared more
common as a presenting feature in the black population. We found
no biphasic age distribution amongst this cohort. Outcome was
generally reasonable for respiratory and mucocutaneous features but
less favourable for musculoskeletal and CNS involvement.
Disclosure statement: All authors have declared no conflicts of
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57. SERUM LEPTIN LEVEL IN PATIENTS WITH
HYPOTHYROIDISM AND SYMPTOMS OF INFLAMMATORY
ARTHRITIS IS SIGNIFICANTLY INCREASED COMPARED
WITH A MATCHED GROUP WITHOUT PERIPHERAL
JOINT-ASSOCIATED SYMPTOMS
Coziana Ciurtin1,2, Ionela Dimofte2, Mihaela Dabu2 and
Bogdan Dabu2
1Department of Rheumatology, UCLH, London, London,
United Kingdom; 2Department of Molecular Biology, Carol Davila
University of Medicine and Pharmacy, Bucharest, Romania
Background: Background: Previous studies have shown the potential
role of leptin in modulation of the inflammatory processes associated
with arthritis. Leptin is considered an important factor of bone
remodeling (1), a protective agent against septic arthritis, a marker
of inflammation in rheumatoid arthritis (2) and an independent regulator
of the TSH levels (3).
Methods: Methods: We have investigated 31 patients with clinical mild
synovitis and inflammatory symptoms affecting their hands and
concomitant diagnosis of hypothyroidism in comparison with 42
patients with clinical hypothyroidism and absence of inflammatory
arthritis symptoms. All the patients were evaluated before the initiation
of hormone replacement therapy. The two groups were matched for
sex (25.8% vs. 26.2% males), age (56.29þ/-9.7 vs. 61.8þ/-11.8 years
old) and BMI (29.5þ/- 2.7 vs. 31.6þ/- 4.34 kg/m2). The leptin serum
levels were quantified using a human leptin EIA kit.
Results: Results: The free T4 levels for the two groups were 0.27þ/-
0.12 vs. 0.31þ/-0.18 ng/dl and the TSH levels were 12.8þ/-2.78 vs.
13.2þ/- 3.75 mU/l, showing no significant difference regarding the
hormonal status of the two groups of patients (p¼0.12 and
p¼0.18).There were no major differences in the level of serum
inflammatory markers - CRP (6.2þ/- 2.8 vs. 5.9þ/-2.7 mg/dl, p¼ 0.09)
and ESR (32þ/-11.5 vs. 36.2þ/- 12.6 mm/h, p¼0.11). The presence of
RF was detected in 11 patients in the first group and in 7 in the second
group. 4 of the patients with symptoms of inflammatory arthritis had
also positive anti CCP antibodies.
The leptin levels were significantly increased within the group with
symptoms of inflammatory arthritis (36.8þ/-4.21 vs. 28.7þ/- 5.2 ng/ml,
p¼0.04).
Conclusions: Conclusion: We can conclude that the hypothesized
role of leptin in the immune response modulation could underline the
significant difference between the presence and absence of the
symptoms of arthritis associated with hypothyroidism. The significant
increased leptin level of the patients fulfilling the criteria of early
rheumatoid arthritis could permit a differentiation between the patterns
of hypothyroidism associated joint symptoms.
Disclosure statement: All authors have declared no conflicts of
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58. CLINICAL EFFECTIVENESS OF PAH SPECIFIC
THERAPIES IN SARCOIDOSIS-RELATED PULMONARY
HYPERTENSION
David Dobarro1, Benjamin E. Schreiber1, Clare Warrell1,
Clive Handler1, Gerry Coghlan1 and Chris Denton1
1Pulmonary Hypertension, Royal Free Hampstead Hospital NHS
Trust, London, United Kingdom
Background: Pulmonary hypertension is a well-known complication of
sarcoidosis. Effectiveness of PH specific therapy is not clear as there
are not randomized placebo-controlled trials. In this study, we analyse
clinical profile, management and outcomes of a cohort of patients with
sarcoidosis and pulmonary hypertension at a national pulmonary
hypertension centre.
Methods: Single centre restrospective analysis of data from patients
with sarcoidosis and pulmonary hypertension diagnosed in right heart
catheter (RHC) at a national pulmonary hypertension centre from 1999
to 2011. We found 23 patients and analysed baseline and follow-up
RHC, baseline right ventricular function, therapy and outcomes.
Results: 23 patients were found (52.2% female, 47.8% male, age at
diagnosis 57.2713.05 years) with a mean follow-up of 26 months.
The rate of death/transplant was 39.1%. 39.5% of patients had some
degree of right ventricular (RV) dysfunction at diagnosis and 60%
received specific pulmonary hypertension (PH) therapy (sildenafil or
bosentan as first line therapy). Baseline data in RHC: Wedge pressure
11,965,321 mmHg, Pulmonary mean (PM) 39,96 11,621 mmHg,
Pulmonary vascular resistance (PVR) 582,84421,786 dyn-s-cm5
and Cardiac Index (CI) of 2,435,7678 l/min/m2. When compared, no
difference was found in terms of mortality/transplant referral regarding
age at diagnosis in years (55,5778 11,84 in alive vs 59,9142 15,09
in dead p¼ 0.41), baseline 6 minutes walking test in meters
(204.09137.29 alive vs 244.67131.36 dead; p¼ 0.39), PM in
mmHg (40.3913.68 alive vs 39.338.15 dead; p¼0.77), PVR in
dyn-s-cm5 (603,42530,74 alive vs 553,12 206,81 dead; p¼ 0.44)
or CI in l/min/m2(2,550,87 alive vs 2.24 0.55 dead; p¼0.38). The
presence of some degree of impaired RV function was the only
analysed factor related to increased mortality/transplant that met
statistical significance (12.5% in normal right ventricular function vs
60% in any degree of impaired right ventricular function, p¼ 0.031). No
difference was found regarding mortality/transplant referral in patients
who received specific PH therapy or not (50% vs 37.5%, respectively,
p¼0.85). The factors related to receive specific PH therapy were
higher PM (45.4511.77 vs 32.356.18; p¼0.01) and PVR
(734.93485.81 vs 3135379.71; p¼ 0.038) and lower CI
(2.070.76 vs 2.920.53; p¼0.02). Despite no improved survival,
patients that received specific PH therapy improved their 6MWT
(þ69 m, p¼0.046), CI (þ0.45 l/m2/min; p¼0.018), and PVR (-189 dyn-
s-cm5; p¼ 0.047) compared with the baseline.
Conclusions: Mortality of patients with pulmonary hypertension and
sarcoidosis is still very high. Echocardiograms during the follow-up
can detect patients with the worst prognosis. Although with the
limitations of a retrospective analysis, our data, added to other small
experiences in the literature, try to confirm that specific PH therapy in
selected individuals can improve haemodynamics and walking
distance.
Disclosure statement: All authors have declared no conflicts of
interest.
iii72 Tuesday 1 May 2012, 10.30 – 11.30 POSTER VIEWING I
59. CLINICAL AND LABORATORY FEATURES OF PATIENTS
PRESENTING TO A RHEUMATOLOGY CLINIC WITH POSITIVE
ANTI-C1Q ANTIBODY SEROLOGY
Jasmine Ishorari1, Chris Bunn1, Huw Beynon1,
Christopher P. Denton1 and Richard Stratton1
1Rheumatology Department, Royal Free Hospital, London,
United Kingdom
Background: Hypocomplementemic urticarial vasculitis syndrome
(HUVS) is a rare disorder characterized by chronic recurrent urticaria,
arthralgia, and often severe systemic involvement. Deficiency of
complement and presence of C1q antibodies are the hallmarks of
this disease .An independent immunological entity, HUVS was first
described in 1973. Leucocytoclastic vasculitis is the main finding on
skin histology and direct immunoflorescence often reveals immuno-
globulin and complement deposition.
Methods: Review of 6 case records, laboratory data and radiology of
patients in the immunology laboratory testing positive for C1q antibody
and who presented to the rheumatology department at the Royal free
hospital between 2001 to 2010, along with a literature review.
Results: Four women and 2 men, with a mean age of 34.5 years (range
24-63 years) were seen. Of the 6, 5 had multiple comorbidities
including rheumatoid arthritis(RA), hypothyroidism, osteoporosis,
asthma, COPD, haemochromatosis and hypertension. All patients
had C1q positive antibodies with titres ranging between 16-48 (n 0-15)
.Four patients had ANA <1:100,2 had ANA >1:100 and all had
negative ENA.All,except one had low C4,(11- 15). C3 was within
normal range in 4 patients, and low in the remaining 3. All had skin
biopsy that confirmed leucocytoclastic urticarial vasculitis.All 6
patients presented with rash, 5 had arthritis,1 presented with airway
obstruction in the form of wheeze which responded to steroids, one
had scleritis and 2 patients had proteinuria.
All patients were given prednisolone, five were given hydroxy-
chloroquine, out of which one maintained remission. Four were given
azathioprine, with no remission. Four were given mycophenolate,with
only one remission. Two patients had cyclophosphomide, causing
disease remission in one. One was given rituximab and one was given
dapsone resulting in disease remission.
Conclusions: HUVS is a clinical entity considered to be different from
SLE. Our experience confirms a high prevalence of cutaneous and
joint involvement,and the association with obstructive lung disease in
severe cases.
The diagnosis was confirmed in all patients with positive anti-C1q
antibodies as well as skin biopsies positive for leucocytoclastic
vasculitis.
All joint and skin symptoms have undergone remission with the
exception of 1 patient who had active resistant disease treated with
rituximab with good results. They were all initially treated with steroids
and then steroid sparing agents.
We have therefore shown that hypocomplementemic urticarial
vasculitis needs to be recognized as a primary autoimmune
disease.High prevelance of cutaneous and joint symptoms and
potential to cause obstructive airways disease, the most feared
complication and eye involvement(scleritis) necessitates the knowl-
edge of this autoimmune entity.
Disclosure statement: All authors have declared no conflicts of
interest.
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60. COMPARISON OF MOBILE AND FIXED BEARING TOTAL
KNEE REPLACEMENTS IN RHEUMATOID ARTHRITIS
Joby J. George Malal1 and Ben Boton-Maggs1
1Orthopaedics, St Helens & Knowsley Teaching Hospitals, Widnes,
United Kingdom
Background: Mobile bearing Total Knee Replacements is a relatively
new innovation and it is postulated that this would improve the results
of Total Knee Arthroplasty. The aim of the study was to compare the
short to medium term results of fixed and mobile bearing total knee
replacements (TKR) in patients with rheumatoid arthritis (RA).
Methods: All TKRs performed in RA patients by a single firm using the
same prosthesis over a four year period were included in the study.
Data was collected prospectively and included demographic
parameters, operative data, pre operative and yearly patient and
physician derived outcome measures including the Oxford and
American Knee Surgery Society (AKSS) scores and revision rates.
Results: A total of 50 patients were operated over the four year
observation period with 24 in the mobile bearing group and 26 in the
fixed bearing group. The average follow period was 46 (range 12 to
74) months for the mobile bearing group and 45 (range 12 to
74) months for the fixed bearing group. One patient in the mobile
bearing cohort and two in the fixed bearing cohort required revision
surgery. Excluding revisions, patients lost to follow up and deaths,
there were 19 patients each in the fixed and mobile bearing cohorts for
analysis. There were no statistically significant differences between the
two cohorts with regard to demographic data, pre operative range of
movement or function, duration of follow up or revision rate. Post
operatively apart for a marginally significant improvement in walking
time at year five for the mobile bearing cohort, there was no
statistically significant difference between the two with respect to
night pain, walking pain, pain score, flexion deformity, range of
movement, Oxford score or AKSS score.
Conclusions: There is no difference in functional outcome between
mobile and fixed bearing TKRs in RA patients on short to medium term
follow up.
Disclosure statement: All authors have declared no conflicts of
interest.
61. DEFINING CRITERIA FOR RHEUMATOID ARTHRITIS
PATIENT-DERIVED DISEASE ACTIVITY SCORE THAT
CORRESPOND TO DISEASE ACTIVITY SCORE 28 AND
CLINICAL DISEASE ACTIVITY INDEX-BASED DISEASE
STATUS AND RESPONSE CRITERIA
Alexander Leung1, Daniel Farewell2 and Ernest Choy1
1Rheumatology, Cardiff University School of Medicine, Cardiff,
United Kingdom; 2Institute of Primary Care & Public Health,
Cardiff University School of Medicine, Cardiff, United Kingdom
Background: Two versions of a patient-based disease activity score
(PDAS1 [with ESR] & PDAS2 [without ESR]) in rheumatoid arthritis (RA)
had been developed and validated. Like DAS28, PDAS1 and PDAS2
are continuous status measures. However, thresholds for defining
response to treatment and remission have not yet been established.
The purpose of this study is to define criteria, based on PDAS1 and
PDAS2, for disease status: remission, low, moderate and high disease
activities and European League Against Rheumatism (EULAR) good
and moderate responses to treatment.
Methods: Data from 299 RA patients (originally used to develop PDAS)
were analysed using receiver operator characteristic (ROC) curves to
determine optimal cutpoints for PDAS1 and PDAS2 to correspond to
validated DAS28 and CDAI criteria for remission, low, medium and
high disease activity. Data from 56 RA patients initiated on Disease-
modifying Anti-Rheumatic Drugs (DMARDs) before and 6 months after
treatment were used to determine optimal thresholds for PDAS1 and
PDAS2 corresponding to EULAR good or moderate responses.
Optimal cut-off points were obtained by maximizing the average of
sensitivity and specificity. Agreement with DAS28 and CDAI response
criteria was assessed with kappa (k) statistics.
Results: Table 1 shows criteria for PDAS1- and PDAS2-based
remission, low, moderate and high disease activity. Key cutpoints for
PDAS1/PDAS2 were, respectively, 3.5, 4.5, 4.8, and 3.8, 4.6, 5.0. Area
under curve (AUC) for the ROC curves ranged from 0.89 to 0.95.
Sensitivities ranged from 79% to 99%, and specificities from 61% to
89%. Moderate to good agreement with DAS28 categories was
observed: respectively, k¼0.44 and 0.31 for PDAS1 and PDAS2.
Corresponding agreements with CDAI were k¼0.3 and 0.4. Crucially,
these agreements are comparable to those of CDAI and DAS28 in the
same group of patients (k¼0.54).
The criteria that correspond to EULAR moderate and good
response were 0.4, 0.8 for PDAS1 and 0.3, 1.2 for PDAS2. Area
under the ROC curve ranged from from 0.88 to 0.93. Sensitivities
ranged from 72% to 100% and specificities from 77% to 94%.
Agreement of DAS28 response with PDAS1 and PDAS2 were k¼ 0.46
and 0.38, respectively. Again, these were comparable to the
agreement between DAS28 and CDAI in this patient group (k¼0.55).
Conclusions: We have established useful criteria for defining high,
medium, and low disease activity as well as remission, good and
moderate response for PDAS1 and PDAS2. They have comparable
agreement to assessor based criteria, and should facilitate the use of
PDAS1 and PDAS2 in routine practice and research.
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TABLE 1 Criteria of PDAS 1 and PDAS for different disease status
Remission Low disease
activity
Moderate
disease activity
High disease
activity
PDAS1 <3.5 3.5-4.4 4.5-4.8 >4.8
PDAS2 <3.8 3.8-4.5 4.6-5.0 >5
Disclosure statement: All authors have declared no conflicts of
interest.
62. PREDICTING ONGOING ACTIVE DISEASE IN EARLY
RHEUMATOID ARTHRITIS USING CLINICAL MEASURES
Nicola J. Gullick1, Adam Young2, Ernest H. Choy3 and
David L. Scott1
1Academic Department of Rheumatology, King’s College London,
London, United Kingdom; 2Rheumatology, St Albans City Hospital,
Cardiff, United Kingdom; 3Section of Rheumatology, Cardiff
University School of Medicine, Cardiff, United Kingdom
Background: UK guidelines for early DMARD therapy in RA favour
combination DMARDs to achieve sustained low disease activity
(DAS28< 3.2) risking over or under-treatment of significant numbers
of patients. A simple algorithm using commonly recorded clinical
factors would enable early identification of poor responders.
Methods: Predictors of persistent disease activity (PDA; DAS28 3.2
at both 6 and 12 months) were investigated in two early RA studies:
ERAN (an observational cohort) and CARDERA (RCT of combination
DMARDs/steroid). Disease activity was measured by DAS28(ESR).
Logistic regression was used to assess predictive capacity of baseline
variables: sex, smoking, duration, RF status, tender joint count (TJ),
swollen joint count (SJ), ESR, initial therapy and HAQ.
Results: 175 patients in ERAN with data at 6 and 12 months were
used to develop the predictive model (mean age 56; 111 female; 62%
RFþ; mean DAS28 4.7, mean symptom duration 8 months). 93% were
treated with a single DMARD initially (39% SZP, 45% MTX, 7% HCQ),
but treatment choice did not predict PDA. HAQ, SJ, TJ and ESR were
individual predictors of PDA. TJ (OR 1.13 CI 1.03, 1.21), HAQ (OR 2.10
CI 1.16, 3.86) and ESR (OR 1.05 CI 1.02, 1.08) remained predictive in
an adjusted model. A simple practical model was generated using
TJ 6, HAQ 1.0, ESR 20, combined in a 4-point score. High scores
(max 3) were associated with PDA. The model was validated in the
CARDERA cohort (n¼465; mean age 54; 325 female; 65% RFþ; mean
DAS28 5.8; mean disease duration 4.4 months), showing similar
predictive capacity, although MTX monotherapy increased the risk of
PDA (OR 2.7, 95% CI 1.4, 5.1). Triple therapy (ciclosporin, MTX &
steroids) reduced PDA in those with all 3 factors, but PDA was still
present in 59%. Use of this model to predict persistent high activity
(DAS28 5.1 at 6 and 12 months) showed similar results in both early
RA cohorts (Table). There were few patients with a score of 0/3
(26 patients in ERAN and 11 in CARDERA) but the majority had a good
outcome, with <20% PDA.
Conclusions: Baseline TJ, HAQ, and ESR can predict PDA in early RA.
Patients at high clinical risk of PDA should be treated with early
aggressive combination DMARDs & steroids, although many patients
will continue to have active disease despite this. Further studies are
required to assess if high-risk patients should be treated preferentially
with early biologics.
TABLE 1 Numbers of predictors and persistently active (DAS28> 3.2) or very active
(DAS28> 5.1) disease
Study Combination of TJ6, HAQ1.0
and ESR 20
p
0 1 2 3
Persistently active disease (DAS28 3.2)
ERAN n (%) 5/26 (19) 16/43 (37) 38/47 (81) 36/40 (90) <0.001
CARDERA (All) n (%) 2/11 (18) 24/65 (37) 103/164 (63) 174/227 (77) <0.001
CARDERA (MTX) (%) 0/2 (0) 6/13 (46) 25/42 (60) 50/60 (83) 0.002
CARDERA
(Triple therapy) (%)
0/1 (0) 6/20 (20) 31/49 (63) 27/46 (59) 0.048
Persistent high disease activity (DAS28 >5.1)
ERAN n (%) 0/26 (0) 2/43 (5) 9/47 (19) 18/40 (45) <0.001
CARDERA (All) n (%) 0/11 (0) 3/65 (5) 25/15 (15) 69/227 (30) <0.001
Disclosure statement: All authors have declared no conflicts of
interest.
63. THE ROLE OF AMINO-PROPEPTIDE OF TYPE III
COLLAGEN AND HYALURONIC ACID AS BIOMARKERS FOR
SYNOVIAL VOLUME IN PATIENTS WITH RHEUMATOID
ARTHRITIS
Chris Wincup1, Ben Fisher1, Peter Charles1 and Peter Taylor2
1Kennedy Institute of Rheumatology, Imperial College, London,
United Kingdom; 2Kennedy Institute of Rheumatology, University of
Oxford, Oxford, United Kingdom
Background: Amino-Propeptide of Type III Collagen (PIIINP) and
Hyaluronic acid (HA) have previously been suggested as serum
biomarkers of total body synovial volume and may be useful in the
assessment of Rheumatoid Arthritis (RA) disease activity. PIIINP
constitutes one of the main forms of collagen found within synovium.
It has previously been documented that PIIINP correlates with
inflammatory markers in RA. In addition has also been suggested
that RA patients with normal PIIINP levels have a better prognosis. HA
is a high molecular weight polysaccharide chain molecule that is
produced by synoviocytes and chondrocytes. It has an important role
in providing joint lubrication within the intra-articular surfaces. HA is
found in high levels in the synovial membrane and synovial fluid.
Previous studies have suggested it can be predictive of disease
severity in early RA. This study aimed to investigate relationships
between serum levels of PIIINP / HA and disease activity including
ultrasonographic indicators of synovial volume in RA using
Spearman’s rank correlation.
Methods: 23 RA patients were recruited from the Early Arthritis Clinic
(EAC) at the Kennedy Institute of Rheumatology, Charing Cross
Hospital. All volunteers consenting to participate in the study under-
went clinical assessment by a physician (DAS-28 and SJC). Serum
was taken for PIIINP, HA, CRP and ESR.
Additionally all patients underwent ultrasonography of all 10
metacarpophalangeal (MCP) joints for
assessment of synovial thickness and Doppler flow.
Results: A significant correlation was noted between SJC-28 and HA
(p¼0.002) and PIIINP (p¼0.018). Similarly PIIINP showed correlation
with DAS-28 (p¼0.01). A correlation between PIIINP and CRP was
also noted (p¼0.009). With respect to imaging, HA showed significant
correlations with both synovial thickness (p¼ 0.048) and power
Doppler flow (p¼0.01).
Conclusions: HA demonstrated strong relationships with imaging
features of disease activity that were comparable with CRP. PIIINP
showed correlation with both 28 SJC and DAS-28 scores. These
findings support the hypothesis that serum HA and PIIINP concentra-
tions are biomarkers of disease activity in early RA. As such, HA and
PIIINP may have a potential role in stratification of poor prognosis in
early RA.
Disclosure statement: All authors have declared no conflicts of
interest.
64. TEMPORAL IMPROVEMENTS IN DISEASE ACTIVITY
IN OUTPATIENTS WITH RHEUMATOID ARTHRITIS
Nicola J. Gullick1,2, Louise C. Pollard1, Bruce W. Kirkham2 and David
L. Scott1
1Academic Department of Rheumatology, King’s College, London,
London, United Kingdom; 2Rheumatology, Guy’s & St Thomas’ NHS
Foundation Trust, London, United Kingdom
Background: Clinical outcomes in rheumatoid arthritis (RA) should
have improved over time due to the expansion of rheumatology
services, use of more intensive conventional treatments and the
advent of biological therapies. We measured the magnitude of
improvements in disease activity in RA outpatients seen between
1997 and 2011.
Methods: We examined changes in DAS28 and its components in: (a)
cross-sectional studies of 95-310 consecutive RA outpatients seen at
one centre seen from 1997-2009; (b) all 4901 outpatient visits in 863
RA patients attending a second centre from 2005-2010.
Results: DAS28 and its constituent measures improved over time in
both centres (Table 1). In Centre 1 mean DAS28 fell from 5.1 to 3.8
over 12 years. In Centre 2 mean DAS28 fell from 4.1 to 3.6 over
5 years, where the aim of treatment to reach a target DAS28 <2.6 was
instituted in 2005. In both centres the average annual fall in DAS28 was
0.1. Mean ESRs showed comparable changes from 35 to 26 over
12 years at Centre 1 and from 25 to 20 at Centre 2. Joint counts and
patient global scores followed the same general pattern, though there
was greater variability with these clinical assessments. There was also
a fall in the frequency of active RA (DAS28 >5.1) from 49% of patients
in 1997 to 17-21% of patients in 2009-10. Increasing numbers of
patients achieved DAS28 remission (DAS28 <2.6), although a
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significant number of patients have persistent moderate activity in both
centres.
Conclusions: Mean DAS28 scores have improved by 1.2 since 1997.
The frequency of high disease activity has halved in outpatients with
RA, with increasing numbers of patients achieving DAS remission. The
rate of improvement is similar across adjacent UK centres. This decline
preceded the biologic era but has continued within it. Improved
specialist care is the most likely explanation for these substantial
improvements, though other explanations cannot be excluded.
Despite these improvements, many patients have persistent moderate
disease activity. The current DAS28 threshold of >5.1 for accessing
biologics no longer appears clinically appropriate and should be
lowered if improvements are going to continue.
TABLE 1 Temporal changes in mean DAS28 scores, percentage high disease
activity (DAS28 >5.1) and remission (DAS28< 2.6)
Centre 1 Centre 2</b)
Year N mean
DAS28
% DAS28
> 5.1
% DAS28
< 2.6
Year N mean
DAS28
% DAS28
> 5.1
% DAS28
< 2.6
1997 194 5.1 49 8 2005 220 4.1 24 17
2002 310 4.7 44 9 2006 802 4.0 25 19
2006 95 4.5 33 9 2007 663 3.8 22 22
2008 171 3.9 22 18 2008 806 3.8 21 26
2009 285 3.8 21 22 2009 531 3.6 17 28
2010 732 3.6 20 30
N¼ number of visits recorded in each year
Disclosure statement: B.K. has received consultancy fees from
Roche, Abbott, Bristol-Myers Squibb and Pfizer, and a research grant
from UCB. All other authors have declared no conflicts of interest.
65. BIOMAKER SIGNATURE IN RHEUMATOID ARTHRITIS
PATIENTS WITH LOW DISEASE ACTIVITY: THE REMIRA
STUDY
Margaret H. Ma1, Saroja Ramanujan2, Guy Cavet2, Doug Haney2,
Gabrielle H. Kingsley1, David Scott1 and Andrew Cope1
1Rheumatology, King’s College London, London, United Kingdom;
2Informatics, Crescendo Bioscience, South San Francisco,
California, United States of America
Background: With intensive therapy, LDA states are becoming
increasingly common in RA patients. Conventional clinical tools
perform poorly in discriminating true remission from persistent sub-
clinical disease. There is an urgent need to improve the definition of
LDA states. A multi-biomarker signature that combines levels of 12
serum biomarkers to produce a score between 1 and 100 was recently
validated as a test for RA disease activity. We examined the use of this
multi-biomarker disease activity (MBDA) test in assessing the hetero-
geneity of LDA states and differentiating remission vs non-remission.
Methods: RA patients on stable therapy with <10 years disease
duration and DAS28ESR<3.2 were recruited into the REMIRA study,
and serum samples were acquired at baseline. Concentrations of 12
protein biomarkers (VCAM-1, EGF, VEGF-A, IL-6, TNF-RI, YKL-40,
MMP-1, MMP-3, leptin, resistin, SAA, CRP) were determined and used
to generate MBDA scores according to a pre-specified algorithm.
Association between the MBDA score and clinical remission was
assessed by calculating the area under the ROC curves (AUROCs) for
different remission criteria. Comparison of biomarker concentrations
between remission and non-remission LDA patients was performed
using the Wilcoxon test and a fixed-sequence procedure to control for
the effects of multiple testing.
Results: 70 RA patients with a mean age of 58 (SD 14) and disease
duration of 50 (SD 31) months were recruited. 61% were female, 82%
were Caucasian, 14% were Afro-Caribbean, and 4% were Asian. 68%
were seropositive. The mean DAS28ESR was 1.84 (SD¼ 0.83), and the
mean DAS28CRP was 1.98 (SD¼ 0.69). Wide variation in biomarker
levels and profiles was seen. SAA was most suppressed and
EGF most elevated relative to historical data. The MBDA score was
significantly associated with remission vs. non-remission
(AUROC¼0.74, 95% CI 0.60,0.85, p<0.001 for Boolean definition).
Individually, IL-6, CRP, and SAA were significantly lower in remission
than in non-remission patients (Table 1). Although pro-inflammatory
biomarkers were generally lower in remission, a small subgroup of
patients had elevated biomarkers and MBDA scores despite being in
clinical remission.
Conclusions: The REMIRA LDA cohort is heterogeneous as reflected
by the wide biomarker variation. The MBDA score can differentiate
between LDA/remission and LDA/non-remission and has a potential
role for disease activity assessment in LDA patients. Longitudinal
follow-up of patients may improve our understanding of the
relationship between elevated biomarkers and disease progression
in patients in the absence of symptoms
TABLE 1 Concentrations of biomarkers between remission and non-remission LDA
patients. IQR¼ Inter-Quartile Range
Biomarker Median (IQR) LDA/
remission
Median (IQR)
LDA/non-remission
p value
IL-6 [pg/ml] 6.0 (4.4-8.0) 10 (6.6-17) 0.001
CRP [mg/L] 1.4 (0.52-2.3) 2.4 (1.1-7.2) 0.009
SAA [mg/L] 0.93 (0.57-1.5) 1.6 (0.90-3.1) 0.01
Disclosure statement: G.C. is an employee with stock options at
Crescendo Bioscience. D.H. is an employee with stock options at
Crescendo Bioscience. S.R. is an employee with stock options
at Crescendo Bioscience. All other authors have declared no conflicts
of interest.
66. SENSITIVITY AND SPECIFICITY OF ANTIBODIES TO
CITRULLINATED VIMENTIN IN RHEUMATOID ARTHRITIS:
EXPERIENCE FROM A LARGE SECONDARY CARE CENTRE
Animesh Singh1, Jo Wilson2, Anthony Isaacs1, Charlotte Wing1,
Maeve McLaughlin1 and Henry Penn1
1Department of Rheumatology, Northwick Park Hospital, London,
United Kingdom; 2Department of Immunology, Northwick Park
Hospital, London, United Kingdom
Background: Rheumatoid arthritis (RA) is a chronic systemic
inflammatory autoimmune disease characterized by a symmetrical
polyarthritis. Numerous serological markers of RA have been
described including rheumatoid factor and antibodies against a
range of citrullinated proteins including anti-Sa (vimentin). More
recently, the anti-mutated citrullinated vimentin (anti-MCV) antibody
ELISA assay has been developed for the detection of IgG antibodies to
vimentin-based peptide. Anti-MCV antibody has been previously
reported to have a sensitivity of 84%, specificity of 87%, positive
predictive value (PPV) of 90% and negative predictive value (NPV) of
79%. We recently audited the diagnostic ability of anti-MCV in a large
secondary care population.
Methods: A retrospective audit of 351 patients seen during 2010 in
the rheumatology department at Northwick Park Hospital for whom
anti-MCV antibodies were requested.
Results: 351 patients had anti-MCV antibodies requested by
members of the rheumatology department between January and
September 2010 (Orgentec anti-MCV assay ORG 248). 93 patients had
a diagnosis of RA and were anti-MCV positive while 14 patients were
diagnosed with RA and were anti-MCV negative. 52 patients had an
alternative diagnoses and were positive for anti-MCV while 192
patients had alternative diagnoses and were negative for anti-MCV.
This gave a sensitivity of 87% (C.I. 79-94%), specificity of 79% (C.I.
73-84%), PPV of 64% (C.I. 56-72%) and NPV of 93% (C.I. 89-96%).
Conclusions: Our results suggest that anti-MCV may have lower
specificity and PPV together with higher NPV as compared to the
literature. This may reflect the more heterogeneous nature of our
secondary care population as compared to those in previously studies.
The increasing use of this assay in primary care also will contribute to
the drop off in specificity and PPV. Our anti-MCV sensitivity data
correlates with previous studies. Further evaluation is required of the
antibody cut-off values needed for a positive result together with
correlation with rheumatoid factor and disease activity.
Disclosure statement: All authors have declared no conflicts of
interest.
67. LONG-TERM SAFETY OF TOCILIZUMAB IN
RHEUMATOID ARTHRITIS CLINICAL TRIALS
Mark C. Genovese1, Anthony Sebba2, Andrea Rubbert-Roth3,
Juan Scali4, Moshe Zilberstein5, Liz Thompson6 and
Ronald Van Vollenhoven7
1Rheumatology, Stanford University Medical Center, Palo Alto,
California, United States of America; 2Rheumatology, University of
South Florida, Palm Harbor, Florida, United States of America;
3Rheumatology, University of Cologne, Cologne, Germany;
4Rheumatology, Durand University Hospital, Buenos Aires,
Argentina; 5Roche, Roche Nutley, Nutley, New Jersey, United States
of America; 6Roche, Roche UK, Welwyn, United Kingdom;
7Rheumatology, Karolinska University Hospital, Stockholm, Sweden
Background: Tocilizumab (TCZ), an inhibitor of interleukin-6 receptor
(IL-6R) signal transduction, has been shown to improve signs and
symptoms and reduce joint damage in patients with rheumatoid
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arthritis (RA). The purpose of this analysis was to assess the long-term
safety of TCZ in adult patients with RA.
Methods: Clinical trial data were pooled for patients receiving at least
1 dose of TCZ in clinical trials (OPTION, TOWARD, RADIATE,
AMBITION, and LITHE), a clinical pharmacology study, and long-
term extension studies (GROWTH95 and GROWTH96).
Results: Through to February 2010, a total of 4009 patients received
TCZ; the median (mean [range]) duration was 3.6 (3.1 [0.0-5.1]) years,
and the total observation time was 12,293 patient-years (PY). Rates of
adverse events (AEs), serious adverse events (SAEs), and serious
infections (Table 1) were consistent with those reported in the RA
population. The overall AE rate was 314.6/100 PY (95% CI: 311.5,
317.7). Infections were the most frequent AE (103.7/100 PY, 95% CI:
101.9, 105.5) and the most common infections were upper respiratory
tract infections and nasopharyngitis. The rate of AEs leading to
withdrawal was
5.2/100 PY. The most common AEs leading to withdrawal were
laboratory abnormalities (1.1/100 PY, transaminase elevations), infec-
tions (1.0/100 PY), and neoplasms (benign, malignant, or unspecified,
0.7/100 PY). The overall SAE rate was 14.7/100 PY (95% CI: 14.0,
15.4). Infections were the most frequent SAE (4.6/100 PY; 95% CI: 4.3,
5.0). The rate of gastrointestinal (GI) perforations was 0.24/100 PY
(95% CI: 0.17, 0.37), consistent with previously reported rates. Most
reported GI perforations (59%, 17/29) were colonic diverticular
perforations. Rates of myocardial infarction (MI) and stroke were 0.3/
100 PY (95% CI: 0.2, 0.4) and 0.2 (95% CI: 0.1, 0.3), respectively, and
were stable over time (Table 1), and similar to expected rates in the RA
population. Eight patients (0.1/100PY) experienced anaphylactic
reactions leading to withdrawal.
Conclusions: Rates of SAEs, serious infections, and cardiovascular
events have remained stable with continued exposure to TCZ in
long-term clinical trials.
Disclosure statement: All authors have declared no conflicts of
interest.
68. THE EFFICACY OF TOCILIZUMAB IN PATIENTS WITH
SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS: 52-WEEK
DATA FROM A PHASE 3 CLINICAL TRIAL
Fabrizio De Benedetti1, Hermine Brunner2, Roger Allen3,
Diane Brown2, Jeffrey Chaitow3, Manuela Pardeo3,
Graciela Espada3, Berit Flato3, Gerd Horneff3, Clare Devlin4,
Andrew Kenwright4, Rayfel Schneider5, Patricia Woo6,
Alberto Martini3, Daniel Lovell2 and Nicola Ruperto3
1Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu`, Rome,
Italy; 2Pediatric Rheumatology Collaborative Study Group [PRCSG],
Cincinnati, Ohio, United States of America; 3Paediatric
Rheumatology International Trials Organisation—IRCCS [PRINTO],
Genova, Italy; 4Roche, Welwyn, United Kingdom; 5Hospital for Sick
Children, University of Toronto, Toronto, Ontario, Canada; 6University
College London Medical School, London, United Kingdom
Background: The phase 3 TENDER trial demonstrated that tocilizu-
mab (TCZ) is effective in the treatment of patients (pts) with systemic
juvenile idiopathic arthritis (sJIA). This analysis examines long-term
response to TCZ during the open-label (OL) extension of TENDER
according to baseline characteristics.
Methods: Pts aged 2-17 yrs with active sJIA who received TCZ or
placebo every 2 wks for 12 wks (part 1) went on to receive OL TCZ in
the extension study (part 2). Stable doses of nonsteroidal anti-
inflammatory drugs (NSAIDs) & methotrexate (MTX) were continued,
with oral corticosteroid (CS) tapering permitted according to pre-
defined criteria. This post hoc analysis examines the proportion of pts
with JIA ACR30-responseþ absence of fever & JIA ACR70-response
at wk52 by baseline demographic & disease characteristics & prior/
baseline treatments.
Results: There were 112 ps in part 1 with 37 randomized to placebo, &
75 to TCZ. At 52wks, at the longer-term extension data cut, the intent-
to-treat (ITT) population consisted of 103 pts. In each subgroup, the
majority of pts achieved JIA ACR30-response plus absence of fever &/
or JIA ACR70-response at wk 52. No substantial differences in
response were observed according to age, region, disease duration,
number of active joints, fever status, C-reactive protein (CRP) level,
oral CS dose, MTX use, & previous biologic treatment (IL-1 or TNF-a
inhibitor).
Conclusions: TCZ provided a sustained response in patients with sJIA
at 52wks across multiple baseline characteristics, including longer
disease duration, highly active and severe disease and previous
treatment with biologic therapy.
Disclosure statement: All authors have declared no conflicts of
interest.
TABLE 1 Safety event rate/100 PY (95% CI) over 12-month periods.
0-12 13-24 25-36 37-48
AEs 418.4 (411.6, 425.2) 297.9 (291.8, 304.1) 273.3 (267.1, 279.6) 251.4 (244.8, 258.0)
SAEs 15.7 (14.4, 17.1) 13.9 (12.6, 15.2) 15.2 (13.7, 16.7) 14.4 (12.8, 16.0)
Serious infections 4.6 (3.9, 5.4) 3.9 (3.2, 4.7) 5.2 (4.3, 6.1) 4.9 (4.0, 5.9)
MI 0.3 (0.1, 0.5) 0.2 (0.1, 0.4) 0.3 (0.1, 0.6) 0.5 (0.3, 0.9)
Stroke 0.3 (0.1, 0.5) 0.1 (0.0, 0.3) 0.2 (0.1, 0.4) 0.1 (0.0, 0.3)
TABLE 1 Efficacy endpoints with TCZ treatment at week 52 by selected baseline characteristics (ITT population)
N at
baseline
JIA ACR30 responseþ fever
absent at week 52, % (r/n)
JIA ACR70 response
at week 52, % (r/n)
Age, y 2-5 27 88.5 (23/26) 88.5 (23/26)
6-12 48 88.1 (37/42) 88.1 (37/42)
13-17 37 85.7 (30/35) 85.7 (30/35)
Region Europe 61 83.6 (46/55) 85.5 (47/55)
North America 24 86.4 (19/22) 86.4 (19/22)
South America 22 100 (21/21) 95.2 (20/21)
Other 5 80.0 (4/5) 80.0 (4/5)
CRP level, mg/l <50 31 92.9 (26/28) 85.7 (24/28)
50 81 85.3 (64/75) 88.0 (66/75)
Disease duration, y <4 56 80.8 (42/52) 90.4 (47/52)
4 56 94.1 (48/51) 84.3 (43/51)
Active joints, n 0-9 35 90.3 (28/31) 90.3 (28/31)
10-29 55 82.4 (42/51) 88.2 (45/51)
31-71 22 95.2 (20/21) 81.0 (17/21)
Fever freeb Yes 50 91.3 (42/46) 82.6 (38/46)
No 62 84.2 (48/57) 91.2 (52/57)
Oral CS dose, mg/kg/dc <0.3 55 86.0 (43/50) 84.0 (42/50)
0.3 57 88.7 (47/53) 90.6 (48/53)
Background MTX use Yes 78 89.0 (65/73) 90.4 (66/73)
No 34 83.3 (25/30) 80.0 (24/30)
Previous biologic treatment Yes 92 88.0 (73/83) 85.5 (71/83)
No 20 85.0 (17/20) 95.0 (19/20)
Previous IL-1 inhibitor
treatment
Yes 54 87.5 (42/48) 83.3 (40/48)
No 58 87.3 (48/55) 90.9 (50/55)
aFever present (any temperature 37.5C in 7 days preceding week 52 visit; bFever present (temperature 37.5C in the 14 days
preceding baseline visit; cPrednisolone equivalent r/n¼ no. of responders/no. patients reaching week 52 visitþ no. patients previously
withdrew due to insufficient therapeutic response.
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69. A RANDOMIZED CONTROLLED TRIAL OF A COGNITIVE
BEHAVIOURAL PATIENT EDUCATION INTERVENTION
VERSUS A TRADITIONAL INFORMATION LEAFLET TO
ADDRESS THE CARDIOVASCULAR ASPECTS OF
RHEUMATOID DISEASE
Holly John1,2, Elizabeth D. Hale1,2, Gareth J. Treharne3, George
D. Kitas1,4 and Douglas Carroll2
1Department of Rheumatology, Dudley Group of Hospitals NHS
Trust, Dudley, United Kingdom; 2Department of Sport and Exercise
Sciences, University of Birmingham, Birmingham, United Kingdom;
3Department of Psychology, University of Otago, Dunedin, New
Zealand; 4Arthritis Research UK Epidemiology Unit, University of
Manchester, Manchester, United Kingdom
Background: Rheumatoid arthritis (RA)-specific European and
national guidelines state that patients should have access to
appropriate information about both the condition and its co-morbid-
ities. Cardiovascular disease (CVD) is responsible for 50% of the
excess mortality for patients with rheumatoid arthritis (RA), yet no
information currently exists written specifically for people with RA.
Generic resources are likely to be inadequate as their advice about
exercise and weight control is not set in the context of the physical and
psychosocial constraints associated with RA. We have previously
designed a novel 8 week cognitive behavioural patient education
intervention designed to effect behavioural change with regard to
modifiable CVD risk factors in people with RA, informed by the Medical
Research Councils’ recommendations for designing and evaluating
complex interventions. This study evaluates this new patient education
resource.
Methods: This was a non-blinded randomized controlled trial with a
delayed intervention arm. Participants were randomized 1:1 to receive
the cognitive behavioural education intervention or a control informa-
tion leaflet. The primary outcome measure was knowledge of CVD in
RA, using a validated self-completion questionnaire; secondary
measures were i) psychological measures relating to effecting
behaviour changes, namely smoking cessation, increasing exercise,
eating a low fat diet and losing weight; ii) actual behaviour changes,
namely smoking status, participation in physical activity and dietary
modifications (quantity of fruit and vegetables consumed, type of milk
used, use of salt or removing fat from meat); iii) clinical risk factors,
namely body mass index, blood pressure and lipid profile. Data were
collected at baseline, 2 and 6 months.
Results: 110 participants consented (52 in intervention group; 58 in
control group). At 6 months, those in the intervention group had
significantly; higher knowledge scores (p< .001); improved beha-
vioural intentions to increase exercise (p< .001), eat a low fat diet
(p¼ .01) and lose weight (p¼ .06); lower mean diastolic blood pressure
(DBP) by 3.7 mmHg, whereas the control groups’ mean DBP increased
by 0.8 mmHg. There was no difference between the groups on actual
behaviours.
Conclusions: Patient education has a significant role to play in CVD
risk factor modification for patients with RA and the detailed
development of this programme likely contributed to its successful
results. It is disappointing that behaviours, as we measured them, did
not change; perhaps the measures we used were not sensitive
enough. The challenge, as always, is how to translate behavioural
intentions into action. Larger studies, powered specifically to look at
behavioural changes are required.
Disclosure statement: All authors have declared no conflicts of
interest.
70. OUTCOME OF WOMEN WITH PREVIOUS CARCINOMA IN
SITU OF THE CERVIX WITH RESPECT TO FEMALE GENITAL
CANCER, FOLLOWING TREATMENT WITH NON-BIOLOGIC
DMARD OR ANTI-TNF FOR RHEUMATOID ARTHRITIS:
RESULTS FROM THE BSRBR
Louise Mercer1, Audrey Low1, James Galloway1, Kath Watson1,
Mark Lunt1, BSRBR Control Centre Consortium1,
Deborah Symmons1 and Kimme Hyrich1, on behalf of the BSRBR2
1Arthritis Research UK Epidemiology Unit, The University of
Manchester, Manchester, United Kingdom; 2British Society for
Rheumatology, Bride House, London, United Kingdom
Background: Little is known about the relationship between anti-TNF
therapy and outcomes in patients with a history of pre-malignant
conditions preceding treatment. BSR guidelines advise ‘exercising
caution when using anti-TNF’ in such patients. This analysis investi-
gated the risk of female genital cancer in women with a previous
history of carcinoma in situ (CIS) of the cervix prior to registration with
the BSRBR.
Methods: The analysis was conducted in the BSRBR, a national
cohort study. Patients with RA starting treatment with the TNF
inhibitors etanercept, infliximab or adalimumab and a biologic-naı¨ve
comparison cohort taking non-biologic therapy (nbDMARD) were
recruited 2001-2009. This analysis was restricted to women with CIS
cervix prior to registration, identified by flagging with the UK cancer
registry (NHS-IC) which reported cancers using ICD codes. The ICD
code for CIS cervix comprised cervical intraepithelial neoplasia (CIN) 3,
with or without mention of severe dysplasia. Rheumatologists were
also asked to report any history of cancer, but not specifically CIS, at
baseline. Subjects were followed until 31/03/2010, first female genital
cancer or death, whichever came first. Incident cancers were identified
in 3 ways; lifelong flagging with NHS-IC; 6 monthly patient and
physician questionnaires for 3 years and annual physician question-
naires thereafter. Incident cancers were defined as any new or
recurrent cancer (including CIS) of the female genital organs.
Results: 238 subjects had previous CIS cervix reported by the cancer
registry among 11738 women registered with the BSRBR; anti-TNF
190/9084 (2.1%) and nbDMARD-only 48/2654 (1.8%). Only 21 (11%)
prior CIS were also reported on the consultant baseline form in the
anti-TNF cohort and 7 (15%) in the nbDMARD cohort. Median time
from previous CIS to registration was 12 years for the anti-TNF cohort
and 14 years for nbDMARD. Seventy-three (38%) anti-TNF treated
patients started therapy within 10 years of CIS cervix. During 893
person-years (pyrs) of follow-up (median 5.2 years) no female genital
cancers were reported in the anti-TNF cohort. In the nbDMARD-only
cohort 2 were reported during 159 pyrs (median 3.9), equating to a
crude incidence rate of 13 per 1000 pyrs (95% confidence interval 2,
45). These were metastatic squamous cell cancer of the vulva and
metastatic cervical cancer. In both cases previous CIS cervix occurred
>10 years prior to registration.
Conclusions: The low level of reporting of pre-existing CIS cervix by
rheumatologists may reflect both 1) rheumatologists choosing not to
report in situ cancers as prior cancers at baseline and 2) history of CIN
being unknown to the prescribing rheumatologist. In this large national
cohort of patients with RA, there were no female genital cancers
among women with pre-existing CIS cervix selected for treatment with
anti-TNF.
Disclosure statement: O.B. received research grants from Abbott,
Merck, Pfizer, Roche, Swedish Orphan Biovitrium and UCB. All other
authors have declared no conflicts of interest.
71. CARDIOVASCULAR MORTALITY RATES (SMR) ARE
ELEVATED IN A NATIONAL COHORT OF SUBJECTS WITH
RHEUMATOID ARTHRITIS COMPARED WITH THE UK
GENERAL POPULATION WHETHER THEY WERE OR WERE
NOT TREATED WITH BIOLOGIC DRUGS: RESULTS FROM
THE BSRBR
Audrey Low1, Louise Mercer1, James Galloway1, Rebecca Davies1,
Kath Watson1, Mark Lunt1, BSRBR Control Centre Consortium2,
William Dixon1, Kimme Hyrich1 and Deborah Symmons1, on behalf
of the BSRBR2
1Arthritis Research UK Epidemiology Unit, The University of
Manchester, Manchester, United Kingdom; 2British Society for
Rheumatology, Bride House, London, United Kingdom
Background: Subjects with RA are at increased risk of cardiovascular
(CV) mortality compared to the general population. However, most
studies were conducted in cohorts dating from 1960s to 2000.
Treatment of RA has changed in the last decade, with earlier and
more aggressive use of non-biologic disease-modifying drugs
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(nbDMARDs) and the introduction of anti tumour necrosis factor (anti-
TNF) therapy. This could lead to a reduction in CV mortality by
reducing the burden of inflammation. This analysis compared CV
mortality in 2 cohorts of subjects with active RA; i) treated with anti-
TNF & ii) biologic-naive, treated with nbDMARDs only, to the UK
general population.
Methods: This analysis included all BSRBR subjects with RA recruited
between 2001-2008. They were flagged with the national death
register. Baseline CV risk factors were obtained from physician
questionnaires. All subjects were followed until 31/07/2010 or death,
whichever came first. The underlying cause of death from death
certificates was reported using International Classification for Diseases
version 10 (ICD-10). Mortality from CV causes was identified using
ICD-10 codes I00-I99, ischaemic heart disease I20-25 and stroke I63-
64. Mortality rates of the UK general population were obtained from
the Office of National Statistics. All-cause and CV-specific standar-
dized mortality ratios (SMR) were separately calculated for both
cohorts.
Results: There were 3767 subjects in the nbDMARD cohort & 12051
subjects in the anti-TNF cohort. Subjects in the nbDMARD cohort were
older, with proportionally fewer females, shorter disease duration,
lower disease activity and had a greater proportion of CV risk factors
compared to the anti-TNF cohort. In both cohorts, subjects were at
significantly increased risk from all-CVD mortality, with SMRs ranging
from 1.2-1.6 (Table). This effect was lower for stroke but the point
estimate suggests there is approximately a 30% increased risk.
Conclusions: Subjects with active RA treated with modern therapies
remain at increased risk of CV mortality compared to the general
population. SMRs only account for age and gender differences and
cannot be directly compared between the cohorts.
Disclosure statement: O.T. received research grants from Abbott,
Swedish Orphan Biovitrum, Merck, Pfizer, Roche and UCB. All other
authors have declared no conflicts of interest.
72. AN AUDIT OF INVESTIGATION OF ANAEMIA IN
RHEUMATOID ARTHRITIS
Sharmili Balarajah1, Amrita Sandhu1, Mercy Ariyo1 and
Elizabeth Rankin1
1University Hospitals Birmingham NHS Foundation Trust,
Birmingham, United Kingdom
Background: Anaemia occurs frequently in rheumatoid arthritis (RA)
and may be multifactorial. We wanted to establish whether anaemic
RA patients are being investigated and to what extent. There are no
national guidelines in this setting.
Methods: The audit took place in the rheumatology outpatient
department of Selly Oak Hospital in 2011. We identified patients who
attended rheumatology clinic with positive levels of anti-CCP (>100
units) from June-December 2010. From this we selected patients
found to be anaemic according to the Trust’s laboratory definition
(females Hb<11.5 g/dl: males Hb< 13.5 g/dl). We recorded MCV,
MCH, platelets and white blood cell count. We looked for evidence
from up to a year after the test showing low Hb, that haematinics,
faecal occult blood estimation, endoscopy or advice to the GP had
been considered. We looked at previous clinic letters for medication
lists. We set a target that 60% of anaemic RA patients should be
further investigated.
Results: Because CCP tests are less likely to be carried out in patients
with well-established disease, disease duration was <10 years. Sixty-
two of 263 strongly CCP positive patients were anaemic. Age range
23-91 years. M:F 21:41. Twenty-one patients had CRP<10 (no data
for 9 patients). All had creatinine<135. Nineteen patients were on
aspirin. Only 13 of anaemic patients were on NSAIDs. 16 were on
prednisolone. Only 1 anaemic patient was on aspirin, NSAID and
prednisolone. Twenty-three were on methotrexate. 3 (4.84%) had
microcytic anaemia, 56 (90.3%) normocytic and 3 (4.84%) macrocytic.
One patient had Hb 5.7 and was pancytopenic. Two females had
Hb<9 g/dl. Of the 62 anaemic patients, only 7 (11.3%) had a complete
set of haematinics carried out. Of these 5 had normal values and
comorbidities, one had low B12, two had low folate, one of whom (a
young female) had low ferritin also. 2 (3.23%) had B12 and folate only,
1 (1.61%) had iron studies only and 49 (79.0%) had none of these
tests. Further full blood count (FBC) was carried out in 48 patients
(77%). Further action related to the anaemia was taken in 12 patients
(19.3%). 9 (14.5%) underwent imaging/endoscopy related to the
anaemia, 5 (8.06%) were referred to other secondary specialties eg
haematology, 4 (6.45%) had letters sent to their GPs asking for their
anaemia to be monitored and 5 (8.06%) had other tests performed. Of
these 12 patients, few had a definitive cause for the anaemia
according to clinic letters. One was diagnosed with pernicious
anaemia and others were having further investigations.
Conclusions: Anaemia in RA is commonly identified yet only a
minority of patients were investigated further for this abnormality, so
our target was not met. The majority of anaemic RA patients had Hb
between 9 and the lower limit of normal for their gender. Extrapolating
from the small number of patients where haematinics were measured
suggests that although the majority have anaemia of chronic disease,
occasionally treatable deficiencies may be missed.
Disclosure statement: All authors have declared no conflicts of
interest.
73. ANTI-TNFa THERAPY TRANSIENTLY IMPROVES HIGH
DENSITY LIPOPROTEIN LEVELS AND MICROVASCULAR
ENDOTHELIAL FUNCTION IN PATIENTS WITH RHEUMATOID
ARTHRITIS: A LONGITUDINAL STUDY
Aamer Sandoo1,2, Jet J. Veldhuijzen van Zanten1,2, Tracey
E. Toms1,3, Douglas Carroll2 and George D. Kitas1,3
1Rheumatology, Dudley Group of Hospitals, Dudley, United
Kingdom; 2School of Sport and Exercise Sciences, University of
Birmingham, Birmingham, United Kingdom; 3Arthritis Research UK
Epidemiology Unit, University of Manchester, Manchester,
United Kingdom
Background: Rheumatoid arthritis (RA) is associated with increased
morbidity and mortality from cardiovascular disease (CVD). This can
be partially attributed to traditional CVD risk factors such as
dyslipidaemia and their downstream effects on endothelial function.
The most common lipid abnormality in RA is reduced levels of high-
density lipoprotein cholesterol (HDL), probably due to active inflam-
mation. In this longitudinal study we hypothesized that anti-tumor
necrosis factor-a (anti-TNFa) therapy in patients with active RA
improves HDL cholesterol, microvascular and macrovascular endothe-
lial function.
Methods: Twenty-three RA patients starting on anti-TNFa treatment
were assessed for HDL cholesterol, and microvascular endothelial
function (Laser Doppler imaging with iontophoresis of acetylcholine
and sodium nitroprusside) and macrovascular endothelial function
(flow-mediated and Glyceryl-trinitrate-mediated dilatation) at baseline,
2-weeks and 3 months of treatment.
Results: Disease activity (CRP, fibrinogen, DAS28) significantly
decreased during the follow-up period. There was a significant
increase from baseline in HDL cholesterol at 2 weeks (1.4 0.3 and
1.50.3 respectively, p<0.05) which was paralleled by a significant
increase in microvascular endothelial-dependent function also at
2 weeks (baseline: 319217, 2 weeks: 437247, p<0.05).
However, both parameters returned towards baseline at 12 weeks.
Conclusions: Anti-TNFa therapy in RA patients appears to be
accompanied by transient but significant improvements in HDL
TABLE 1.
Biologic-naive (n¼ 3767) Anti-TNF (n¼12051)
Follow-up (person-years) 14892 63811
Mean age (SD) 60.1 (12.4) 56.1 (12.3)
Females (%) 72.4 76.2
Median disease duration, years (IQR) 6 (1-15) 11 (6-19)
Mean baseline DAS28 (SD) 5.1 (1.3) 6.6 (1.0)
Prior CVD (%) 39.2 35.6
Ever smoked (%) 63.6 60.2
Observed Expected SMR 95% CI Observed Expected SMR 95% CI
All-cause mortality 369 246.5 1.5 1.4, 1.7 1182 682.2 1.7 1.6, 1.8
All-cardiovascular disease (I00-I99) 100 80.1 1.2 1.0, 1.5 340 206.6 1.6 1.5, 1.8
Ischaemic heart disease (I20-25) 52 38.2 1.4 1.0, 1.8 184 101.4 1.8 1.6, 2.1
Stroke (I63-64) 14 11.0 1.3 0.7, 2.1 38 30.1 1.3 0.9, 1.7
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cholesterol, which coexists with an improvement in microvascular
endothelial-dependent function.
Disclosure statement: All authors have declared no conflicts of
interest.
74. PREDICTORS OF SUBENDOCARDIAL VIABILITY RATIO
IN PATIENTS WITH RHEUMATOID ARTHRITIS: THE ROLE
OF INFLAMMATION AND CLASSICAL CARDIOVASCULAR
DISEASE RISK FACTORS
Aamer Sandoo1,2, Jacqueline P. Smith1 and George D. Kitas1,3
1Rheumatology, Dudley Group of Hospitals, Dudley,
United Kingdom; 2School of Sport and Exercise Sciences, University
of Birmingham, Birmingham, United Kingdom; 3Arthritis Research
UK Epidemiology Unit, University of Manchester, Manchester,
United Kingdom
Background: Rheumatoid arthritis (RA) is associated with increased
morbidity and mortality from cardiovascular disease (CVD). In
particular, RA patients are at a greater risk from myocardial infarction
when compared with the general population. There is some evidence
that myocardial microvascular dysfunction in RA might be related to
RA-related inflammation, but the few studies that have addressed this
have included small sample sizes and have mainly used invasive
assessments of coronary endothelial function. Subendocardial viability
ratio (SEVR) has emerged as a novel marker of myocardial oxygen
demand (coronary perfusion) and oxygen consumption (cardiac
workload) and as such provides a non-invasive measure of myocardial
ischaemia. The aim of the present study was to identify specific
predictors of SEVR in patients with RA.
Methods: 173 consecutive rheumatoid arthritis (RA) patients (age
(meanSD) 6112, 132 females) underwent measurements of SEVR
using pulse wave analysis. Low SEVR readings reflected increased
myocardial ischaemia. A blood sample was also obtained and
analysed for routine laboratory biochemistry, lipids, haematology,
erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP).
Results: Linear and binary regression analysis was performed to
determine univariate predictors of SEVR in patients with RA. This
analysis revealed that ESR (b¼.18, p¼ .02) and CRP (b¼.21,
p¼ .005) were associated with SEVR. From the classical CVD risk
factors, only systolic blood pressure (SBP) (b¼.18, p¼ .02) was
associated with SEVR. However, there were trends for an inverse
association between BMI (p¼ .07), total cholesterol (p¼ .07) and
SEVR.
Conclusions: Inflammation appears to be an important predictor of
SEVR in patients with RA and may contribute to myocardial ischaemia
in this population along with SBP. However, prospective studies which
aim to examine the long-term effects of inflammation and classical
CVD risk factors on SEVR are required.
Disclosure statement: All authors have declared no conflicts of
interest.
75. IS THE NATURAL HISTORY OF INTERSTITIAL LUNG
DISEASE IN RHEUMATOID ARTHRITIS CHANGING?
Saadia Malik1,2, Elizabeth Toberty1, Nishanthi Thalayasingam1,
Jennifer Hamilton1 and Clive Kelly1,2
1QEH Rheumatology, Gateshead, United Kingdom; 2Medicine,
University of Newcastle upon Tyne, Newcastle upon Tyne,
United Kingdom
Background: There has been increasing recognition of the importance
of respiratory disease in patients with rheumatoid arthritis (RA) over the
last five years. Interstitial lung disease (ILD) is the only complication of
RA increasing in prevalence and accounts for around 6% of all RA
deaths, with a mean survival of just 3 years following diagnosis in
several historic series. However, treatment regimes have begun to
change and we have assessed the effect of this on the survival rates
associated with RA-ILD.
Methods: We have identified 50 patients with clinically significant
(respiratory symptoms and / or signs) RA-ILD from a population of
1,600 RA patients over 10 years. Diagnosis was confirmed on high
resolution computed tomography (HRCT) of the lungs. We recorded
the nature and extent of ILD on HRCT. Serology was compared to a
control group of RA patients without lung disease. Pulmonary function
was monitored serially to assess progression. All treatment given was
noted and we analysed outcome data based on all cause and
pulmonary mortality.
Results: Fifty patients with confirmed RA-ILD were identified, giving a
prevalence of 3.2%. Twenty patients were male, giving a female:male
ratio of 3:2 Mean age at diagnosis of ILD was 67 (46-87) years, and
mean duration of RA at diagnosis of ILD was 4 (0-37) years. Usual
interstitial pneumonia was found in 64%, non-specific interstitial
pneumonia in 28% and cryptogenic organizing pneumonia in 8%.
Positive CCP antibodies were found in 86% of RA-ILD patients
(controls 60%) with mean titres of 215 (controls 89). Those with
progressive ILD were treated aggressively and anti-TNF therapy was
avoided in all patients (see Table 1). All cause (pulmonary) mortality
was 20% (10%) over 10 years, with a mean survival of over 10 years.
No treatment related deaths occurred.
Conclusions: RA-ILD is a common and potentially fatal disorder which
influences therapeutic decision making. The natural history of the
disease may be improving. The evidence we present suggests
selective therapy may contribute towards a better outcome.
TABLE 1 Treatment given to patients for progressive RA-ILD
Treatment % of patients
Mycophenolate 40
Rituximab 20
Cyclophosphamide 12
Methylprednisone 8
Anti-TNF drugs 0
Disclosure statement: All authors have declared no conflicts of
interest.
76. SEVERE URINARY TRACT INFECTIONS IN PATIENTS
WITH RHEUMATOID ARTHRITIS
Daniel Puntis1, Saadia Malik1, Jennifer Hamilton1,
Vadivelu Saravanan1, Martin Rynne1, Carol Heycock1 and
Clive Kelly1
1QEH Rheumatology, Gateshead, United Kingdom
Background: The aim of this study was to describe the incidence of
urinary tract infections (UTIs) leading to hospitalization or delaying
hospital discharge in a large cohort of patients with rheumatoid
arthritis (RA). Comorbidity from RA has recently focussed on outcomes
of cardiovascular and pulmonary disease, but serious infections are an
increasingly well recognized complication of RA. Recent work has
demonstrated how the incidence of pneumonia can be reduced in RA,
but little attention has been paid to the incidence of UTIs in RA, or to
the associated comorbidity.
Methods: This study assessed all patients with RA hospitalized over a
12 month period with a discharge diagnosis including UTI. Patients
were identified through a PAS records search in a single large centre,
and case controls without RA matched for age and gender were
identified. Clinical notes were manually examined by 2 observers. We
recorded: age, gender, duration of RA, number of UTIs, all RA therapy,
all comorbidity, results of urine and blood cultures with antibiotic
sensitivities, readmission rates, treatment and outcome. We calculated
the relative risk of developing UTI in patients with RA and the factors
influencing this.
Results: The overall annual incidence of hospitalization with a UTI
amongst RA patients was 2.09%, as against 0.97% for controls
(RR¼2.16). These figures derived from a population of 2,200 RA
patients (90% female) with a mean age of 76 years. The use of long
term oral steroids was associated with a RR of 4.46 for admission with
UTI and this rose to 9.07 in those on steroids without disease-
modifying anti-rheumatic drugs (DMARDs). Positive cultures for E Coli
were found in 51% of RA patients. Relevant co-morbidities included
permanent catheters, vaginal prolapse, cancer and diabetes.
Readmission was common.
Conclusions: RA was associated with a significantly higher incidence
of UTI, particularly in older females. This caused significant morbidity,
although mortality was low. Predisposing factors included oral
steroids, urethral trauma and diabetes. Poor hand hygiene as a
result of deformity may also contribute. We recommend avoidance of
long term steroids and catheters where possible, and the use of low
dose prophylactic antibiotics where these factors are unavoidable or
UTIs reoccur.
Disclosure statement: All authors have declared no conflicts of
interest.
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77. THORACIC HRCT STUDY TO ASSESS FOR
PRE-EXISTENT LUNG DISEASE IN RHEUMATOID ARTHRITIS
PATIENTS DUE TO START ANTI-TNF THERAPY
Rizwan Rajak1, Rhian Goodfellow1, Ceril Rhys-Dillon1,
Richard Winter1, Phil Wardle1 and James C. Martin1
1Rheumatology, Cwm Taf Health Board, Llantrisant, United Kingdom
Background: Anti-tumour necrosis factor inhibitor induced interstitial
lung disease (aTNF-ILD) is emerging as a particularly worrying biologic
associated disease with high mortality rates (one third of cases). In
aTNF-ILD patients who had established ILD prior to commencing
aTNF, mortality is up to two thirds of cases; with such high mortality
rates in mind we investigated whether high resolution CT chest scans
(HRCT) provided a better diagnostic tool than the current screening
combination of chest radiography(CXR) and clinical assessment at
identifying clinically significant lung disease in rheumatoid arthritis(RA)
patients who are due to start aTNF.
Methods: A 1 year prospective study was undertaken between
June‘10 and ‘11 where RA patients, due to start aTNF, were pre-
screened with a chest HRCT in addition to CXR and clinical
assessment. Clinically significant radiological abnormalities was
defined as radiographic lung findings that correlated with respiratory
symptoms leading to a pulmonary diagnosis.
Results: 29 patients in total were evaluated. Mean age was 60 years
with a 5:1 female/male ratio. Mean duration of RA was 8 years. 34.5%
had had smoking exposure (current/ex-smoker). 66% were rheuma-
toid factor positive.
Two thirds of cases showed concordance between HRCT and CXR
findings. Of those with nonconcordant results, 8 had a normal CXR but
abnormal HRCT (however, all had minimal HRCT changes). No patient
from the nonconcordance group had clinically significant findings (all
were asymptomatic). 2 cases were detected to have pre-existing ILD;
1 was asymptomatic with minimal changes on HRCT not present on
CXR, the other had correlating changes on HRCT and CXR and the
patient reported exertional breathlessness. Only 2 cases in the whole
cohort exhibited symptoms on initial assessment, both from the
HRCT/CXR concordance group (the latter mentioned case with ILD
and another with bronchiectasis).
Conclusions: There does not appear to be an obvious advantage in
using HRCT in the initial screening armoury to assess for pre-existing
lung disease in RA patients who are due to commence aTNF. 2
patients who were found to have pre-existing ILD: in one patient
diagnosis was easily achieve via CXR and symptom assessment, and
in the other patient subtle HRCT changes were seen which were
clinically insignificant. All patients were commenced on aTNF, even in
those who had abnormalities on HRCT as the changes were not
deemed clinically relevant enough to preclude treatment.
With the high mortality rates of aTNF-ILD as seen in the BSR-
biologics register, the question of whether aTNF should be avoided in
patients with asymptomatic mild ILD remains unanswered. Using
HRCT to screen patients who are symptomatic with abnormal CXRs
remains the more prudent approach.
Disclosure statement: All authors have declared no conflicts of
interest.
78. THE EFFECT OF ANTI-INFLAMMATORY THERAPY ON
LIPID SUB-FRACTIONS AND VASCULAR FUNCTION IN
RHEUMATOID ARTHRITIS: A PROSPECTIVE STUDY
Tracey Toms1, Aamer Sandoo1, Jacqueline Smith1, Susan Cadman1,
Peter Nightingale2 and George Kitas1,3
1Rheumatology, Dudley Group of Hospitals NHS Trust, Dudley,
United Kingdom; 2Wolfson Computer Laboratory, Birmingham
University, Birmingham, United Kingdom; 3Arthritis Research UK
Epidemiology Unit, Manchester University, Manchester,
United Kingdom
Background: Rheumatoid arthritis (RA) associates with increased
cardiovascular risk. Dyslipidaemia may contribute to this via altera-
tions in lipid levels and structure. The lipoprotein sub-fraction profile
(LSFP) is altered in RA but it remains unknown whether suppression of
inflammation affects the LSFP and whether this associates with
alterations in vascular function. We assessed longitudinally the effects
of anti-inflammatory therapy (anti-TNF, rituximab and glucocorticoids)
on LSFP and vascular function in RA.
Methods: HDL2, HDL3, small dense LDL (sdLDL) levels and vascular
function were measured longitudinally (baseline, 2 weeks and
3 months) in 57 RA patients receiving anti-TNF (n¼ 35), intravenous
glucocorticoids (n¼ 12), and rituximab (n¼10); and two control
populations (15 RA on stable DMARD therapy and 40 healthy controls)
Results: At baseline, HDL2 and HDL2:HDL3 ratio were lower and
HDL3 higher in RA patients compared to healthy controls. After anti-
inflammatory therapy, HDL2 increased at 2 weeks, but returned to
baseline levels at 3 months. Amongst patients treated with intravenous
glucocorticoids HDL2 (p¼0.004) and sdLDL levels (p¼ 0.002)
increased at 2 weeks (returning to baseline at 3 months) and HDL3
levels decreased at 3 months (p 0.001). At baseline HDL3 levels
negatively correlated with microvascular function (r¼0.385,
p¼0.039). Longitudinally, there were no robust associations between
lipoprotein sub-fractions and endothelial function.
Conclusions: The LSFP is altered in RA; suppression of inflammation
via anti-inflammatory therapy produces only transient changes in the
LSFP, which are not reflected into improved vascular function.
Disclosure statement: All authors have declared no conflicts of
interest.
79. HIGH CRP IS THE BEST MARKER OF DYSLIPIDAEMIA IN
PATIENTS WITH EARLY INFLAMMATORY POLYARTHRITIS:
RESULTS FROM THE NORFOLK ARTHRITIS REGISTRY
Awal Z. Alhusain1, Suzanne M. Verstappen1, Hoda Mirjafari1,
Mark Lunt1, Valentine Charlton-Menys2, Diane Bunn3,
Deborah Symmons1, Paul Durrington2 and Ian Bruce1
1Arthritis Research UK Epidemiology Unit, University of Manchester,
Manchester, United Kingdom; 2Cardiovascular Research Group,
University of Manchester, Manchester, United Kingdom; 3Norfolk
Arthritis Register, University of East Anglia, Norwich, United Kingdom
Background: Patients with inflammatory conditions such as rheuma-
toid arthritis (RA) have an increased risk for cardiovascular disease
(CVD). Although a number of genetic, environmental and serological
factors contribute to CVD, dyslipidaemia have a pivotal role in
atherogenesis. The association between disease parameters and
dyslipidaemia has been widely investigated, but with controversial
results.
The aim of this study is i) to characterize lipids and apolipoproteins
in patients with early inflammatory polyarthritis (IP) and ii) to investigate
the association between lipid profiles and disease characteristics in
patients with early IP.
Methods: Patients with early IP were recruited from the Norfolk
Arthritis Register (NOAR), a primary inception cohort. We included
adults over 18 years old with 2 or more swollen joints for more than
four weeks, who were recruited after January 1st 2000. At inclusion,
we performed a detailed interview which included assessment of joint
count (tender and swollen joint count), symptom onset and functional
disability (HAQ). Blood samples were collected and stored for routine
measurements including CRP, rheumatoid factor, anti-CCP antibodies
(ACPA) and lipid profiles. The association between markers of disease
activity and lipid sub-fractions was examined using linear regression
with adjustment for age and gender.
Results: At baseline, the median (IQR) age of the study cohort was 58
(47, 68) years and median (IQR) of symptom duration was 8 (4.5,
15) months; 67% of the patients were female, 538 (42.7%) patients
were RF-positive and 394 (31%) were ACPA-positive. The 1987 ACR
criteria for RA was fulfilled by 568 (45%) and the median (IQR) DAS-
28crp was 3.68 (2.82, 4.62) and CRP 11 (5.4, 20.8) mg/l. About half of
the patients were treated with DMARDs, 25% were exposed to
steroids. The commonest lipid abnormality in this population was low
HDL (465 37 %). A significant negative association was found
between CRP and Total Cholesterol b-coeff (95% CI): 0.006 (0.011,
0.002), LDL: 0.004 (0.007, 0.0005), Triglycerides: 0.004
(0.006, 0.001), and ApoA-1: 0.001 (0.004, 0.0002). DAS-28
was associated with lower ApoA-1 b-coeff (95% CI): 0.04 (0.069,
0.014), the tender joints was associated with higher Triglycerides:
0.005 (0.001, 0.007), and the swollen joint count with lower HDL:
0.004 (0.009, 0.0008).
Conclusions: In patients with early IP the most prevalent lipid
abnormality was low HDL which was associated with higher swollen
joint counts. Other alterations in lipid sub-fractions were mainly
associated with CRP which seems to be the inflammatory feature
most consistently associated with dyslipidemia in this population.
Disclosure statement: All authors have declared no conflicts of
interest.
80. RHEUMATOID ARTHRITIS PATIENTS ARE TOO FAT
AND UNFIT
Jennifer K. Cooney1, Jeanette M. Thom1, Jonathan P. Moore1,
Andrew Lemmey1, Jeremy G. Jones2, Peter J. Maddison1 and
Yasmeen A. Ahmad2
1School of Sport Health and Exercise Science, Bangor University,
Bangor, United Kingdom; 2Department of Rheumatology,
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United Kingdom
Background: In RA there is a 1½ - 2 fold increase in the incidence of
cardiovascular disease (CVD) and traditional risk factors (TRFs) do not
fully explain this increased incidence. RA patients are typically known
to have poor cardio-respiratory fitness (CRF) which is a known
independent CVD risk factor. Yet on the whole the measurement of
CRF is generally ignored because it is difficult to assess in a clinical
setting. The aim of this study was to assess RA patients’ CRF using a
simple tool and to determine whether poor CRF correlated with TRFs
and body composition.
Methods: 100 RA patients (69 female, 31 male) attending rheumatol-
ogy clinics were recruited. CRF was measured using the Siconolfi Step
Test. RA activity, TRFs and anthropometric characteristics (BMI, waist
hip ratio and body fat percent) were assessed. Statistical associations
were measured using Pearsons correlation.
Results: Table 1 shows the RA, TRF and anthropometric character-
istics. This group had well controlled disease with mild disability.
The main elevated TRF was the LDL-c with 41% fulfilling the metabolic
syndrome (MetS) criteria. Based on body fat, 83% of patients were
overweight or obese. 65% of patients were able to complete the
step test however their fitness level was very poor, 20.3 and
26.3 ml.kg1.min1 for females and males respectively. Poor fitness
was associated with the metabolic syndrome and a less favourable
body composition. There was no correlation with RA, SBP, TC or
LDL-c variables. 35% of patients were unable to do the step test.
This group reported higher disability and pain, and had a greater
prevalence of obesity and MetS when compared to those who
completed the step test.
Conclusions: CRF is an independent CVD risk factor but this is not
routinely measured as there has been no tool available for health
professionals. We have demonstrated that the step test can provide a
measurement of fitness in a clinical setting. The RA patient’s fitness
was very poor. Despite this poor fitness TRFs were not markedly
elevated but was associated with the metabolic syndrome and levels
of obesity. The obesity was even more marked in those who were
unable to do the test. This study has highlighted the alarming levels of
obesity and poor fitness in a typical well controlled RA population.
Thus more attention and understanding is required on addressing
these factors rather than the TRFs alone.
TABLE 1.
Age (yrs) 59.6 10.2
Disease duration (yrs) 10.4 9.1
DAS28 CRP 2.8 1.4
HAQ 0.87 0.76
Blood pressure (mmHg) SBP 140 20 DBP 81 12
TC (mmol/l) 5.2 1.1
TG (mmol/l) 1.5 0.7
LDL-c (mmol/l) 3.1 1.0
HDL-c (mmol/l) 1.5 0.5
Metabolic syndrome (%) 41
Body fat % Female 43.6 12.9 Male 24.2 7.2
Waist hip ratio Female 0.87 0.05 Male 0.97 0.06
Disclosure statement: All authors have declared no conflicts of
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81. DEPRESSION AND RHEUMATOID ARTHRITIS: THE
PREVALENCE AND PREDICTORS OF DEPRESSION IN A
RHEUMATOID ARTHRITIS POPULATION
Tazeen J. Ahmed1, Francesca Leone1 and Patrick D. Kiely1
1St George’s Healthcare NHS Trust, London, United Kingdom
Background: Rheumatoid arthritis (RA) and depression are debilitat-
ing illnesses that cause social and personal limitation. RA affects 1%
and depression 2-4% of the population, these two illnesses can
coexist. The prevalence of depression in RA patients is between 8%
and 67% depending on the diagnostic tool and study population.
Depression in RA is related to psychosocial variables such as mood,
social support, coping strategies, negative life events, perceived stress
and to disability and measures of function. Although a history of
depression is related to current depressive symptoms, age, sex and
disease duration are not often correlated with depressive symptoms.
Assessing and treating coexisting depression in active RA can improve
functional status.The aims of this study were to ascertain the
prevalence of depression in a secondary care RA population using
the PHQ 9, a short self completed questionnaire recommended for use
in primary care and investigate any predictive relationship between the
PHQ 9 score and routine demographic, functional status and current
disease variables.
Methods: Patients were recruited from the Rheumatology outpatient
clinics of St Georges Hospital, Tooting, London. The patients
completed a PHQ 9 questionnaire, a HAQ and a questionnaire
regarding demographic data, previous comorbidity, cardiovascular
risk factors and previous mental health. Within two weeks of
completing the questionnaires, patients were invited to have a physical
examination. The DAS 28, ESR, CRP, duration of early morning
stiffness and visual analogue scores for global arthritis activity (global
VAS) and pain (pain VAS) were collected.
Results: 97 patients were recruited. 78% were female, with a mean
age of 57.2 years and mean RA duration of 13.4 years. The prevalence
of depression in the sample was 23.9% (score of >10 out of a possible
27). There were statistically significant differences between the groups
of depressed and non-depressed in terms of HAQ, ESR, global VAS,
pain VAS and the DAS 28 score on univariate analysis (p< 0.05). Using
multivariate analysis, the global VAS had the strongest influence on the
PHQ 9 score where a 1 mm change in global VAS predicts a 0.116
(0.067-0.166, 95% confidence interval) change in the PHQ9 score, i.e.
a 10 mm change in the VAS will predict a 1 (1.16) unit rise in the PHQ 9
score. The composite score DAS 28 was the strongest predictor of
being depressed. The odds ratio for being depressed is 1.6 for each
unit increase in DAS 28.
Conclusions: Using the PHQ 9, the prevalence of depression in this
population with established RA is 23.9%. The PHQ 9 is a useful tool for
screening for depression in an RA population and should be
considered in those with a rising VAS for global activity or high DAS
28 to ascertain the need for psychological intervention.
Disclosure statement: All authors have declared no conflicts of
interest.
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82. AN AUDIT OF THE TREATMENT OF RAYNAUD’S
PHENOMENON SECONDARY TO CONNECTIVE TISSUE
DISEASE AND THE COST-EFFECTIVENESS STUDY OF THESE
TREATMENTS
Hannah K. Browne1 and Ceril Rhys-Dillon1
1Rheumatology Dept, Royal Glamorgan Hospital, Llantrisant,
United Kingdom
Background: There is currently no guidance from NICE or the British
Society of Rheumatology (BSR) on treating Raynaud’s secondary to
connective tissue disease ‘CTD’. The Royal Free Hospital (RFH) has
‘‘An algorithm for ‘best treatment’ of ischaemic digital ulceration in
systemic sclerosis’’. Aside from this, it tends to be clinical experience
that governs the treatment strategy. The RFH’s algorithm contains
several therapies that are not licensed for treatment of Raynaud’s,
despite regular use in clinical practice. A cost comparison of these
therapies could help utilize resources more effectively.
Methods: 56 patients with secondary Raynaud’s, who attended CTD
clinics at RGH from November 2010 to June 2011 were included in this
audit. Data was collected using patient’s medical notes retrospec-
tively. Information recorded included patient’s age, gender, underlying
CTD and length of time since diagnosis, history of ulcers, current and
previously tried Raynaud’s treatments and whether these treatments
provided symptom relief. The RFH’s algorithm was used as a gold
standard. Costs for sildenafil and tadalafil are from The British National
Formulary (61st edition). Costs for iloprost infusions were obtained
from consultation with a specialist rheumatology nurse at RGH.
Results: 23.2% of patients had never received treatment for their
Raynaud’s. Of the treated patients, 91% had been prescribed calcium
channel blockers ‘CCB’, 19% statins, 19% aspirin and 28% SSRIs for
their Raynaud’s. This is ‘background vascular therapy’. 30% of treated
patients had been prescribed sildenafil, with only 5% at the ‘RFH
recommended’ starting dose (25 mg tds). 77% of sildenafil patients
experienced symptom relief. 26% of treated patients had tried iloprost.
Of these iloprost patients, 73% experienced symptom relief due to the
prostaglandin analogue and 91% had also been on sildenafil.
20% of patients had experienced a digital ulcer ‘DU’ with 16%
experiencing 3þ DUs at any one time. Despite this, none had been
prescribed bosentan. Instead, all patients with 3þ DUs had been
commenced on sildenafil. No patients were prescribed tadalafil. A 5-
day admission for an inpatient iloprost infusion totals £2032.85
whereas a day-case 5 day infusion totals £912.85. Sildenafil 25 mg
tds costs £4544.25 per year, compared to 50 mg bd costing £3525.90
per year.
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Tadalafil 20 mg od costs £2457.00 per year. 20 mg every other day
(literature is divided between the recommended dose) costs £1228.50.
Conclusions: The prescription of background vascular therapy -
especially CCBs, was consistent throughout practice. However,
treatments for more severe disease (sildenafil, iloprost and bosentan)
were not as consistently prescribed when compared to the gold
standard, with large discrepancies between patients. Using informa-
tion from the cost-effectiveness study, recommendations could be
made to save money without being detrimental to patient’s treatment.
Disclosure statement: All authors have declared no conflicts of
interest.
83. ANTI-CENTROMERE ANTIBODY PREDICTS FALL IN
ANKLE BRACHIAL PRESSURE INDEX IN PATIENTS WITH
SYSTEMIC SCLEROSIS
Surabhi Wig1, Aurelie Chevance2, Tonia Moore1, Joanne Manning1,
Andy Vail2 and Ariane L. Herrick1
1Musculoskeletal Research Group, School of Translational Medicine,
Manchester Academic Health Science Centre, Salford Royal NHS
Foundation Trust, Salford, United Kingdom; 2School of Community
Based Medicine, University of Manchester, Manchester Academic
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United Kingdom
Background: Vascular abnormalities have long been recognized as
being central to the pathogenesis of SSc,which has been suggested to
be primarily a vascular disease. Although the microvasculature is
primarily involved,some studies have demonstrated an increased
prevalence of large (proximal) vessel disease. To detect large vessel
disease early, we routinely check the ankle brachial pressure index
(ABPI) on an annual basis. Prompt detection of clinically significant
lower limb peripheral vascular disease, especially in patients with SSc
and a compromised microcirculation, may be limb-saving. The aims of
this retrospective study were to a) examine change over time in ABPI in
a cohort of patients with SSc b) examine whether limited cutaneous
disease subtype, disease duration, smoking habit, or anti-centromere
antibody are associated with a fall in ABPI over time.
Methods: The clinical, laboratory and ABPI data of 217 patients with
SSc attending between 1996 and 2011 were reviewed retrospectively.
Patients were followed for a median of 8 years. When measuring ABPI,
both the dorsalis pedis and posterior tibial pressures were measured,
and the ABPI calculated for each lower limb, using the higher value, by
dividing ankle pressure by the brachial artery pressure. For each lower
limb of each patient, linear regressions were used to estimate the
average gradient of each ABPI trajectory over time. Factors were
assessed for their association with these gradients using multiple
regression. The factors included in the multiple regression were age,
gender, disease subtype, duration of Raynaud’s phenomenon (RP),
duration of SSc from the first non-RP clinical feature (in log), smoking
habit, and anti-centromere antibody status.
Results: 204 patients (83% female, median age 60 (range 23-
90) years) had at least three serial measurements of ABPI and so
were included in analyses. 75% had limited cutaneous and 25%
diffuse cutaneous SSc. Median duration of RP was 10 years and of
SSc 5 years. 77% were non-smokers, 12 % ex-smokers and 12 %
current smokers. 70 (34%) were anti-centromere antibody positive.
ABPI was around 1 (normal) in most patients. Most patients had
consistent APBI over time (average gradient near 0). Multiple
regression analysis showed that the only factor significantly associated
with a fall in ABPI was a positive anti-centromere antibody (p¼0.008).
Conclusions: Most patients with SSc have a normal ABPI and this
remains consistent over time. A reduced ABPI in combination with
SSc-related microvascular disease is potentially limb-threatening. Our
findings suggest that clinicians should be particularly vigilant for the
possibility of lower limb macrovascular disease in patients who are
anti-centromere antibody positive. Our findings provide further
evidence for the association between anti-centromere antibody and
severity of vascular disease in SSc.
Disclosure statement: All authors have declared no conflicts of
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84. EXPRESSION PROFILING OF SKIN AND LUNG TISSUE
AND EXPLANTED FIBROBLASTS IN THE TbRIIK-FIB
TRANSGENIC MOUSE MODEL OF SCLERODERMA
Emma Derrett-Smith1, Rachel Hoyles1, Pia Moinzadeh1,
Cecilia Chighizola1, Korsa Khan1, Voon Ong1, David Abraham1 and
Christopher P. Denton1
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Background: Gene expression profiling of skin or lung tissue and
fibroblasts in explant culture have been used to study intrinsic subsets
and pathogenic mechanisms in systemic sclerosis. There are technical
challenges integrating the results although the methods are often
complementary. We have applied this strategy to analyse a transgenic
mouse model that is a phenocopy of many of the histological and
biochemical features of SSc. This mouse strain has ligand dependent
upregulation of TGFb signalling due to altered TbRII receptor
expression in fibroblasts.
Methods: In this study we have analysed gene expression profiles of
whole skin and lung from littermate TbRIIk-fib mice and fibroblasts
cultured from neonatal or adult skin and lung tissue (n¼3 per group)
using the illumina microarray platform. RNA was extracted, quantified
and assessed for quality using standard methods. Validation of the
data and additional quantitation of key gene expression was
performed using quantitative RT-PCR assay with replicate samples.
Results: Cluster analysis identifies key gene profiles that are specific
for skin or lung fibroblasts and also that are altered in whole tissues. In
general the differential gene expression was much more marked in
whole tissue and differences were more marked in neonatal compared
with adult fibroblasts consistent with the higher levels of transgene
expression previously described in younger mice. In particular, genes
related to cytoskeletal and extracellular matrix structure and function
(aSMA, troponin, tropomyosin 1, collagens type I, III, VI, VIII, XVII,
matrix metalloproteinases 3, 9, 10, 13, 17, Timp3), endothelin
(endothelin-1, Ednrb, Ednra), TGFb (Ltbp1, TGFb1, 2, 3, Ctgf), BMP
(Bmp2, 4, Bmpr1) and VEGF (Vegfa, Vegfc) signalling axes and innate
immunity (Il-6, Il-11, Il-13, Il-1r, Crp, Saa) were found to be differentially
expressed both in transgenic whole skin, lung and explanted
fibroblasts. In addition, genes coding for Pecam1 (p¼ 0.03) and
Elastin (p¼0.003) were upregulated strongly in whole lung and skin.
Some of these key genes that demonstrated significantly dysregulated
expression in transgenic mouse skin and lung are summarized in more
detail in Table 1.
Conclusions: These data are reminiscent of studies of human SSc
tissue and illustrate another potential complementary strength or
mouse models in better understanding the disease.
TABLE 1.
Gene Target tissue Relative
transgenic
expression
P value
Mus musculus matrix metallopro-
teinase 3 (Mmp3), mRNA
Lung fibroblast 1.94 0.02
Mus musculus transforming growth
factor beta 1 (Tgfb1), mRNA
Lung fibroblast 1.14 0.01
Mus musculus pleiotrophin (Ptn),
mRNA
Skin fibroblast 0.59 0.1
Mus musculus dual specificity
phosphatase 1 (Dusp1), mRNA
Skin fibroblast 0.28 0.0004
Mus musculus homeo box B7
(Hoxb7), mRNA
Skin fibroblast 0.49 0.01
Mus musculus annexin A1 (Anxa1),
mRNA
Whole lung 0.43 0.05
Mus musculus integrin alpha 6
(Itga6), mRNA
Whole lung 1.89 0.02
Mus musculus collagen, type XII,
alpha 1 (Col12a1), mRNA
Whole skin 0.82 0.01
Mus musculus similar to fibrillarin,
transcript variant 1
(LOC100044829)
Whole skin 0.40 0.02
Mus musculus vascular endothelial
growth factor (Vegfa) transcript
variant 2, mRNA
Whole skin 1.86 0.05
Disclosure statement: All authors have declared no conflicts of
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85. BIG IS BEAUTIFUL: BODY SIZE AND SURVIVAL IN
CONNECTIVE TISSUE DISEASE ASSOCIATED PULMONARY
ARTERIAL HYPERTENSION
Benjamin E. Schreiber1, David Dobarro1, Clare E. Warrell1,
Clive Handler1, Christopher P. Denton1 and Gerry Coghlan1
1Royal Free Hampstead NHS Trust, London, United Kingdom
Background: The relationship of body size to survival in connective
tissue disease associated pulmonary arterial hypertension has not
been elucidated.
Methods: Single centre retrospective analysis of data from patients
with connective tissue disease undergoing diagnositc right heart
catheters at a national pulmonary hypertension centre from 1999-
2010. We have analysed baseline parameters at the time of right heart
catheterization (RHC) and survival. Body surface area (BSA, m2) was
recorded at the time of the RHC in all patients. Weight, height and
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body mass index (BMI, kg/m2) were measured at the time of
pulmonary function tests and were only included if within 3 months
of the RHC.
Results: 913 patients were available for analysis. Pulmonary hyper-
tension (as defined by mean pulmonary artery pressure,
mPAP 25 mmHg) was diagnosed in 574 (62.9%) of these patients.
Of these patients 283 had pulmonary arterial hypertension (PAH)
(mPAP 25, wedge15, no lung fibrosis). In the 283 patients with
CTD-PAH, mean BSA was 1.72 m2. BMI data was only available for 90
of these patients, in whom mean BMI was 26.2 kg/m2. We compared
larger patients (BSA 1.72 m2) to smaller patients (BSA<1.72m2).
Larger patients were more frequently male (34% vs 4%, p< 0.0005)
and more frequently had systemic sclerosis (91% vs 80%, p¼0.01).
Ages were similar (60 vs 58, p¼0.32) as were pulmonary artery
pressures (42 vs 40, p¼0.24). However, cardiac output was higher in
the larger patients (5.0 vs 4.0 litres/minute, p< 0.00005) and
pulmonary vascular resistance was therefore lower (587 vs 746
dynes.s.cm-5, p¼ 0.006). Cardiac index was similar in the two
groups (2.65 vs 2.53 l/min/m2, p¼0.20). In patients with PAH, larger
patients had a 37.3% lower mortality than smaller patients (p¼0.01 by
log-rank). However, even after adjustment for age, gender, systemic
sclerosis diagnosis, mean pulmonary artery pressure and cardiac
output, a BSA above the mean was associated with approximately half
the mortality (HR 0.54, p¼0.003, 95% CI 0.36,0.81 on Cox multi-
variable analysis). BMI was only available in 96 (34%) of these patients.
Obese patients (BMI30 kg/m2) had a strong trend towards better
survival compared to non-obese patients (BMI<30 kg/m2) but with the
smaller patient numbers this did not reach significance (p¼0.076).
Conclusions: We have shown that in patients with connective tissue
disease pulmonary arterial hypertension, larger patients have a
significantly improved survival compared to smaller patients, even
after adjustment for demographics and pulmonary haemodynamics.
This is a surprising finding and it raises the question of whether
unmeasured confounders are likely to be responsible.
Disclosure statement: All authors have declared no conflicts of
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86. SURGICAL PROCEDURES ON THE FINGERS IN
PATIENTS WITH SYSTEMIC SCLEROSIS
Rebecca Sykes1, Lindsay Muir2, Holly Ennis1 and Ariane L. Herrick1
1Musculoskeletal Research Group, School of Translational Medicine,
Manchester Academic Health Science Centre, University of
Manchester, Manchester, United Kingdom; 2Department of Hand
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Background: Digital ulcers (DU) are a common, disabling feature of
systemic sclerosis (SSc). Even intensive medical management includ-
ing vasodilator therapy, antibiotics and skilled nursing input may prove
ineffective. For this reason, in our centre, limited early surgical
intervention is playing an increasingly important role in minimizing
the effects of infection and preventing tissue loss. Our objective was to
test the hypothesis that in our tertiary centre numbers of amputations
have decreased over the past 10 years in parallel with an increase in
earlier, less radical surgical interventions. A secondary objective was
to look for associations between type of surgical procedure and
gender and autoantibody status.
Methods: In this retrospective study the annual number of digital
amputations, debridements, digital sympathectomies and calcinosis
excisions in patients with SSc attending between January 2001 and
December 2010 were recorded. Relationships between surgical
procedures, gender and autoantibody status were analysed using
chi-squared and Fisher’s exact tests, as appropriate.
Results: 392 patients with SSc attended the SSc clinic during the
10 year time frame of whom 55 underwent surgery for DU. A total
of 139 procedures were carried out: 91 (65%) debridements, 21 (15%)
amputations, 17(12%) calcinosis removals and 10 (7%) digital
sympathectomies. The number of debridements and sympathec-
tomies remained relatively constant while the number of calcinosis
excisions increased over time (Table 1). The number of digital
amputations decreased significantly over the ten year period
(p¼0.02).
Male gender was associated with a higher risk of requiring an
amputation (compared to the other three procedures) when compared
to females (p¼0.04). Anticentromere or anti-Scl-70 positive patients
were more likely to have had calcinosis excision (p¼ 0.03, 0.04
respectively) compared to those autoantibody negative.
Conclusions: Numbers of amputations decreased significantly over
the past 10 years, reflecting a trend towards earlier referral for surgery
and a more conservative surgical approach (debridement and
calcinosis excision rather than amputation) as well as intensive
medical management and an open door policy for DU. Gender and
autoantibody status may influence the type of surgical intervention
required.
TABLE 1 Numbers of different surgical procedures performed from 2001 to 2010
Year Amputations Debridements Sympathectomies Calcinosis
excisions
2001 5 2 0 1
2002 0 3 0 3
2003 2 10 2 0
2004 4 17 1 0
2005 1 9 2 0
2006 0 7 1 3
2007 4 12 2 3
2008 2 10 2 1
2009 2 9 0 1
2010 1 12 0 5
Total 21 91 10 17
Disclosure statement: All authors have declared no conflicts of
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87. FAK/SRC INHIBITION ALLEVIATES THE PERSISTENT
FIBROTIC PHENOTYPE OF LESIONAL SCLERODERMA
FIBROBLASTS
Xu Shiwen1, Katherine Thompson2, Korsa Khan1, Shangxi Liu2,
Christopher P. Denton1, Andrew Leask2 and David J. Abraham1
1Rheumatology, Royal Free Hospital, London, United Kingdom;
2Dentistry and Physiology and Pharmacology, University of Western
Ontario, London, Ontario, Canada
Background: Systemic sclerosis (SSc, scleroderma) are characterized
by the excessive production and remodelling of extracellular matrix
(ECM) often culminating in organ failure and death. Fibrosis, believed
to result from a hyperactive tissue repair program, is characterized by
the abnormal presence of the myofibroblast, a specialized type of
fibroblast that overexpresses the highly contractile protein smooth
muscle actin, which displays excessive adhesive properties. The
precise contribution of adhesive signaling, which involves integrin-
mediated activation of focal adhesion kinase (FAK)/src, to the fibrotic
phenotype of cutaneous SSc fibroblasts is unclear.
Methods: Fibroblasts (n¼6) and skin biopsies were obtained from
control and SSc tissue, and derived from mouse embryonic and
mouse integrin beta1 wild-type and knockout. Proteins and RNAs
including phospho-FAK, FAK, CCN2, vinculin, alpha-SMA and type I
collagen antibodies were examined by immunofluorescence staining,
RT-PCR and Western blot analysis. Cells were incubated for 24 hours
in the presence or absence of anti-integrin beta1 antibody, N-acetyl
cysteine (NAC) or PP2 (10 uM). In addition, the ability matrix
remodelling in collagen contraction models and migration assays
were also examined.
Results: Histological analysis of SSc dermal tissues reveals p-FAK
protein expression in SSc fibroblasts, but not in fibroblasts of control
dermis. FAK phosphorylation is reduced in integrin beta1 knockout
mouse dermal fibroblasts. Neutralizing anti-integrin beta1 antibody or
the antioxidant NAC reduces FAK phosphorylation in SSc fibroblasts.
These results show integrin beta1 and reactive oxygen species (ROS)
are required for the elevated FAK phosphorylation in SSc fibroblasts.
The FAK/src inhibitor PP2 significantly decreases expression of pro-
fibrotic mRNAs and proteins in normal and SSc dermal fibroblasts,
such as CCN2, alpha-SMA and type I collagen (p<0.05). When normal
and SSc fibroblasts were subjected to the floating collagen gel model
of ECM contraction and the scratch wound assay of cell migration, in
the presence or absence of PP2 and anti-integrin beta1 antibody, both
of them reduced the enhanced ability of SSc fibroblasts to contract a
collagen gel matrix and migration.
Conclusions: These results suggest that the excessive adhesion of
SSc fibroblasts to ECM is intimately involved with the fibrotic
phenotype of this cell type; blocking adhesive signaling may be
beneficial in controlling fibrosis.
Disclosure statement: All authors have declared no conflicts of
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Background: The autoantibody specificity of patients with systemic
sclerosis (SSc) is associated with clinically distinct subgroups and can
provide valuable prognostic information for clinicians. The prevalence
of specific autoantibodies and their clinical associations has been
shown to vary according to geographical location and ethnicity. We
report the clinical features of our cohort of SSc patients whose
autoantibody status has been comprehensively assessed using an
array of laboratory techniques allowing characterization of the less
common SSc-specific autoantibodies such as anti-U3-RNP and anti-
Th/To.
Methods: Sera from 203 patients with SSc were analysed by
immunofluorescence, immunoprecipitation and immunodiffusion.
Case-notes were scrutinized for patient demographics and clinical
phenotype.
Results: The majority of patients were female (87%) with limited
disease (77%) and the mean age of diagnosis was 52 years [SD 6]. The
median highest recorded modified Rodnan skin score (mRSS) was 7
(range 1-51). Mutually exclusive SSc-specific antibodies were identi-
fied in 80% with the most frequent being anticentromere antibody
(ACA) at 49%. 18% had SSc-associated autoantibodies (see table 1).
One patient had both anti-topoisomerase I (topo I) and anti-U1RNP.
ACA was associated with limited disease, telangiectasia, calcinosis,
lower mRSS and older age at diagnosis (p%0.05). PAH was present in
6%of ACA-positive patients (confirmed by right heart catheter) which
was not significantly greater than in ACA-negative patients (p¼0.16).
Diffuse skin involvement and interstitial lung disease were more
common in those with anti-topo I (p¼0.04). Anti-RNA polymerase
antibodies were more frequently found in those with higher mRSS,
diffuse disease and renal crises (p<0.01). Patients with a history of
myosits were more likely to have antibodies to U1RNP, PM-Scl and
Jo-1 (p%0.02). A small number of patients had anti-nucleolar
antibodies. Anti-Th/To was associated with diffuse disease (67% of
patients, p¼0.01) and anti-U3RNP with cardiac disease (50% of
patients, p¼0.01).
Conclusions: The autoantibody specificity and clinical associations in
this cohort of patients is similar to previous reports from Caucasian
and British cohorts. The prevalence of anti-nucleolar autoantibodies
was consistent with previous reports (2–5% in most studies). We were
surprised by the high prevalence of dcSSc in patients with anti-Th/To,
and cardiac complications associated with anti-U3-RNP, although low
patient numbers in each group may account for such findings.
TABLE 1 Frequencies of antinuclear antibodies in patients with SSc
ANA type Number of patients (%)
SSc-specific
ACA Anti-topo I Anti-RNAP (I/II/III)
Anti-Th/To Anti-U3RNP Anti-PM-Scl
99 (49) 29 (14) 17 (8) 6 (3) 6 (3) 5 (2.5)
SSc-associated
Anti-U1RNP Anti-Ro/La Anti-Jo1
Anti-mitochondrial
14 (7) 13 (6) 4 (2) 6 (3)
Other
Unidentified ANA negative 13 (6) 6 (3)
Disclosure statement: All authors have declared no conflicts of
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Background: The absence of a serum test reflecting activity or
severity in Scleroderma (SSc) is a major burden both for clinical
intervention studies and for clinical management. Recently, a large
multicentre study has identified an algorithm of three serum
biomarkers as predictive of severity and clinical outcome in Chronic
Liver Disease. The algorithm, known as Enhanced Liver Fibrosis (ELF),
includes the measurement of serum concentrations of hyaluronic acid,
tissue inhibitor of matrix metalloproteinases-1 and aminoterminal
propeptide of procollagen type III. Aim: To evaluate the performance
of ELF test as a surrogate measure of fibrosis in SSc.
Methods: 210 SSc patients were enrolled in the study. All patients
were investigated for clinical and serological subset, disease duration
(d.d.), vascular, skin, joint, tendon, muscle, esophago-gastrointestinal,
lung, heart and kidney involvement, disease severity, disease activity
and HAQ-DI. ELF score was determined blindly by an independent
commercial service (iQur, London, UK). Correlations were calculated
using Spearman’s correlation test. Mann-Whitney test was used to
perform comparison between groups. All the variables found to be
correlated in univariate analysis were subsequently assessed by step-
wise regression analysis. Data were analysed using SPSS18 software.
Results: The mean ELF score in SSc patients sera was 8.711. ELF
score significantly correlated with: mRSS (r¼0.28;p< 0.0001), FVC
(r¼0.16; p¼0.0287), DLCO (r¼0.32; p< 0.0001), EScSG-Activity
Index (r¼0.23; p¼0.02), total Medsger’s disease severity score
(r¼0.3; p<0.0001) and severity score of skin (r¼0.31; p<0.0001),
joint/tendon (r¼0.23; p¼0.0007), muscle (r¼ 0.27;p<0.0001), GI
tract(r¼0.17;p¼ 0.0144), heart (r¼ 0.22; p¼0.0011), HAQ-DI
(r¼0.32; p<0.00001), ESR (r¼0.25;p¼0.0003), age (r¼0.41;
p<0.0001). Step-wise regression analysis identified mRSS (standar-
dized beta¼0.299, p< 0.0001), age (standardized beta¼0.289,
p¼0.001), DLCO (standardized beta¼0.245, p¼0.004) and
gender (standardized beta¼0.235, p¼ 0.005) as independently
associated with ELF score. The median ELF score was significantly
higher in patients with diffuse cutaneous SSc (dcSSc) enrolled within
the first year of the disease than in age/gender-matched limited
cutaneous SSc patients with >5 year-d.d. (p¼ 0.0152) and not
significantly higher when compared with matched dcSSc with >3
year-d.d. The median ELF score was higher in SSc patients with chest
HRCT fibrosis and DLCO FVC<80% predicted value, than in SSc
controls matched for age, gender, subset, mRSS and d.d.(p¼0.0079).
Conclusions: The ELF test is a simple serum test that significantly
correlates with several measures of fibrosis in SSc. It has a clear face
validity for measuring the concentration of molecules involved in
extracellular matrix turnover and correlates with fibrotic severity and
activity in SSc. ELF test should be considered as outcome measure
in clinical trials.
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Background: An increased FVC:TLco ratio is an independent
predictor of isolated pulmonary arterial hypertension (PAH) in systemic
sclerosis (SSc). Patients with SSc, particularly in the context of anti-
centromere autoantibodies (ACA), often have an isolated reduction in
TLco in the absence of clinical or right heart catheter (RHC) features of
PAH. We report the findings of a case control study evaluating the
impact of ACA-carriage on pulmonary function test (PFT) results in
patients with SSc, in the absence of known PAH or interstitial lung
disease (ILD).
Methods: A retrospective case note review of all patients with SSc
from our database who had attended clinic over the previous year was
undertaken. Notes were scrutinized for autoantibody specificity and
the previous PFT and transthoracic echocardiogram (TTE) results.
Patients with ILD (confirmed on HRCT) or PAH (mean pulmonary artery
pressure [PAP] of >25 mmHg at RHC) were excluded from analysis.
The remaining patients were divided according to ACA carriage and a
comparison of PFT results from the 2 groups was undertaken.
Results: The case notes of 93 patients with SSc were reviewed.
Twenty nine patients were excluded from subsequent analysis; 17 with
ILD, 9 with PAH, 2 with coexistent ILD and PAH, and 1 patient currently
awaiting RHC assessment for possible PAH. Of the remaining 64
patients, 35 patients (53.8%) were ACA positive. The remainder carried
uncharacterized ANA (n¼ 8), or autoantibodies to Scl-70 (5), U3-RNP
(4), PM-Scl (3) U1-RNP (2), ANA negative (1), RNA Polymerase III (1),
Th/To (1) and others (4).
Median age was higher in the ACA group (63 vs. 57 yrs, p¼0.03).
The majority of patients in each group had limited cutaneous SSc (34/
35 vs. 27/29, p¼0.59). The median FVC was significantly greater in the
ACA group (109% vs 93%, p¼ 0.004) whereas the TLco was lower
(61.5% vs. 71%, p¼0.009). The resulting FVC:TLco was significantly
higher in the ACA group (1.72 vs. 1.29, p< 0.001). Surprisingly, the
median estimated PAP on TTE (where reported) was lower in the ACA
group although this trend was not statistically significant (24 mmHg vs.
30 mmHg, p¼ 0.37).
Conclusions: To our knowledge, this is the first case-control study to
evaluate the impact of ACA-carriage on PFT results in patients with
SSc, without established cardiopulmonary disease. In such patients,
ACA carriage is associated with a lower TLco, supra-normal FVC and
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secondary elevation of the FVC:TLco. Our findings suggest a high
prevalence of sub-clinical indolent pulmonary vasculopathy in patients
with ACA. Approximately 15% of patients with SSc develop PAH. The
long-term sequelae of a sub-clinical pulmonary vasculopthy in patients
who do not go on to develop clinical PAH are unknown. Similarly,
studies are needed to evaluate the potentially disease-modifying
impact of early intervention, based on the FVC:TLco in asymptomatic
patients with SSc, on the future development of PAH.
Disclosure statement: N.M. is on the advisory board of Actlelion. J.P.
has received honoraria from Actlelion. All other authors have declared
no conflicts of interest.
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Background: We have previously reported that a cohort of patients
with diffuse cutaneous systemic sclerosis (dcSSc) with elevated serum
IL-6 levels is associated with high modified Rodnan skin score (mRSS).
In this study we examine the potential profibrotic effects of IL-6 and its
downstream signalling pathways in patients with early dcSSc.
Methods: Using skin biopsies obtained from patients with early dcSSc
(n¼ 10, mean disease duration, MeanSEM: 35 9.5 months) and
healthy controls (n¼5), colocalization of IL-6 with aSMA and phospho-
STAT3 were determined with immunohistochemical techniques.
The effect of IL-6 trans-signalling on extracellular matrix (ECM)
production was assessed on fibroblasts grown by explant culture
from skin of SSc patients and healthy controls. Downstream signalling
pathways regulated by IL-6 and soluble IL-6 receptor was examined
using pharmacological inhibitors. These were stimulated overnight
with IL-6 (0-50 ng/ml) and sIL-6R (20 ng/ml).
Results: Compared to healthy controls, there was greater dermal IL-6
expression in patients with early dcSSc. IL-6 expression was strongly
associated with vascular structures and perivascular inflammatory
infiltrate in 8/10 patients. Immunostaining for downstream IL-6
signaling molecules showed an increased expression of pSTAT3 in
all cases with early dSSc particularly in the perivascular inflammatory
foci and vascular structures. Similar co localization of IL-6 and aSMA
was observed in a majority of skin sections with early dcSSc. To
explore the effect of IL-6 trans-signalling on ECM synthesis, incubation
of dermal fibroblasts from healthy controls with either IL-6 alone
(25–50 ng/ml) or sIL-6R (20 ng/ml) alone had no effect on collagen,
aSMA and CTGF production. However, there was upregulation of
collagen synthesis in normal fibroblasts (34.32.45 vs 9.88 1.54
Densitometry Image Unit (DIU) controls, p<0.05) in response to IL-6
(25 ng/ml) and sIL-6R (20 ng/ml). Similar induction of aSMA and CTGF
by 12-fold and 15-fold (p<0.01) respectively were observed in normal
fibroblasts incubated with a combination of IL-6 and sIL-6R. The IL-6
trans-signalling activation of collagen synthesis in normal fibroblasts
was abrogated by AG490 (3.6-fold) and S3I-201 (3.5-fold, p<0.02),
that targets JAK2 and STAT3 signalling pathways respectively. Time-
course analysis indicates that IL-6 trans-signalling induces maximal
activation of pJAK2 and pSTAT3 at 45 min and this was diminished by
2 hours in normal fibroblasts. Constitutive activation of both JAK2 and
STAT3 pathways was observed in SSc fibroblasts and further
activation by the addition of IL-6 and sIL-6R occurred at 15 minutes
and this was sustained at 1 hour.
Conclusions: Our results confirm overexpression of IL-6 in early stage
dcSSc and demonstrate a potent profibrotic effect of IL-6 trans-
signalling via the canonical JAK2/STAT3 pathways. The data also
support targeting IL-6 trans-signalling as a potential antifibrotic
therapy in SSc.
Disclosure statement: All authors have declared no conflicts of
interest.
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Background: Raynaud’s phenomenon often precedes the diagnosis
of systemic sclerosis (SSc) and may be regarded as the first symptom
of the disease in many cases. Conversely only a minority of cases of
isolated Raynaud’s phenomenon (RP) progress to defined connective
tissue disease (CTD) including SSc. We have explored the predictive
potential of ANA positivity and nailfold capillaroscopy for identifying
cases of RP that may progress to CTD and explored the time between
onset of RP and SSc-specific ANA pattern in a large UK patient cohort.
Methods: To ascertain progression of Raynaud’s to CTD patients with
isolated RP (n¼ 569) presenting to our centre were evaluated for
antinuclear autoantibodies and for scleroderma-typical capillary
changes using nailfold capillaroscopy. To explore the duration of
isolated RP in cases evolving to SSc patients with definite SSc
(n¼ 2150) were evaluated from our clinical database, which was
developed to determine and follow the current disease status of SSc
patients.
Results: 569 patients with isolated RP were characterized by a mean
age of 43 years (þ13 y), were predominantly female (85%) and had
already a mean duration of Raynaud phenomenon features at
presentation of 13 years (þ13 y). Further evaluation revealed that 7%
showed antinuclear autoantibodies (ANAs) and 17% showed grade III
abnormalities in nailfold capillaroscopy at their first visit. During our
follow-up period of 1500 patient years (mean¼ 4.6 years) only 1.5%
(8/569) of cases developed further clinical features of SSc (7/8 had
positive capillaries and ANAs at first presentation) and 0.5% (3/569)
developed autoantibodies (3/3 had positive capillaries at presentation).
Conversely, for those with definite SSc the interval between the
onset of the RP and definite SSc onset varied significantly between
disease subsets and autoantibodies, being shortest for the dcSSc
(2.3þ6.5years) variant and longest for the lcSSc (8.4þ11.5years)
disease variant (p< 0.0001). According to the antibody status, the
interval between RP- and SSc-onset was shortest for patients with anti
RNA-Polymerase III (ARA) (1.7þ 6.4years) and longest for ACA
antibodies (10.8þ 12.5years) (p<0.0001).
Conclusions: Since classification criteria for earlier diagnosis of SSc
are being developed the duration of pre-existing RP may be an
important determinant of the profile of SSc cases identified through
screening. Our analysis revealed that over 95% of patients with
isolated RP, negative autoimmune serology on more than one visit and
normal capillaroscopy score (less than grade 2) showed no progres-
sion to CTD. Duration of antecedent RP differs substantially between
disease subsets and SSc-specific ANA patters and so a cohort of SSc
cases that is selected based upon pre-existing RP may be less likely to
include diffuse disease or ARA positive cases. This study has
significant implications for strategies for earlier diagnosis of SSc that
focus on RP.
Disclosure statement: All authors have declared no conflicts of
interest.
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Background: Systemic sclerosis (SSc) is characterized by vascular
damage, autoimmunity and fibrosis. Clinical heterogeneity is a
hallmark of SSc and it is likely that this is determined at least in part
by genetic factors. Differences in expression and signaling through IL7
receptor (IL7R) have been identified as factors determining clinical
activity in other autoimmune rheumatic diseases such as SLE but no
detailed genetic studies of IL7 and IL7R in SSc have been undertaken.
We investigated whether genetic alterations exist in SSc patients that
may associate with clinical phenotypes and whether differences in the
IL7 serum level exist among different SSc subsets.
Methods: Patients with SSc (n¼728) and healthy controls (n¼260)
were genotyped for SNPs in the gene region of IL7R and IL7. All
patients and controls were UK Caucasian and classified according the
autoantibody status and organ involvement. Genotyping was per-
formed by the KASPar system (allele specific PCR, KBiosciences, UK).
We used logistic regression analysis to compare the distribution of
IL7R/IL7 polymorphisms.
Furthermore, serum of 130 SSc patients and 44 healthy controls
were used to determine the IL7 level, using a high sensitivity Human
IL7 assay. The distribution of IL7 values by groups were analysed
using the non-parametric Mann-Whitney test.
Results: No significant differences in the genotype distribution were
observed between SSc and control group, all of which were in Hardy-
Weinberg equilibrium. However, there was a significant difference
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between SSc patients being positive versus negative for ATA in four
SNPs located in the IL7R region, rs11567685 (p¼0.0075, OR for CC
genotype 1.469, 95%-CI 1.11-1.95), rs11567751 (p¼ 0.007, OR for TT
1.467, 95%-CI 1.11-1.94), rs987107 (p¼ 0.0081, OR for TT 1.456,
95%-CI 1.10-1.92) and rs3194051 (p¼0.0072, OR for GG 1.466, 95%-
CI 1.11-1.94).
Median IL7 serum levels were increased in patients suffering from
the diffuse (14.907.48 ng/ml) compared to patients with the limited
form (8.95 5.27 ng/ml; p<0.0001). Patients, positive for ACA showed
a significant lower median IL7 serum level (p<0.005), whereas
patients with anti-RNAP antibodies showed a significant higher IL7
serum level compared to patients without or with other antibodies
(p<0.007).
Conclusions: Here we report that homozygous carriers of the minor
allele in four SNPs of the IL7R gene region were significantly
associated with a positive ATA status in SSc patients. This gene has
been described to be associated with immune regulation in other
autoimmune diseases opening a possibility of a common autoimmune
genetic pathway. This is the first study which reports a potential
association of Il7R gene in SSc susceptibility. Additional independent
cohorts should be analysed to confirm our findings. In addition, due to
the significant differences of IL 7 serum levels in different SSc subsets,
indicates that IL7 expression may be a potential candidate biomarker
in disease assessment.
Disclosure statement: All authors have declared no conflicts of
interest.
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Background: Raynaud’s phenomenon (RP) and hand ischaemia
cause significant morbidity in patients with systemic sclerosis (SSc).
The Raynaud’s Condition Score (RCS) is used to assess severity but is
limited by subjectivity. The Hand Ischaemia Score (HIS) has been
developed in conjunction with input from patients and clinicians with
expertise in systemic sclerosis. We present interim data from an
ongoing study, which explores the reproducibility of the HIS and
compares the ability of HIS and RCS to discriminate between patients
with/without digital ulcers, either using a protocol suitable for use in
clinical trials or a simulated clinic setting.
Methods: Recruitment to date includes: 8 patients with SSc (3 with
digital ulcers) and 16 healthy controls. RCS and HIS were performed
on 3 different occasions. Two visits used a ‘‘Trial’’ protocol involving
abstinence from vasoactive drugs, alcohol and caffeine for 12 h prior to
the visit and equilibriation seated on a couch in a calorimeter at 228C
for 20 minutes before recording whereas the ‘‘Clinic’’ protocol involved
measurements taken with patient seated in standard clinic setting,
with no preparation. HIS consisted of separate Vasomotor,
Established Ischaemia and Progressive Ischaemia domains, which
can be summed to give a total.
Results: The dynamic range of the HIS was greater than the RCS
ranging from 0 to 32 (RCS; 0-5.9). The correlation between HIS scores
taken at Trial visits 1 and 2 was good (8 data pairs; Spearman r (for
SSc data) is 0.84; p value¼ 0.01). Correlation between Trial visits
(average HIS) and the clinic visits also appears reasonable but
increased patient numbers are required to evaluate (6 data pairs;
Spearman r 0.81; p value not significant).
Conclusions: The HIS is reproducible in a Trial protocol and initial data
suggest that it will also be usable in a Clinic setting. The HIS appears a
better tool for discriminating severe from mild hand ischaemia, based
on presence/absence of digital ulcers.
HC
Median
(IQR)
SSc
Median
(IQR)
SSC_DU
negative
Median (IQR)
SSc_DU
positive
Median (IQR)
Significance of
differenceDU
negative vs DU
positive
HIS 0 (0) 19 (5.5) 13 (7) 23 (NA) p< 0.04
RCS 0 (0) 3.2 (2.8) 2.4 (2.0) 3.9 (NA) P¼ not significant
Disclosure statement: All authors have declared no conflicts of
interest.
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Background: Hand ischaemia may herald the onset of the multi-
system vasculopathy in systemic sclerosis (SSc). Objective, quantita-
tive measures of microvascular disease are required to evaluate
therapeutic strategies. Outcome measures currently used include
digital ulcer count (DUC) and the Raynaud’s Condition Score (RCS),
which are limited by subjectivity and/or inadequate dynamic range. We
present interim data from an ongoing pilot exploring two novel
techniques: measurement of regional oxygen saturation (RSO2) and
measurement of regional tissue perfusion (TP). The utility of each type
of measurement was considered by comparing dynamic range,
reproducibility and ability to distinguish between patients and controls
or patients with/without digital ulcers (DU).
Methods: Patients with SSc were recruited from the connective tissue
disease clinic and healthy controls by advertisement in the hospital.
Severity of hand ischaemia was assessed using RCS, TP (by laser
Doppler flowimetry) and RSO2 (using near-infrared spectroscopy).
The dynamic range of each measure was recorded as the difference
between highest and lowest value recorded in the cohort. The
significance of differences in measurements between groups was
assessed using the Mann-Whitney U test. Measurements were made
at two separate visits, using a Trial Protocol to minimize variance
(abstinence from vasoactive drugs, alcohol and caffeine for 12 h prior
to the visit, and postural and temperature (228C) equilibriation for
20 minutes before recording). The reproducibility of each type of
measurement was assessed between the two visits using the
Spearman rank correlation coefficient (r).
Results: Recruitment to date includes: 9 patients with SSc (4 with
digital ulcers) and 16 healthy controls. The dynamic range of RCS was
10-fold smaller than for RSO2 and  100-fold smaller than TP (see
Table 1). RCS and TP values were significantly different between
patients and controls but not between SSc patients with/without DU.
In contrast RSO2 did not discriminate between patients and controls
but was significantly lower in the SSc patients with DU. The
reproducibility of both RCS and TP were poor, despite the measures
taken to reduce variance. However, reproducibility of RSO2 was good
between Trial Protocol visits and also between Trial Protocol and a
simulated Clinic visit (no abstinence from vasoactive agents, or
equilibriation) (r¼0.7; p<0.001)
Conclusions: RSO2 emerges as the most promising outcome
measure for clinical trials of vasoactive agent in SSc-hand ischaemia.
It combines adequate resolution with reproducibility and an ability to
report on degree of severity of tissue ischaemia.
TABLE 1.
Dynamic
range
Median (interquartile range) Significance Reproducibility
Healthy
controls
SSc
(DUneg)
SSc
(DUpos)
HC vs
all SSc
DUneg vs
DUpos
all SSc
RCS 0-6 0.0 (0) 2.4 (2.0) 3.9 (N/A) p¼0.001 p (ns) r¼ 0.46 (ns)
TP 0-600 (PU) 334 (215) 168 (362) 82 (177) p¼0.02 p (ns) r¼ 0.31 (ns)
RSO2 50-98 (%) 76 (14) 71 (12) 61 (8) p (ns) p¼0.01 r¼ 0.55
(p< 0.01)
Disclosure statement: All authors have declared no conflicts of
interest.
SPONDYLOARTHROPATHIES
(INCLUDING PSORIATIC ARTHRITIS)
96. DISCOVERTEBRAL EROSION IN PATIENTS WITH
ENTEROPATHIC ARTHRITIS DETECTED BY MRI
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Background: Discovertebral erosion (DE) is a well known manifesta-
tion of Ankylosing Spondylitis (AS), which diagnosis is sometimes
delayed, particularly in patients with an insidious mode of onset and
non-specific symptoms. In other spondyloarthritis (SpA) the data on
the prevalence of DE are lacking. MRI, an accepted modality for
imaging the axial involvement of SpA is considered the modality of
choice for the radiological diagnosis of DE. Aim of this study was to
analyse the prevalence and clinical features of DE in patients with
enteropatic arthritis (EA) using MRI.
Methods: 72 EA patients (39/33 F/M; mean ageSD: 39.68þ/-7.65),
and 50 healthy subjects as controls, entered in this study. All patients
and controls underwent a rheumatological and gastroenterological
clinical examination and demographic features were recorded
and performed MRI. For each patients we recorded the following
data: disease duration of IBD and arthritis, history of tuberculosis,
staphylococci, streptococci and gram-negative bacteria infections
and occurrence of previous trauma to the spine. The clinical
disease activity were assessed using the BASMI, BASFI, BASDAI,
Harvey-Bradshaw Index (HBI) and the Simple Clinical Colitis Activity
Index (SCCAI). The MRI images were read by two observers, who were
blinded to the status of the subjects.
Results: On the basis of ASAS criteria 43 EA patients (24/19 F/M;
mean age: 34.726.88), were included in the study. 23 patients had
axial subset (axEA) (53.5%) and 20 peripheral subset (phEA) (46.5%).
22 patients with EA showed DE (30.55%) (p<0.05). Among the 22
subjects, 15 had axEA (68.18%) and 7 phEA (31.82%) (p¼0.009).
Stratifying according to arthritis subset, the number of DE resulted
significantly higher in subjects with axEA than those with phEA (45
vs 9, p<0.001), in addition in the axEA subset the lesions showed
a significant direct correlation with arthritis duration (r¼0.431,
p¼0.040). Patients with DE showed a BASDAI, BASMI and BASFI
significantly higher than patients without (p<0.05). Age at enrolment,
age at IBD and arthritis onset, IBD duration, arthritis duration and IBD
activity resulted similar in subjects with and those without DE
(p>0.05).
Conclusions: In our study the prevalence of DE in EA patients was
30.55%, an higher frequency than the other SpA. We found an high
prevalence of DE among axEA patients (68.18%), confirming that DE
are an important characteristic aspect of the axial involvement in SpA.
The high prevalence in our patients may be ascribable to the persistent
inflammation in the gut of IBD patients which cause a persistent
inflammation at mesenteric and paraaortic lymphonodes, which,
becoming chronic, would cause inflammation of ligaments and joint
structures at the spine as suggested by Romanus and Yden.
Moreover, we found an high prevalence also in phEA patients
(31.82%) suggesting that DE are an important aspects of all subsets
of EA patients and may be a characterizing features of the overlap
subset (type 3).
Disclosure statement: All authors have declared no conflicts of
interest.
97. USE OF THE WORLD HEALTH ORGANIZATION
FRACTURE RISK ASSESSMENT TOOL IN ANKYLOSING
SPONDYLITIS
Dinny Wallis1, Amanda Thomas1, Ingrid Hill1, Brisa France1 and
Raj Sengupta1
1Rheumatology, Royal National Hospital for Rheumatic Diseases,
Bath, Bath, United Kingdom
Background: Osteoporosis and vertebral fractures are well recog-
nized complications of ankylosing spondylitis (AS), but there is
evidence that rheumatologists do not routinely assess patients with
AS for osteoporosis. There are no agreed guidelines for screening AS
patients for osteoporosis. ASAS / EULAR recommendations for the
management of AS state that rheumatologists should be aware of an
increased risk of osteoporosis, but due to the lack of evidence base,
do not make any recommendations on management.
Methods: Consecutive AS patients (who fulfilled mNYC criteria)
attending an inpatient rehabilitation course completed an osteoporosis
risk factor questionnaire (age, sex, low trauma fracture in adulthood,
parental hip fracture, current smoking, alcohol intake more than 21
units per week, diagnosis of rheumatoid arthritis (RA), and ever taken
glucocorticoids). Risk factors were entered into the online FRAX tool,
and National Osteoporosis Guideline Group (NOGG) advice was
recorded (‘‘lifestyle advice and reassurance’’, ‘‘measure bone mineral
density (BMD)’’, or ‘‘treat’’). Notes were reviewed for patients who had
a non-reassuring NOGG outcome.
Results: 108 patients (71.3% male) completed the questionnaire.
Mean age was 46.6 y. Mean body mass index was 27.4. 10/108 (9.2%)
had a BMI <22 kg/m2. 16/108 (14.8%) had sustained a fracture. 12/
108 (11.1%) had a history of parental hip fracture. 24/108 (22.2%) were
current smokers. None had RA. 10/108 (9.3%) drank more than 21
units alcohol per week.
Using FRAX, 88/108 (81.5%) had a reassuring outcome. In 12/108
(11.1%) the outcome was ‘‘measure BMD’’. Notes were available for 8
patients: BMD had been measured in 5/8 (normal in 2/5, osteopenia in
3/5). Of the 3 patients with osteopenia, one was intolerant of
bisphosphonates and was taking calcitonin with calcium and vitamin
D, one was on calcium and vitamin D alone, and one had been advised
about dietary calcium intake.
In 8/108 (7.4%) the outcome was ‘‘treat’’. Notes were available for
7/8. None were taking antiresorptive therapy or calcium with vitamin D.
One patient was taking vitamin D supplements alone. BMD had been
measured in 5/7 patients (normal in 2/5, osteopenia in 3/5).
Of the 16 patients who reported a previous fracture, reassurance
was advised in 3 patients, measurement of BMD was advised in 6, and
treatment advised in 7.
Conclusions: Using FRAX and NOGG guidance, BMD measurement
and/or treatment of osteoporosis were advised in 18.5% of this group
of AS patients. Use of FRAX identified patients at risk who had not had
BMD measured and were not being treated for osteoporosis. Using
FRAX routinely may help clinicians to identify AS patients at risk of
osteoporosis. However, long term prospective studies are required to
evaluate the effectiveness and risks of osteoporosis treatments in AS,
especially given the young age of many patients.
Disclosure statement: All authors have declared no conflicts of
interest.
98. PREDICTING JOINT AND SKIN REMISSION AT 24 WEEKS
IN PATIENTS WITH PSORIATIC ARTHRITIS
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Background: In patients with persistent, active psoriatic arthritis
(PsA), therapy adjustment is recommended in order to achieve low
disease activity (LDA) or remission. The purpose of this analysis was to
determine the optimal timing for adalimumab (ADA) treatment
adjustment in subjects with PsA who fail to demonstrate a significant
clinical response, when combined joint and skin remission or LDA at
week 24 is the treatment target.
Methods: ADEPT was a 24-week, phase 3, randomized, placebo-
controlled trial of ADA for the treatment of active PsA. Treatment
groups were randomized following stratification of subjects according
to methotrexate usage (>3 months duration) and extent of psoriasis
(3% BSA). This post hoc analysis evaluated intent-to-treat subjects
with 3% BSA involvement at baseline. The probability of combined
joint and skin remission (defined as DAS28<2.6þPASI90) or LDA
(defined as DAS28<3.2þPASI75) following 24 weeks of therapy was
calculated on a continuous scale as a function of joint improvement
(DAS28, improvement >0.6), skin improvement (PASI50 responder),
or both from baseline at weeks 4, 8, 12, and 16. A 15% probability was
defined as the threshold below which treatment adjustment would be
recommended.
Results: Subjects randomized to placebo failed to achieve the less
stringent LDA criteria and were not considered in further analyses. In
contrast, 27% and 43% from the ADA group achieved remission and
LDA at 24 weeks, respectively. Despite a lack of significant joint
improvement (DAS28 0.6) prior to 16 weeks of ADA treatment,
some subjects remained able to achieve joint and skin remission
criteria at 24 weeks. In contrast, subjects failing to demonstrate
improvements in both joint and skin (DAS28 0.6 and PASI50 non-
response) by week 8 were unlikely to achieve combined remission at
24 weeks. When the treatment target was changed to LDA, subjects
lacking significant improvements in joint and skin maintained a >15%
probability until 16 weeks.
Conclusions: Treatment with ADA led to significantly higher percen-
tages of subjects in combined clinical remission (DAS28< 2.6þ
PASI90) or LDA (DAS28<3.2þPASI75) when compared with placebo.
When treatment adjustment recommendations are made on the basis
of a 15% probability threshold, clinicians should consider waiting up to
16 weeks before adjusting ADA therapy in patients without significant
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clinical improvement (DAS28 0.6þPASI50 non-response) when
combined remission or LDA are the treatment targets.
TABLE 1 Percentage of subjects predicted to achieve remissiona/LDAb at 24 weeks
on the basis of joint or combined joint and skin improvements
Parameter Adalimumab
Wk 4 Wk 8 Wk 12 Wk 16
Joint improvement DAS28 0.6 25 / 33 18 / 18 18 / 18 10 / 10
Joint and skin improvement
DAS28 0.6 and/or PASI50
non-responder
18 / 32 8 / 17 10 / 15 7 / 7
aRemission was defined as DAS28 <2.6þPASI90 response; bLDA was defined as
DAS28 <3.2þPASI75 response.
Disclosure statement: M.D. received research grants and consul-
tancy fees from Abbott, Pfizer, Roche, UCB, BMS and Merck. M.H. is
an employee of, and may hold stock/options in, Abbott. E.K. received
research grants from Abbott, Amgen, AstraZeneca, Bristol-Myers
Squibb, Centocor, F Hoffmann-LaRoche, Genzyme, Merck, Novartis,
Pfizer and UCB, consultancy fees or other remuneration from Abbott,
AstraZeneca, Biotest, Bristol-Myers Squibb, Centocor, F Hoffmann-
LaRoche, Genentech, Merck, Nycomed, Pfizer and UCB, and is a
member of the speakers bureaus of Abbott, Bristol-Myers Squibb, F
Hoffman-LaRoche, Merck, Pfizer and UCB. P.M. received research
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99. SEVERITY OF BASELINE SKIN DISEASE DOES NOT
CORRELATE WITH CLINICAL, PATIENT-REPORTED OR
RADIOGRAPHIC RESPONSES IN PATIENTS WITH PSORIATIC
ARTHRITIS TREATED WITH ADALIMUMAB
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Background: Treatment with adalimumab (ADA) diminishes joint and
skin disease activity, improves quality of life, and limits radiographic
progression in patients with active psoriatic arthritis (PsA). The extent
to which psoriasis severity [measured as a function of the psoriasis
activity and severity index (PASI)] correlates with clinical, patient-
reported, and radiographic outcomes in response to ADA treatment is
unknown. This analysis explored the relationship between baseline
psoriasis with joint and skin disease activity, quality of life measures,
and radiographic progression in patients with active PsA following
treatment with ADA or placebo (PBO).
Methods: ADEPT was a phase 3, randomized, PBO-controlled, 24-
week trial of ADA for the treatment of active PsA. Treatment groups
were stratified by methotrexate usage (>3 months duration, 51% of
patients) and extent of psoriasis (3% BSA, 45% of patients). In this
post hoc analysis, 24-week observed data from patients with active
skin involvement at baseline (3% BSA) were categorized by severity
of psoriasis (PASI <10 or 10). Joint disease was assessed through
the 28-joint disease activity score (DAS28), and as 50%/70%
improvements in the American College of Rheumatology (ACR) criteria
and moderate/good responses in European League Against
Rheumatism (EULAR) criteria. Skin disease was assessed as 50%/
75%/90% improvements in PASI. Patient-reported outcomes included
the Dermatology Life Quality Index (DLQI) and Patient Global
Assessment (PaGA). Radiographic progression was assessed as the
change from baseline in modified total Sharp score (mTSS).
Results: A total of 69 patients with baseline skin disease from each
group (PBO and ADA) had disease activity measures at week 24; 50
and 53 patients randomized to PBO and ADA had PASI involvement
<10, whereas 19 and 16 from the PBO and ADA arms had PASI
involvement 10 at baseline, respectively. Compared with PBO,
treatment with ADA led to significant improvements in joint disease
activity (mean DAS28, ACR50/70 responses, and moderate/good
EULAR responses) at week 24, irrespective of psoriasis involvement at
baseline. No differences were detected in joint disease improvements
between the PASI categories within either treatment arm. Similarly,
treatment with ADA led to significant improvements in PASI 50%/75%/
90% responses as well as in DLQI and PaGA at week 24 when
compared with PBO that were not different between baseline PASI
categories. Further, by week 24, radiographic progression was
significantly reduced in the ADA arm in both PASI categories (PBO:
PASI <10¼ 1.0, PASI 10¼ 1.4; ADA: PASI <10¼ 0.1, PASI
10¼0.4, both P< .05).
Conclusions: Regardless of the severity of baseline skin disease,
treatment of patients with ADA led to similar and significant
improvements in joint, skin, quality of life, and radiographic progres-
sion over patients treated with PBO.
Disclosure statement: M.H. is an employee of, and may hold stock or
options in, Abbott. R.L. received research grants/research support
from Abbott, Amgen, Centocor, Pfizer/Wyeth, UCB and BMS, is a
consultant to Abbott, Amgen, Centocor, Pfizer/Wyeth, UCB and BMS,
and is a member of the speakers bureaus of Abbott, Amgen, Centocor,
Pfizer/Wyeth, UCB, BMS. P.M. received research grants and con-
sultancy fees or other remuneration from Abbott, and is a member of
the speakers bureau of Abbott. D.N. is an employee of, and may hold
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100. BASDAI: IT IS EASIER AND QUICKER TO USE NUMERIC
RATING SCALES RATHER THAN VISUAL ANALOGUE SCALES
Rachel A. Winfield1, Claire Dyke1, Mark Clemence1 and
Kirsten Mackay1
1Rheumatology, South Devon Healthcare NHS Foundation Trust,
Torbay, United Kingdom
Background: Disease activity in ankylosing spondylitis (AS) is
generally measured using the Bath Ankylosing Spondylitis Disease
Activity Index (BASDAI) which focuses on fatigue, spinal pain,
peripheral pain, enthesopathy and morning stiffness (1). The BASDAI
is normally measured using VAS, a 100 mm horizontal line on which an
individual marks the degree of a certain symptom for example pain or
stiffness. An alternative method of measuring the BASDAI is with the
NRS which is an 11 point scale in which subjects mark their answer by
putting a cross through the appropriate number. Arguably the VAS is
more accurate as the number of potential answers is greater, however
Jensen et al. discovered that this is not necessarily the case (2). Others
also advocate the use of the NRS as it is easier to use. Van Tubergen
et al. pointed out that the NRS can be used verbally whereas the VAS
is only used in written form (3). The VAS is also subject to
measurement and reproduction errors (e.g. with photocopying the
line is frequently less than 100 mm).
Given the above we hypothesized that the NRS would be easier to
use and quicker to calculate. We wanted to assess whether there
would be any difference between the two scoring systems.
Methods: Consecutive subjects attending an AS clinic (54 patients)
were asked to complete a VAS-BASDAI / spinal pain and handed it in.
Fifteen minutes later they were asked to fill out the NRS-BASDAI /
spinal pain. The results of both were calculated and the difference
between the two recorded. Checking for significant difference
between the scores was calculated using t-testing.
Results: The NRS-BASDAI took 13 seconds to calculate on average
while the VAS-BASDAI took over 1 minute 15 seconds to calculate.
This may mean an extra 10 minutes or so for an average clinic spent
calculating BASDAI results. This could enable a clinician to see one
extra patient per clinic. There were fewer errors on the NRS-BASDAI
compared to the VAS-BASDAI and all but one patient found the NRS-
BASDAI easier to fill in.
When comparing the BASDAI scores between the VAS and NRS
there was no significant difference on t-testing (p¼0.43). There was
also no significant difference when comparing the spinal pain scores
on t-testing (p¼0.23).
Conclusions: NRS-BASDAI is easier and quicker to use and is more
patient friendly. Using the NRS-BASDAI may enable clinicians to see
more patients in an average clinic. There is no significant difference
between the VAS or NRS scores for either the BASDAI or the spinal
pain score.
Disclosure statement: All authors have declared no conflicts of
interest.
101. ASSESSING FATIGUE IN ANKYLOSING SPONDYLITIS:
THE IMPORTANCE OF FREQUENCY AND SEVERITY
Kirstie L. Haywood1, Jon Packham2,3 and Kelvin P. Jordan2
1Royal College of Nursing Research Institute, School of Health and
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Background: Current guidance recommends assessment of AS
fatigue severity using a single item visual analogue scale (VAS) [1].
The BSR-AS Register assesses fatigue severity with the Chalder
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Fatigue Scale. Although considered important by AS patients [2], little
is known about the value of assessing fatigue frequency, and its
relationship with severity.
Methods: Single-items taken from the EASi-QoL [2] and the BASDAI
[1] were used to measure fatigue frequency and severity, respectively.
These items were included in a questionnaire containing AS-specific
and generic measures, completed by participants in a large UK-wide
survey at baseline and 6-months [2]. Respondents were categorized at
baseline into four groups according to item cut-off points for fatigue
frequency (non/a little of time Vs. some/most/all of time) and severity
(<5 Vs.  5 on a scale 0-10, where 10 is most severe): 1) no fatigue; 2)
frequent not severe; 3) severe not frequent; 4) frequent and severe. The
four groups were compared across all measures at baseline and on
fatigue status at six months.
Results: 611/621 (98.4%) respondents completed both items at
baseline and 467/470 (99%) at 6-months. Of baseline responders who
experienced fatigue (n¼ 451;74%), 75% reported frequent and severe,
15% frequent not severe, and 10% severe not frequent. There was no
difference between groups on gender, age, or years with AS. Patients
reporting frequent and severe fatigue had worse scores than other
groups across all measures (Table 1). Patients reporting only frequent
fatigue had similar scores to those reporting only severe fatigue but
worse than those without fatigue. 81% of non-fatigued patients and
79% of those with frequent and severe fatigue at baseline did not
change their level of fatigue at 6-months. However, 80% of patients
with frequent or severe fatigue at baseline changed, mainly to no
fatigue (43%) or to both frequent and severe fatigue (30%).
Conclusions: Routinely assessing both frequency and severity of
fatigue are important in understanding the impact of fatigue and its
change over time. Not assessing frequency could result in the failure to
identify patients with significant fatigue. However, the multi-dimen-
sional nature of fatigue should be further explored in AS to identify the
most appropriate and acceptable method of assessment.
Disclosure statement: K.H. received an unrestricted educational
research grant for this study from Wyeth. K.J. received an unrestricted
educational research grant for this study from Wyeth. J.P. received an
unrestricted educational research grant for this study from Wyeth.
TABLE 1 Health status by level of fatigue [mean (SD)]
No fatigue Frequent
only
Severe
only
Frequent
and severe
p-value
n 160 67 45 339
SF36 Vitalitya 52.5(7.7) 43.3(8.4) 42.3(7.0) 33.1(8.3) <0.001
HADS depression (0-12) 2.4(2.2) 4.7(2.8) 4.8(2.9) 7.9(4.1) <0.001
EasiQoL Physical (0-24) 3.4(3.2) 6.0(3.7) 6.3(4.1) 11.8(5.4) <0.001
EasiQoL Social (0-20) 2.1(2.0) 4.9(2.8) 4.4(3.4) 10.4(4.5) <0.001
ASQOL (0-18) 1.9(2.4) 5.0(3.8) 5.5(3.8) 11.6(4.4) <0.001
BASFI (0-10) 1.9(1.6) 3.2(1.9) 4.1(2.4) 6.2(2.4) <0.001
a Mean general population 50,<50 worse health
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102. SELF-MANAGING FATIGUE IN ANKYLOSING
SPONDYLITIS AND POTENTIAL INTERVENTIONS: A
QUALITATIVE STUDY OF PATIENTS’ PERSPECTIVES
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1College of Medicine, Swansea University, Swansea,
United Kingdom
Background: Fatigue is a major component of living with ankylosing
spondylitis (AS) and has been identified as a priority research area.
This study examines the effects of fatigue, self-management techni-
ques, and the acceptability of future research strategies aimed at
alleviating fatigue in AS.
Methods: This qualitative study involved participants who are
members of an existing population-based ankylosing spondilytis
(PAS) cohort. Participants with a score of >5/10 on the fatigue
component of their BASDAI were invited to participate in one of two
focus groups. Topics discussed included, (1) effects of fatigue, (2) self-
management strategies and (3) future research ideas to help combat
fatigue. All participants gave informed consent. The focus groups were
audio-recorded and the transcripts were analysed using thematic
analysis.
Results: Participants consisted of 3 males/4 females (group 1) and 4
males/3 females (group 2), aged between 35 and 73 years (mean
age 53 years). All participants were Caucasian and resided in the
Abertawe Bro-Morgannwg University Health Board area. (1) The
effects of fatigue are multi-dimensional including physical, emotional
and psychological components, with pain/stiffness, disruption of
social activities (socializing with family/friends) and low mood identified
as frequent symptoms and consequences of fatigue. (2) The most
commonly reported self-management strategy for fatigue was a
balanced combination of activity (exercise) and rest. (3) In terms of
future research strategies for managing the multidimensional aspects
of fatigue, participants expressed a preference for investigating
psychological therapies rather than pharmacological ‘medication’.
Mindfulness-Based Stress Reduction was introduced and felt to be a
therapy worth researching for both pain and fatigue in AS. Group
course delivery of therapy was popular, with the option of homework
based delivery for people who were not able to attend a group course.
Conclusions: Fatigue has significant effects on multiple aspects of AS
patients’ lives. Patients are however usually left to manage their fatigue
without any formal guidance or support. From this research we can
conclude there is a need for future research to evaluate innovative
therapeutic interventions to address the multi-faceted aspects of
fatigue in AS, rather than research which focuses purely on
medication.
Disclosure statement: All authors have declared no conflicts of
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103. QUALITY OF LIFE IN PSORIATIC ARTHRITIS:
COMPARATIVE RESULTS WITH RHEUMATOID ARTHRITIS
USING SF36 IN TRIALS USING METHOTREXATE
Gabrielle H. Kingsley1, Fowzia Ibrahim1 and David L. Scott1
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Background: Treating inflammatory arthritis with disease-modifying
anti-rheumatic drugs (DMARDs) like methotrexate should improve
quality of life (QoL) as well as improving synovitis. We assessed
6-month changes in SF-36 in: (a) a placebo controlled trial of
methotrexate in psoriatic arthritis (PsA); (b) another trial of methotrex-
ate in rheumatoid arthritis (RA). Our aims were: (a) to define the impact
of PsA on QoL; (b) to compare this with RA; (c) to evaluate the impact
of methotrexate in PsA.
Methods: We studied SF-36 profiles in 112 PsA patients treated with
placebo, 109 PsA patients treated with methotrexate. We also studied
117 RA patients receiving methotrexate. No patient had previously had
methotrexate (given to target dose of 15 mg weekly). We related our
results to ‘‘Normal’’ SF-36 scores in published data from 2042 healthy
UK controls.
Results: Baseline SF-36 scores were low in PsA and RA (Table). PsA
patients showed small improvements over 6 months across all SF36
domains (mean 14%, range 7-31%); these improvements were similar
with methotrexate and placebo. However, PsA patients treated with
methotrexate had higher 6 month changes in health scores than those
receiving placebo (mean 62 (SD 27) vs 51 (29); p¼0.004). PsA patients
who were PsARC responders at 6 months also had higher changes in
all SF-36 domains and significantly greater change in health scores
(p<0.01 for methotrexate and placebo groups). In RA initial QoL
scores were worse; there were also larger changes with methotrexate
across all SF-36 domains (mean 38%, range 7%-125%). The largest
differences in initial values and 6-month changes between PsA and RA
were in role physical and role emotional (indicating RA has more
effects on roles due to physical and mental problems). The 6-month
change in health score in RA patients receiving methotrexate was
similar (mean 62 (SD 32)) to PsA patients receiving methotrexate.
Conclusions: PsA and RA both reduced QoL. It was lowest in RA,
though PsA substantially impaired QoL. PsA showed small improve-
ments in SF-36 domains over 6 months with no evidence methotrexate
gave more benefit than placebo; but methotrexate improved patients’
global assessments of health, reflecting its symptom-modifying effect.
There was no placebo-control group for the RA patients.
TABLE 1 Initial and 6-month percentage change in SF-36 scores in psoriatic arthritis
and rheumatoid arthritis patients
Domain Normal PsA placebo PsA methotrexate RA methotrexate
n¼ 2042 n¼112 n¼109 n¼ 117
Initial 6-month
change
Initial 6-month
change
Initial 6-month
change
Physical functioning 84 49 8 56 11 34 24
Role physical 81 36 31 45 36 16 125
Pain 80 42 21 47 32 35 34
General health 72 46 7 49 12 45 7
Vitality 64 41 20 47 11 32 25
Social functioning 87 62 15 70 11 49 27
Role emotional 88 53 21 60 18 40 53
Mental health 77 64 17 67 7 60 13
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104. EARLY AND SUSTAINED REMISSION ASSOCIATED
WITH NORMALIZED PHYSICAL FUNCTION, HEALTH-
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Background: To evaluate the impact of golimumab(GLM) on disease
remission, physical function, work productivity and healthcare utiliza-
tion in patients with psoriatic arthritis (PsA) over 2yrs.
Methods: GO-REVEAL was a multicentre, randomized, placebo-
controlled study. Adult patients with active PsA (n¼405) were
randomized to GLM (50 or 100 mg) q4wks or placebo. At wk16,
patients with inadequate response entered early escape. All placebo-
treated patients received GLM50mg from wk24. Clinical responses
were analysed using 20% improvement by the American College of
Rheumatology criteria(ACR20) and 75% improvement by Psoriasis
Area and Severity Index(PASI75); remission was measured by disease
activity score (DAS28 <2.6). Patient reported outcomes included
health assessment questionnaire(HAQ), self-reported productivity and
medical visits. Comparisons between GLM and placebo-treated
patients before wk24 were performed using ANOVA on van der
Waerden normal scores for continuous outcomes or Chi-square test.
Results: At baseline, mean age was 47.0 yrs and 63% of patients were
male. Baseline HAQ was 1.02 and PASI score was 7.8. Compared to
placebo, a greater proportion of patients treated with GLM achieved
DAS28 remission as early as wk4 (16.3% vs. 3.6%, p<0.001) and
wk14 (30.6% vs. 1.9%, p< 0.001). Increased remission was observed
over time with over 50% of patients treated with GLM achieving
remission at wk104. A greater proportion of GLM-treated patients
achieved ACR20 and PASI75 response, a normalized physical function
(HAQ 0.5) or quality of life, or had significantly improved work
productivity compared to placebo-treated patients at wk14 (all p-
values<0.01). These improvements were sustained over time through
wks52 and 104. A greater proportion of patients in DAS28 remission
also achieved normal physical function, or had significantly improved
work productivity from baseline at wks 52 and 104, when compared to
those not in remission. Improvement in employability, reduced time
lost from work by patients and care-givers and reduced healthcare
utilization were observed at wks 52 and 104, especially among those
who achieved DAS28 remission. The overall safety profile of GLM
through wk 104 was similar to other anti-TNFa agents used for the
treatment of PsA.
Conclusions: GLM treatment induced early and sustained remission
(DAS28< 2.6), resulting in long-term improvements in physical func-
tion, health-related quality of life, work productivity and reduction in
healthcare utilization in PsA patients.
Disclosure statement: A.B. is an employee of Janssen. C.C. is an
employee of Janssen. T.G. is an employee of Janssen. D.G. is an
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105. EFFECT OF SECUKINUMAB ON SIGNS AND
SYMPTOMS OF PSORIATIC ARTHRITIS: RESULTS OF A
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PLACEBO-CONTROLLED TRIAL
Iain McInnes1, Joachim Sieper2, Ju¨rgen Braun3, Paul Emery4,
De´sire´e van der Heijde5, John Isaacs6,7, Georg Dahmen8,
Ju¨rgen Wollenhaupt9, Hendrik Schulze-Koops10, Sandro Gsteiger11,
Arthur Bertolino1,2, Wolfgang Hueber1,3 and Paul P. Tak1,4
1Glasgow Biomedical Research Centre, University of Glasgow,
Glasgow, United Kingdom; 2Department of Gastroenterology,
Charite` Campus Benjamin Franklin, Berlin, Germany; 3Department of
Medicine, Rheumazentrum Ruhrgebiet, Herne, Germany; 4Leeds
Institute of Molecular Medicine, University of Leeds, Leeds,
United Kingdom; 5Department of Rheumatology, Leiden University
Medical Center, Leiden, Netherlands; 6Newcastle University,
Newcastle upon Tyne, United Kingdom; 7Freeman Hospital,
Newcastle upon Tyne, United Kingdom; 8Department of Medicine,
Praxis fuer Klinische Studien, Hamburg, Germany; 9Klinik fu¨r
Rheumatologie, Eilbeck Hospital, Hamburg, Germany; 10Klinikum
Innenstadt der Ludwig-Maximilians-Universita¨t, Rheumatologie,
Munich, Germany; 11Modelling & Simulation Statistics, Novartis
Pharma AG, Basel, Switzerland; 12Translational Medicine
Dermatology, Novartis Institutes for BioMedical Research, Basel,
Switzerland; 13Translational Medicine Autoimmunity, Novartis
Institutes for BioMedical Research, Basel, Switzerland; 14Division of
Clinical Immunology and Rheumatology, University of Amsterdam,
Amsterdam, Netherlands
Background: This study evaluated the preliminary efficacy and safety
of secukinumab, an anti-Interleukin (IL)-17A monoclonal antibody in
PsA.
Methods: 42 patients with active PsA fulfilling CASPAR criteria
received in 2:1 ratio 2 injections of secukinumab (10 mg/kg) or placebo
(3 wks apart). Primary endpoint was proportion of ACR20 responders
at Wk 6 in active vs placebo (one-sided p-value <0.1).
Results: 35 (83.3%) patients completed the study (secukinumab
n¼ 25; placebo n¼10). Due to protocol violations 4 patients on
secukinumab and 1 on placebo were excluded from efficacy analysis.
3 patients on secukinumab and 4 on placebo discontinued prema-
turely (lack of efficacy/withdrawal of consent). Demographics and
baseline characteristics were balanced between groups for age, sex
and parameters including mean (SD) SJC (secukinumab vs placebo):
8.3 (5.6) vs 9.5 (5.4); TJC 23.5 (19.4) vs 22.6 (11.0); DAS28 4.8 (1.2)
vs 4.8 (1.2); MASES 3.0 (4.1) vs 3.4 (2.3). Co-existing psoriasis, prior
TNFi exposure and co-medication with DMARDS were present in 23,
11 and 21 patients on secukinumab and in 11, 5 and 10 on placebo,
respectively. At Wk 6, ACR20 response rate was 39% (9/23) on
secukinumab vs 23% (3/13) on placebo (P¼ 0.27). ACR20 response
rates at Wk 12 and 28 were 39% (9/23) vs 15% (2/13) and 43% (10/23)
vs 18% (2/11) for secukinumab vs placebo, respectively. ACR50/70
response rates at Wk 6 on secukinumab vs placebo were 17% vs 8 %
and 9% vs 0%, respectively. CRP reductions at Wk 6 compared to
baseline were greater on secukinumab (median [range]: 4.9 [0.3, 43.0]
at baseline vs 3.0 [0.2, 15.2] at Wk 6) than on placebo (6.2 [1.3, 39.7] at
baseline vs 5.0 [0.8, 29.6] at Wk 6). Post-hoc comparisons between
TNFi naı¨ve vs TNFi pre-exposed subgroups of patients suggested that
ACR20/50/70 response rates may be higher in TNFi naı¨ve subgroup.
Further, post-hoc inspection of response rates in the polyarticular vs.
oligoarticular subgroups did not reveal clinically relevant differences.
Overall rate of AEs was comparable in secukinumab vs placebo: 26
(94%) vs 11 (79%). One severe AE (cellulitis hand) occurred on
secukinumab (not suspected as study drug-related by investigator). 7
serious AEs were reported in 4 secukinumab patients- tendon rupture/
carpal tunnel syndrome/cellulitis, obesity, fall, breast cancer (diag-
nosed prior to dosing and inclusion constituting a protocol violation)
and 1 with placebo- polyarthritis. Infections were reported in 16 (57%)
patients on secukinumab and 7 (50%) on placebo.
Conclusions: The primary endpoint was not met, but a substantial
proportion of patients showed rapid and sustained improvements of
clinical scores and acute phase parameters up to Wk 28. The safety
profile of secukinumab was favorable. Trends towards a beneficial
clinical effect support the rationale for larger clinical trials to assess
clinical effectiveness.
Disclosure statement: A.B. is an employee of Novartis. S.G. is an
employee of Novartis. W.H. is an employee of Novartis. I.M. received
consultancy fees and/or research grants from AstraZeneca, BMS,
Centocor, GSK, Merck, Novartis, Novo Nordisk, Pfizer, Roche and
UCB. P.T. received consultancy fees and/or research grants from
Abbott, Arthrogen, AstraZeneca, Bristol-Myers Squibb, Chemo
Centryx, Eli Lilly, Novartis, NovImmune, NovoNordisk, Pfizer, Merck,
MerckSerono, Roche, and is an employee of GlaxoSmithKline. D.V.
received consultancy fees and/or research grants from Abbott,
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106. A CCR6 VARIANT STRONGLY ASSOCIATED WITH
RHEUMATOID ARTHRITIS IN TWO POPULATIONS IS
NOT ASSOCIATED WITH ANKYLOSING SPONDYLITIS
Carla J. Cohen1, Tugce Karaderi1, Jennifer J. Pointon1,2 and
Bryan P. Wordsworth1,2
1NIHR Oxford Musculoskeletal Biomedical Research Unit,
Botnar Research Centre, Oxford, United Kingdom; 2NIHR Oxford
Comprehensive Biomedical Research Centre, Botnar Research
Centre, Oxford, United Kingdom
Background: There is genetic overlap between the inflammatory
conditions ankylosing spondylitis (AS), rheumatoid arthritis (RA) and
Crohn’s disease (CD). Two single nucleotide polymorphisms (SNPs) in
CCR6 are strongly associated with RA in Europeans (rs3093023,
p¼3.3107) and Japanese (rs3093024, p¼ 7.71019); also a
robust association (p¼1.0 1012) between rs2301436 (in the CCR6
region) and CD has been reported. We tested rs3093024 for
association with AS; rs3093024 is in strong linkage disequilibrium
(LD) with a trialleleic dinucleotide polymorphism that affects CCR6
expression.
Methods: AS patients were either members of the National Ankylosing
Spondylitis Society (UK), attendees at the Nuffield Orthopaedic Centre
(Oxford, UK) or referrals from rheumatologists elsewhere in the UK. All
patients gave informed consent, fulfilled the modified New York criteria
for the diagnosis of AS and were of British white European origin. DNA
was prepared by standard methods from peripheral blood or saliva.
KASPar technology (KBiosciences, Hoddesdon, UK) was used to
genotype 2081 AS cases and 1807 controls (720 blood donors and
1127 individuals with osteoarthritis) for rs3093024. Additional control
data came from the 1958 British Birth Cohort (58BBC) (deposited by P
Deloukas, Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10
1SA, UK; http://www.b58cgene.sgul.ac.uk/index.php October 2008).
This study makes use of data generated by the WTCCC under award
076113.3, the list of investigators who contributed to the data is
available at http://www.wtccc.org.uk.
Results: Genotypes adhered to Hardy-Weinberg equilibrium (p>0.2).
We found no association between rs3093024 and AS: allelic chi-
square test p> 0.5, genotypic Cochrane-Armitage test for trend
p>0.9, odds ratio 1.0, 95% confidence interval (95% CI)¼0.9-1.1,
case and control minor allele frequency (MAF)¼0.44. We extended
our control group to include rs3093024 genotypes on a further 1414
individuals from 58BBC (MAF¼0.43) and again found no association
with AS, Cochrane-Armitage test for trend p>0.4, OR¼1.0, 95%
CI¼1.0-1.1. We performed a meta-analysis (3533 cases and 6974
controls) of our study and data from the Wellcome Trust Case Control
Study 2 (after removing overlapping samples). The Mantel-Haenszel
fixed effects pooled odds ratio¼ 1.1, p¼ 0.04, 95% CI 1.00-1.1,
Cochran Q statistic p¼0.1, power >90% to detect an OR of 1.1, a
genetic effect size equivalent to that seen in the RA studies.
Conclusions: Our findings suggest no association between rs3093024
and AS. Four SNPs, rs3093003, rs3798315, rs3093009 in CCR6 and
rs2301436 in the CCR6 region have previously been genotyped in AS
case control studies none has shown an association. These SNPs are
not in strong LD with rs3093024 (r2< 0.007). Taken together these
findings suggest that there is no genetic association between CCR6
and AS.
Disclosure statement: All authors have declared no conflicts of
interest.
107. THE EFFECT OF PHYSICAL ACTIVITY AND
MOTIVATION ON FUNCTION IN ANKYLOSING SPONDYLITIS
Roxanne Cooksey1, Helen Davies1, Michael S. Dennis1,
Stefan Siebert1 and Sinead Brophy1
1College of Medicine, Swansea University, Swansea,
United Kingdom
Background: Exercise is reported to improve function for people with
ankylosing spondylitis (AS) but it is not clear if this association is causal
or if patients with milder disease find it easier to exercise. This study
examines the effect of exercise and motivation to exercise on function,
while controlling for disease severity.
Methods: Participants who were members of an existing AS cohort
were asked to complete questionnaires about physical activity (IPAQ-
SF), motivation to exercise (BREQ-2), function (BASFI) and disease
severity (BASDAI). Path analysis on STATA was used to examine the
correlation between factors associated with function.
Results: The response rate to the questionnaire was 97% (326/336).
The majority of participants reported to be physically active at a
moderate to high level (71%, 238/336) using the IPAQ-SF. Both
exercise and motivation to exercise independently improve function for
people with AS, especially for those with more severe disease
(BASDAI >3.5). Patients with milder disease (BASDAI<3.5)need to
be highly motivated and to undertake high levels of activity to see an
improvement in functional level. The motivation to exercise not only
has a direct effect on function, but also an indirect effect of improving
activity levels which in turn, improves function.
Conclusions: Exercise does improve function in AS, particularly for
those with severe disease. In addition, motivation alone improved
function as much as exercising itself. Therefore, interventions targeting
motivation to exercise would have as much effect on improving
function as interventions just offering exercise opportunities. Future
interventions to improve the function of AS patients should therefore
target both motivation to exercise and opportunities to exercise.
Disclosure statement: All authors have declared no conflicts of
interest.
108. A RAPID SINGLE-TUBE METHOD FOR TYPING
RS4349859, THE SNP THAT TAGS HLA-B27
Sarah Keidel1,2, Jennifer J. Pointon1,2, Claire Farrar3,
Tugce Karaderi2, Louise H. Appleton1,2 and Bryan P. Wordsworth1,2
1NIHR Oxford Comprehensive Biomedical Research Centre, Botnar
Research Centre, Oxford, United Kingdom; 2NIHR Oxford
Musculoskeletal Biomedical Research Unit, Botnar Research Centre,
Oxford, United Kingdom; 3NIHR Thames Valley CLRN, Botnar
Research Centre, Oxford, United Kingdom
Background: Ankylosing spondylitis (AS) is an inflammatory arthro-
pathy affecting up to 5 per 1000 Europeans. It is strongly familial with
heritability estimated at >90%. The association with HLA-B27 is very
strong but only represents about 30% of the total genetic component
of the disease. Recently a single nucleotide polymorphism (SNP),
rs4349859, that tags HLA-B27 with high sensitivity and specificity
(98%) has been identified, simplifying HLA-B27 typing in AS patients.
Here we describe a single tube assay for rs4349859 using asymmetric
PCR followed by unlabelled probe melting analysis (ULPMA) that is
performed in a real time PCR machine.
Methods: AS patients were either members of the National Ankylosing
Spondylitis Society (UK), attendees at the Nuffield Orthopaedic Centre
(Oxford, UK) or referrals from rheumatologists elsewhere in the UK.
All patients gave informed consent, fulfilled the modified New York
criteria for the diagnosis of AS and were of British white European
origin. DNA was prepared by standard methods from peripheral blood
or saliva. The ULPMA PCR is carried out in a real time PCR machine in
the presence of EvaGreen PCR master mix (VWR International). In this
assay the forward primer is at one tenth the concentration of the
reverse primer and the PCR is carried out in the presence of an
unlabelled 29mer 3’phosphate-blocked probe complimentary to the
product of the reverse primer with the SNP in the middle. Genotypes
are distinguished from the melting curves of the unlabelled probe and
PCR product. To confirm the accuracy of the ULPMA method, 200
patients were typed both by restriction fragment length polymorphism
analysis of PCR products using TaqaI and by ULPMA. Thereafter
patients were typed by ULPMA.
Results: There was 100% concordance between the two assays
for rs4349859. In our patient cohort we found 4% patients were
homozygous for HLA-B27 (AA for rs4349859), 80% were heterozygous
(GA for rs4349859) and 16% were HLA-B27 negative (GG for
rs4349859) making 84% HLA-B-27 positive and 16% HLA-B27
negative.
Conclusions: We have developed a single tube method for a SNP
rs4349859 that accurately types the HLA-B27 status. This method
allows the PCR amplification and the detection of genotypes to
be carried out rapidly in a single closed tube obviating the need for
time-consuming post-PCR sample transfer or manipulation. It is highly
suitable for medium scale assessment of HLA-B27 status in AS
patients.
Disclosure statement: All authors have declared no conflicts of
interest.
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109. REFERRAL RECOMMENDATIONS FOR AN EARLY
INFLAMMATORY BACK PAIN SERVICE
Rebecca Adshead1, Hasan Tahir1, Mandy Greenwood1 and
Simon P. Donnelly1
1Rheumatology, Whipps Cross University Hospital Trust, London,
United Kingdom
Background: Inflammatory back pain (IBP) is the key presenting
feature of axial sponlyloarthropathy (SpA). Several IBP criteria sets
exist such as Calin, Berlin and ASAS to help differentiate from
mechanical low back pain (MLBP). Only one criteria set defined by
ASAS has been validated in early disease. Limited referral criteria exist
for Early Inflammatory Back Pain Services (EIBPS). We examine
individual clinical features of axial SpA, compare the different criteria
sets and suggest new referral criteria for an Early Inflammatory Back
Pain service.
Methods: Patients were referred to an EIBPS with possible inflam-
matory back pain and a symptom duration >3M. They were diagnosed
with axial SpA if they fulfilled the Modified New York or ASAS criteria.
Patients with back pain due to causes other than axial SpA were
labelled Non-SpA. Individual and combinations of parameters were
compared. ROC Curve analysis assessed the specificity, sensitivity
and likelihood ratios of each clinical parameter.
Results: 92 referred cases were analysed. 36 patients were diagnosed
with axial SpA. 56 did not fulfil the criteria for a specific SpA. Age of
onset was <40years, alternating buttock pain, improvement with
exercise, no improvement with rest, morning stiffness >30 minutes
yielded the best balance between sensitivity (91%) and specificity
(45%) if at least 3 of these parameters were fulfilled (NPS 4 – Table 1).
Conclusions: Among the 3 published IBP criteria sets, Berlin and
Calin demonstrate the highest sensitivity. All criteria sets performed
poorly with differentiating axial SpA patients with IBP from patients
without any evidence of SpA. Our proposed referral criteria (NPS4) for
Early Inflammatory Back Pain Services identified the largest number of
axial SpA patients when compared with the other sets. This is
fundamental to any referral criteria designed to capture all IBP
patients. Future studies to validate this criteria set is recommended.
TABLE 1 Individual and combinations of parameters associated with IBP (letters
refer to individual parameters)
Individual Parameter/
criteria set
Minimum
Parameter
Number
Sensitivity Specificity Positive
LR
(95% CI)
Negative
LR
(95% CI)
Back Pain >3 M (h) 1 0.05 1.05 0
Onset of pain < 40yrs (e) 0.89 0.09 0.97 1.24
Insidious onset (g) 0.81 0.32 1.19 0.60
Not improved with rest (c) 0.86 0.45 1.52 0.33
AM stiffness (a) 0.80 0.48 1.49 0.46
Nocturnal waking pain (f) 0.67 0.52 1.38 0.64
Improve with exercise (b) 0.72 0.55 1.57 0.53
Alternating buttock pain (d) 0.53 0.77 0.27 0.61
Calin(a,b,e,g,h) 4 out of 5 0.80 0.46 1.47 0.44
Berlin (a,b,d,f) 2 out of 4 0.81 0.46 1.50 0.42
ASAS (b,c,e,f,g) 4 out of 5 0.69 0.52 1.44 0.59
New Parameter Set (NPS)
1 (a,b,c,e)
3 out of 4 0.86 0.57 1.51 0.32
NPS 2 (b,a,d,e) 3 out of 4 0.72 0.57 1.69 0.49
NPS 3 (b,c,a,d,e) 4 out of 5 0.69 0.59 1.69 0.51
NPS 4 (b,c,a,d,e) 3 out of 5 0.91 0.45 1.66 0.19
NPS 5 (b, a,d,f,e) 3 out of 5 0.81 0.46 1.50 0.42
NPS 6 (a,b,c,d,f) 4 out of 5 0.62 0.67 1.90 0.59
Disclosure statement: All authors have declared no conflicts of
interest.
110. ASSESSING PSORIATIC ARTHRITIS: A MODULAR
APPROACH
Julekha Wajed1 and Bruce Kirkham1
1Rheumatology, Guy’s & St Thomas’ Hospital, London,
United Kingdom
Background: Psoriatic arthritis is a complex condition that can involve
the combination of peripheral arthritis, enthesitis, dactylitis, axial
symptoms and psoriasis. Assessment of these components can lead
to new composite disease activity measures, which can be used in the
future to guide therapy in clinic.
As part of an initiative promoting the concept of ‘Treat-to-Target’
in routine practice, a group of rheumatologists, dermatologists and
nurse specialists considered the challenge of comprehensively
assessing all components of psoriatic disease in routine clinics.
They proposed a modular approach for assessing psoriatic disease,
with skin and axial disease initially assessed by questionnaire. We
investigated the use of this questionnaire approach in routine
outpatient clinics.
Methods: A trained receptionist gave out 2 questionnaires to all
patients with psoriatic arthritis, attending routine follow up appoint-
ments at our hospital. It asked 2 simple questions:
1. Have you been suffering from any neck or back pain recently?
2. Do you have psoriasis at the moment?
If they answered yes to question 1, they proceeded with the Bath
Ankylosing Spondilitis Disease Activity Index (BASDAI). If they
answered yes to question 2, they completed the Dermatology Life
Quality Index (DLQI). A BASDAI score >4 would indicate active
spondylitis. DLQI >5 showed significant skin involvement, and a DLQI
>10 would warrant a Dermatology review.
Questionnaires were formatted in a tick-box format, and collected
over a trial period of 1 month. Patients completed the questionnaires in
the waiting area prior to their appointment, which were reviewed at
their consultation with the doctor.
Results: 32 questionnaires were given out and completed. All patients
found them easy to understand and straightforward to answer. 25
patients (78.1%) had co-existing neck or back pain. 16 patients (64%)
had a BASDAI score >4. 21 patients (65.6%) were identified with co-
existing psoriasis, of which 6 patients (28.6%) had a DLQI >5 and
2 patients had a DLQI >10.
Conclusions: These screening questionnaires were acceptable to
patients and easy to complete. 78.1% of our patients reported axial
involvement, with over half having a BASDAI score >4.0, indicating
active spondylitis. This could have a significant implication on their
disease management, as a similar score 3 months later may make
them eligible for tumour necrosis factor (TNF) inhibitor therapy.
65.6% of our patient group reported skin involvement, of whom 6
had a DLQI >5, illustrating the significant impact it had on their
lives.
We propose the use of these simple questionnaires in routine
practice, to promote a modular approach for the assessment of
psoriatic arthritis. The questionnaires identify skin and axial skeleton
involvement early, so that appropriate referrals can be instigated
quickly, and treatment optimized in all aspects of the psoriatic
spectrum. We suggest this will help identify patients’ needs and help
best treatment choice.
Disclosure statement: B.K. received research grants from Abbott,
Pfizer, BMS and UCB. All other authors have declared no conflicts of
interest.
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